Document:

[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.
​

Exhibit 10.34
​
​
​
​
​
​
COLLABORATION AND LICENSE AGREEMENT
BY AND BETWEEN
XENCOR, INC.
AND
JANSSEN BIOTECH, INC.
​
Dated December 4, 2020
​

​

​
Table of Contents
Page
ARTICLE 1 DEFINITIONS‌1
ARTICLE 2 GOVERNANCE‌20
2.1Joint Research Committee.‌20
2.2Joint Development Committee.‌20
2.3Joint Finance Committee.‌21
2.4Meetings and Minutes.‌21
2.5Decision-Making.‌22
2.6Subcommittees.‌23
2.7Alliance Managers.‌24
ARTICLE 3 RESEARCH‌24
3.1Overview.‌24
3.2Research Plan.‌24
3.3Conduct of Research Program Activities.‌24
3.4Binding Domains.‌25
3.5Research Program Costs.‌25
3.6Records; Reports.‌25
3.7Candidate Selection.‌26
3.8Materials.‌26
ARTICLE 4 DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION‌27
4.1General.‌27
4.2Xencor Assistance.‌27
4.3Diligence.‌27
4.4Conduct of Activities.‌27
ARTICLE 5 PROSTATE COMBINATION REGIMEN STUDIES‌28
5.1Definitions.‌28
5.2Prostate Combination Regimen Study Proposals.‌28
5.3Conduct of Permitted Prostate Combination Regimen Studies.‌30
ARTICLE 6 XENCOR OPTION RIGHTS‌30
6.1General.‌30
6.2Co-Funding Option.‌31

i
​

​

6.3Co-Detailing Option.‌40
ARTICLE 7 FINANCIAL PROVISIONS‌42
7.1Upfront Payment.‌42
7.2Development and Regulatory Milestones.‌42
7.3Sales Milestones.‌42
7.4Royalties.‌43
7.5Payment Terms.‌48
7.6Records; Audits.‌48
7.7Taxes.‌49
ARTICLE 8 LICENSE GRANTS; EXCLUSIVITY‌50
8.1Grants.‌50
8.2Sublicensing.‌52
8.3No Implied Licenses.‌52
8.4Exclusivity.‌52
ARTICLE 9 INTELLECTUAL PROPERTY‌55
9.1Patent Representatives.‌55
9.2Inventions.‌55
9.3Prosecution of Patents.‌56
9.4Patent Enforcement.‌58
9.5Patent Term Extensions.‌61
9.6Regulatory Data Protection.‌61
9.7Patent Invalidity Claims.‌61
9.8Claimed Infringement.‌62
9.9Acquirer Intellectual Property.‌62
9.10Trademarks.‌63
ARTICLE 10 CONFIDENTIALITY AND PUBLICITY‌63
10.1Non-Disclosure and Non-Use.‌63
10.2Exceptions.‌64
10.3Authorized Disclosure.‌64
10.4Terms of Agreement.‌65
10.5Publicity.‌66
10.6Prior Non-Disclosure Agreement.‌66
10.7Equitable Relief.‌66
10.8Publications.‌66

ii
​

​

ARTICLE 11 REPRESENTATIONS AND WARRANTIES; CERTAIN COVENANTS‌67
11.1Representations of Authority.‌67
11.2Consents.‌67
11.3No Conflict.‌67
11.4Enforceability.‌67
11.5Additional Representations and Warranties of Xencor.‌68
11.6No Warranties.‌70
11.7No Debarment or Exclusion.‌70
11.8Compliance with Anti-Corruption Laws.‌71
11.9Additional Third Party Technology.‌73
11.10[***]‌73
ARTICLE 12 INDEMNIFICATION; INSURANCE‌74
12.1Indemnification by Janssen.‌74
12.2Indemnification by Xencor.‌74
12.3Indemnification Procedures.‌75
12.4Insurance.‌76
ARTICLE 13 TERM AND TERMINATION‌76
13.1Term.‌76
13.2Termination for Material Breach.‌76
13.3Termination by Janssen Without Cause.‌77
13.4Termination if No Candidate Selection.‌77
13.5Provisions for Insolvency.‌77
13.6Effects of Termination or Expiration.‌79
ARTICLE 14 EFFORTS TO OBTAIN CLEARANCES‌84
14.1Commercially Reasonable Efforts.‌84
14.2Antitrust Filing.‌84
ARTICLE 15 DISPUTE RESOLUTION‌85
15.1Exclusive Dispute Resolution Mechanism.‌85
15.2Referral to Executive Officers.‌85
15.3Mediation.‌85
15.4Arbitration.‌86
15.5Waiver.‌87
ARTICLE 16 MISCELLANEOUS‌87
16.1Assignment; Successors.‌87

iii
​

​

16.2Performance by Affiliates.‌88
16.3Subcontracting.‌88
16.4No Consequential or Punitive Damages.‌88
16.5Choice of Law.‌88
16.6Submission to Jurisdiction.‌89
16.7Notices.‌89
16.8Severability.‌89
16.9Captions.‌90
16.10Further Actions.‌90
16.11Amendment; No Waiver.‌90
16.12Integration.‌90
16.13Independent Contractors; No Agency.‌90
16.14Force Majeure.‌90
16.15Counterparts; Signatures.‌91
16.16Construction.‌91
​
​
​
​

iv
​

​

COLLABORATION AND LICENSE AGREEMENT
This Collaboration and License Agreement (the “Agreement”) is made and effective as of December 4, 2020 (the “Execution Date”) by and between Xencor, Inc., a Delaware corporation (“Xencor”), on the one hand, and Janssen Biotech, Inc., a Pennsylvania company (“Janssen”), on the other hand.  Xencor and Janssen are referred to herein each individually as a “Party” and collectively as the “Parties.”
INTRODUCTION
WHEREAS, Xencor is engaged in the research of pharmaceutical products and controls certain patents, know-how and other rights related to the Licensed Antibodies and Licensed Products (as defined below);
WHEREAS, Janssen has considerable knowledge and experience in developing and commercializing products in the oncology field throughout the world;
WHEREAS, the Parties believe that a collaboration arrangement between the Parties regarding the research of the Licensed Antibodies would be desirable and Xencor desires to grant to Janssen, and Janssen desires to obtain from Xencor, an exclusive, worldwide license to develop, manufacture and commercialize Licensed Antibodies and Licensed Products; and
WHEREAS, the Parties therefore desire to provide for such research collaboration and license on and subject to the terms and conditions set forth herein.
NOW, THEREFORE, for and in consideration of the mutual covenants contained herein, the Parties agree as follows:
ARTICLE 1​
DEFINITIONS
1.1“Acquirer” means any Third Party that is a counterparty in any Change of Control transaction and any of such Third Party’s Affiliates. 
1.2“Action” means any claim, action, cause of action or suit (whether in contract or tort or otherwise), litigation (whether at law or in equity, whether civil or criminal), controversy, assessment, arbitration, investigation, hearing, charge, complaint, demand, notice or proceeding of, to, from, by or before any Governmental Authority.
1.3“Affiliate” means, with respect to a Person, any other Person directly or indirectly controlling, controlled by, or under common control with, such first Person at any time for so long as such Person controls, is controlled by or is under common control with such first Person.  For purposes of this definition, the term “control” (including the correlative meanings of the terms “controlled by” and “under common control with”), as used with respect to any Person, means (a) in the case of a Person that is a corporate entity, direct or indirect ownership of 50% or more of the stock or shares having the right to vote for the election of directors and (b) in the case of a Person that is an entity, but is not a corporate entity, the possession, directly or indirectly, of the power to direct or cause the direction of the management policies of such Person, whether through the ownership of voting securities, or by contract, or otherwise. 

1
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

1.4“Antibody” means [***].
1.5“Bispecific” in reference to an Antibody means [***].
1.6“Binding Domain” means the region of an Antibody that binds to the antigen targeted by such Antibody (or if such Antibody is multivalent, binds to one of the epitopes targeted by such Antibody) [***]. 
1.7“Business Day” means a day on which banking institutions in New York, New York are open for business.
1.8“Calendar Quarter” means a quarter based on the Johnson & Johnson Universal Calendar for that quarter (a copy of which is attached hereto as Exhibit 1.8).
1.9“Calendar Year” means a year based on the Johnson & Johnson Universal Calendar for that year (a copy of which is attached hereto as Exhibit 1.8).
1.10“CD28 Binding Domain” means a Binding Domain which binds any epitope of CD28. 
1.11“Change of Control” means, at any time on or after the date of this Agreement, with respect to Xencor (and any of its successors):
(a)the acquisition, directly or indirectly, by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a “Specified Person”), of Beneficial Ownership of 50% or more of either (i) the then outstanding ordinary (or common) shares of such company (the “Outstanding Common Stock”) or (ii) the combined voting power of the then outstanding voting securities of such company entitled to vote generally in the election of directors (the “Outstanding Voting Securities”); provided, however, that for purposes of this subclause (a), any acquisition of securities of such company by any Person pursuant to a transaction which complies with clauses (i) and (ii) of subclause (c) of this definition will not constitute a Change of Control of such company;
(b)individuals who, as of the date hereof, constitute the Board of Directors of such company (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board of Directors of such company; provided, however, that any individual becoming a director subsequent to the date hereof whose election, or nomination for election by such company’s shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board will be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of any Person other than the Board of Directors of such company;
(c)consummation of a merger, consolidation, or other similar extraordinary transaction, or sale or other disposition of all or substantially all of the assets (any of the foregoing, a “Business Combination”) of such company, in each case, unless, 

2
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

immediately following such Business Combination, (i) the individuals and entities who were the Beneficial Owners, respectively, of the Outstanding Common Stock and Outstanding Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation or other entity resulting from such Business Combination (including a corporation which as a result of such transaction owns the then outstanding securities of such company or all or substantially all of such company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Outstanding Common Stock and Outstanding Voting Securities, as the case may be, and (ii) more than 50% of the members of the board of directors of the corporation resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board of Directors of such company, providing for such Business Combination;
(d)approval by the shareholders of such company of a complete liquidation or dissolution of such company; or
(e)the sale or disposition to a Third Party of assets or businesses that constitute 50% or more of the total revenue or assets of a Party (determined on a consolidated basis), including such Party’s assets or business related to the Licensed Antibodies and Licensed Products.

For purposes of this definition, a Person will be deemed the “Beneficial Owner” of, and will be deemed to “beneficially own”, and will be deemed to have “Beneficial Ownership” of, any securities:
(i)which such Person or any of such Person’s Affiliates is deemed to “beneficially own” within the meaning of Rule 13d-3 promulgated under the Exchange Act; or
(ii)which such Person or any of such Person’s Affiliates has, directly or indirectly: (1) the right to acquire (whether such right is exercisable immediately or only after the passage of time) pursuant to any agreement, arrangement or understanding (written or oral), or upon the exercise of conversion rights, exchange rights, rights, warrants or options, or otherwise; provided, however, that a Person will not be deemed under this clause (1) to be the Beneficial Owner of, or to beneficially own, or to have Beneficial Ownership of, any securities tendered pursuant to a tender or exchange offer made by or on behalf of such Person or any of such Person’s Affiliates until such tendered securities are accepted for purchase or exchange thereunder or cease to be subject to withdrawal by the tendering security holder; or (2) the right to vote or dispose of, including pursuant to any agreement, arrangement or understanding (written or oral); provided, however, that a Person will not be deemed under this clause (2) to be the Beneficial Owner of, or to beneficially own, or to have Beneficial Ownership of, any security if (x) the agreement, arrangement or understanding (written or oral) 

3
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

to vote such security arises solely from a revocable proxy or consent given to such Person in response to a public proxy or consent solicitation made generally to all holders of the Outstanding Common Stock or Outstanding Voting Securities of the issuer of such security in accordance with the applicable rules and regulations under the Exchange Act and (y) the beneficial ownership of such security is not also then reportable on Schedule 13D or 13G under the Exchange Act (or any comparable or successor report); or
(iii)which are beneficially owned, directly or indirectly, by any other Person with which such Person (or any of such Person’s Affiliates) has (1) any agreement, arrangement or understanding (written or oral) for the purpose of acquiring, holding, voting (except pursuant to a revocable proxy as described in the proviso to subclause (ii)(2) of this definition) or disposing of any ordinary (or common) shares or voting securities of the issuer of such security or (2) any agreement, arrangement or understanding (written or oral) to cooperate in obtaining, changing or influencing the control of the issuer of such security; or
(iv)which are the subject of, or the reference securities for, or that underlie, any Derivative Interest of such Person or any of such Person’s Affiliates, with the number of ordinary (or common) shares or voting securities deemed Beneficially Owned being the notional or other number of ordinary (or common) shares or voting securities specified in (or determined pursuant to) the documentation evidencing the Derivative Interest as being subject to be acquired upon the exercise or settlement of the Derivative Interest or as the basis upon which the value or settlement amount of such Derivative Interest is to be calculated in whole or in part.
1.12“Clinical Study” means any study in which human subjects are dosed or treated with a drug or biological product, whether approved or investigational.
1.13“Combination Product” means (a) any product containing a Licensed Antibody and one or more other active compounds or active ingredients in a fixed-dose formulation, or (b) any combination of a Licensed Product sold together with another drug or biological product in a single package or container for a single price.
1.14“Combination Regimen” means the administration of two or more drugs or biological products together for the treatment, diagnosis or prophylaxis of any Indication, including a Licensed Product and at least one other distinct drug or biological product that is not a Licensed Product, where such Licensed Product and other drug or biological product are packaged and sold separately.
1.15“Commercialization” or “Commercialize” means marketing, promoting, detailing, distributing, importing, exporting, offering for sale or selling a drug or biological product, including medical affairs activities (other than Included Medical Affairs Studies), regulatory activities directed to obtaining pricing and reimbursement approvals, price calculations and related reporting to Governmental Authorities, and interacting with Regulatory Authorities with respect to the foregoing.  Commercialization does not include any activities that are Development activities or Manufacturing activities.

4
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

(a)“Commercialization Approval” means, with respect to a Licensed Product and any country or regulatory jurisdiction, receipt of [***].
1.16“Commercially Reasonable Efforts” means [***].
1.17“Committee” means the JRC, JDC, and, if Xencor exercises the Co-Funding Option, JFC.
1.18“Consent” means, with respect to a certain matter, that Xencor has provided consent to such matter as evidenced in a writing executed by Xencor.
1.19“Controlled” or “Control” means, when used in reference to Know-How, Patents, Confidential Information or intellectual property rights, the legal authority or right (either by ownership or license (other than a license granted pursuant to this Agreement)) of a Party (or any of its Affiliates) to grant a license or sublicense of such Know-How, Patents, Confidential Information or intellectual property rights to the other Party, or to otherwise disclose such Know-How, Patents, Confidential Information or intellectual property rights to the other Party, without violating or breaching the terms of any agreement with any Third Party, or misappropriating such Know-How, Patents, Confidential Information or intellectual property rights of any Third Party, such Third Party agreement existing (a) as of the Execution Date or (b) subsequent to the Execution Date if (in the case of this clause (b)) such Party first acquired rights to such Know-How, Patents, Confidential Information or intellectual property rights pursuant to such agreement.  [***].  
1.20“Cover”, “Covering” and “Covered” means, with respect to a Patent and an invention, that, in the absence of ownership of or a license under such Patent, the practice of such invention (e.g., with respect to a Patent in the U.S., the manufacture, use, sale, offer for sale or importation of such invention) would infringe a claim of such Patent [***].  
1.21“CPI” means the Consumer Price Index-Urban Wage Earners and Clerical Workers, U.S. City Average, All Items, 1982-1984=100, published by the U.S. Department of Labor, Bureau of Labor Statistics (or its successor equivalent index) in the U.S.
1.22“Currency Hedge Rate” means the Johnson & Johnson currency hedge rate, which is the result of the effectively performed currency hedging at Johnson & Johnson for the upcoming Calendar Year and will be set up once a Calendar Year and will remain constant throughout such Calendar Year.  The Johnson & Johnson currency hedge rate is calculated as a weighted average hedge rate of the outstanding external foreign currency forward hedge contracts of Johnson & Johnson with Third Party banks.
1.23“Derivative” means [***].  
1.24“Derivative Interest” means any derivative security (as defined under Rule 16a-1 under the Exchange Act) that increases in value as the value of some other ordinary (or common) share or voting security increases, including, but not limited to, a long convertible security, a long call option and a short put option position, in each case regardless of whether (x) such 

5
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

derivative security conveys any voting rights in such other ordinary (or common) share or voting security, (y) such derivative security is required to be, or is capable of being, settled through delivery of such other ordinary (or common) share or voting security or (z) any transaction hedges the economic effect of such derivative security.
1.25“Development” means:
(a)non-clinical and clinical research and drug development activities designed to generate data to support Commercialization Approval of a drug or biological product, including assay development, toxicology, pharmacology, data collection and management, statistical analysis, Clinical Studies (including Included Medical Affairs Studies) and development of companion diagnostics;
(b)test method development and stability testing, process development, process validation, process scale-up, formulation development, delivery system development, quality assurance and quality control development, technology transfer and other related activities directed to establishing Manufacturing of a drug or biological product (collectively, “CMC Development Activities”);
(c)regulatory activities relating to Clinical Studies and CMC Development Activities, including the preparation and submission of IND/CTAs;
(d)regulatory activities in support of obtaining and maintaining Marketing Approval, including the preparation and submission of Drug Approval Applications, regulatory affairs, project management, drug safety surveillance and REMS programs as required by the FDA or other Regulatory Authorities;
(e)Early Access Programs; and
(f)pharmacovigilance activities with respect to a drug or biological product, including establishing, updating and maintaining of a global safety database.

Notwithstanding the foregoing, Development excludes any Research activities conducted under the Research Program and any Commercialization activities.
1.26“Diligent Efforts” means[***].
1.27“DOJ” means the United States Department of Justice.
1.28“Drug Approval Application” means: (a) a Biologics License Application submitted to the FDA pursuant to Section 351(a) of the Public Health Service Act and the regulations promulgated thereunder (“BLA”); (b) an application for authorization to market and/or sell a biological product submitted to a Regulatory Authority in any country or jurisdiction other than the U.S., including, with respect to the European Union, a marketing authorization application filed with the EMA pursuant to the Centralized Approval Procedure or with the applicable Regulatory Authority of a country in the European Economic Area with respect to the 

6
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

decentralized procedure, mutual recognition or any national approval procedure (“MAA”); or (c) with respect to any biological product for which a BLA or MAA has been approved by the applicable Regulatory Authority, an application to supplement or amend such BLA or MAA to expand the approved label for such biological product to include use of such biological product for an additional Indication (“Supplemental Application”).
1.29“Early Access Program” or “EAP” means any program to provide patients in a country with a Licensed Product before receipt of Marketing Approval and before First Commercial Sale in such country in which the use of the Licensed Product is not primarily intended to obtain information about the safety or effectiveness of such Licensed Product, including Treatment INDs / Protocols, Named Patient Programs and Compassionate Use programs.  For clarity, an EAP with respect to a Licensed Product may continue to be performed following receipt of Marketing Approval of such Licensed Product and costs may continue to be incurred in accordance with the performance of such EAP after Marketing Approval.
1.30“Effective Date” means the first Business Day immediately following the date on which the Parties have actual knowledge that all applicable waiting periods under the HSR Act with respect to the transactions contemplated hereunder have expired or have been terminated.  Upon the request of either Party, the Parties will memorialize the Effective Date, as defined in the immediately preceding sentence, in a written document for the Parties’ records.
1.31“European Union” or “EU” means: (a) the countries of the European Economic Area, as it is constituted on the Execution Date and as it may be modified from time to time after the Execution Date; and (b) the United Kingdom.
1.32“EMA” means the European Medicines Agency or any successor agency thereto.
1.33“Exchange Act” means the Securities Exchange Act of 1934, as amended.
1.34“Exploitation” or “Exploit” means to make, have made, use, have used, offer to sell, sell, have sold, import, export and otherwise practice or exploit, including to Research, Develop, Manufacture and Commercialize.
1.35“FDA” means the United States Food and Drug Administration or any successor agency thereto.
1.36“Field” means all diagnostic, prophylactic and therapeutic uses.
1.37“First Commercial Sale” means, with respect to a Licensed Product in a country, the first commercial sale of such Licensed Product in such country.  Sales for Clinical Study purposes, Early Access Programs or similar uses will not constitute a First Commercial Sale.  In addition, sales of a Licensed Product by and between a Party and its Affiliates, licensees and sublicensees, or between the Parties (or their respective Affiliates, licensees or sublicensees) will not constitute a First Commercial Sale.  For the avoidance of doubt sales of a Licensed Product made on a named patient basis will not constitute a First Commercial Sale for the purposes of this definition.

7
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

1.38“First Phase 3 Commencement Date” means [***].
1.39“FTC” means the United States Federal Trade Commission. 
1.40“GAAP” means generally accepted accounting principles in the United States, consistently applied.  Unless otherwise defined or stated, financial terms will be calculated by the accrual method under GAAP.
1.41“Good Clinical Practice” or “GCP” means the current standards for clinical trials for pharmaceuticals, as set forth in the applicable regulations and ICH guidance, including ICH E6, as amended from time to time, and such standards of good clinical practice as are required by the European Union and other organizations and governmental agencies in countries in which a Licensed Product is intended to be tested to the extent such standards are not less stringent than United States Good Clinical Practice.
1.42“Good Laboratory Practice” or “GLP” means the current standards for laboratory activities for pharmaceuticals, as set forth in the FDA’s Good Laboratory Practice regulations at 21 C.F.R. Part 58 or the Good Laboratory Practice principles of the Organization for Economic Co-Operation and Development, as amended from time to time, and such standards of good laboratory practice as are required by the European Union and other organizations and governmental agencies in countries in which a Licensed Product is intended to be sold, to the extent such standards are not less stringent than United States Good Laboratory Practice.
1.43“Good Manufacturing Practice” or “GMP” means the part of quality assurance which ensures that products are consistently produced and controlled in accordance with the quality standards appropriate to their intended use as defined in 21 C.F.R. Parts 210 and 211, European Directive 2003/94/EC, Eudralex 4, Annex 16, and applicable United States, European Union, Canadian and ICH Guidance and/or regulatory requirements for a product.
1.44“Governmental Authority” means any national, federal, state or local government, or political subdivision thereof, or any multinational organization or authority or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body.
1.45“Government Health Care Programs” means the Medicare program (Title XVIII of the Social Security Act), the Medicaid program (Title XIX of the Social Security Act), TRICARE, the Federal Employee Health Benefits Program, and other foreign, federal, state and local governmental health care plans and programs.
1.46“HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder.
1.47“IND/CTA” means an Investigational New Drug Application filed with FDA or a similar application filed with an applicable Regulatory Authority outside of the United States, 

8
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

such as a clinical trial application or a clinical trial notification, or any other equivalent or related regulatory submission, license or authorization.
1.48“Indication” means [***].
1.49“Janssen Binding Domain” means (a) any Janssen proprietary Target Prostate Antigen Binding Domain designated and provided by Janssen to Xencor for incorporation into Licensed Antibodies under the Research Program under Section 3.4.1, or (b) [***].
1.50“Janssen Research Intellectual Property” means, collectively, the Janssen Research Know-How and Janssen Research Patents.
1.51“Janssen Research Know-How” means all Know-How relating to a Janssen Binding Domain Controlled by Janssen or its Affiliates as of the Execution Date or at any time during the Research Program Term that is necessary for the Research of any of the Licensed Antibodies.
1.52“Janssen Research Patents” means all Patents Controlled by Janssen or its Affiliates as of the Execution Date or at any time during the Research Program Term to the extent that such Patents claim the composition of matter of any Janssen Binding Domain.
1.53“Know-How” means all technical, scientific and other know-how and information, trade secrets, knowledge, technology, means, methods, processes, practices, formulas, instructions, skills, techniques, procedures, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, apparatuses, specifications, data, results and other material, including Manufacturing procedures, test procedures, and purification and isolation techniques in written, electronic or any other form, and all other discoveries, developments, inventions (whether or not patented or patentable), and tangible embodiments of any of the foregoing, in each case that is not generally known to the public.  Know-How does not include any Patents.  
1.54“Law” means any federal, state, local, foreign or multinational law, statute, standard, ordinance, code, rule, regulation, resolution or promulgation, or any order by any court, regulatory agency or other Governmental Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force or effect of law.
1.55“Licensed Antibody” means [***].  
1.56“Licensed Product” means any pharmaceutical product in any form containing one or more Licensed Antibodies as an active ingredient, in any dosage form, formulation or method of delivery.  For clarity, if one or more products contains, as its only active ingredient, the same Licensed Antibody, all such products will be considered the same Licensed Product (except for any products that are Combination Products).
1.57“Major European Countries” means France, Germany, Italy, Spain and the United Kingdom.

9
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

1.58“Manufacturing” or “Manufacture” means activities directed to producing, manufacturing, processing, filling, finishing, packaging, labeling, quality assurance testing and release, shipping and storage of a drug or biological product.
1.59“Marketing Approval” means approval of a Drug Approval Application by the applicable Regulatory Authority.
1.60[***]. 
1.61[***]. 
1.62“MHLW” means the Ministry of Health, Labour and Welfare in Japan.
1.63“Net Sales” means the gross amounts invoiced on sales of a Licensed Product by Janssen, or any of its Affiliates or sublicensees to a Third Party purchaser in an arms-length transaction, less the following customary and commercially reasonable deductions, determined in accordance with GAAP and internal policies and actually taken, paid, accrued, allocated, or allowed based on good faith estimates:
(a)trade, cash and/or quantity discounts, allowances, and credits, excluding commissions for commercialization;
(b)excise taxes, use taxes, tariffs, sales taxes and customs duties, and/or other government charges imposed on the sale of Licensed Product (including VAT, but only to the extent that such VAT taxes are not reimbursable or refundable), specifically excluding, for clarity, any income taxes assessed against the income arising from such sale;
(c)compulsory or negotiated payments and cash rebates or other expenditures to governmental authorities (or designated beneficiaries thereof) in the context of any national or local health insurance programs or similar programs; including, but not limited to, pay-for-performance agreements, risk sharing agreements as well as government levied fees as a result of the PPACA;
(d)rebates, chargebacks, administrative fees, and discounts (or equivalent thereof) to managed health care organizations, group purchasing organizations, insurers, pharmacy benefit managers (or equivalent thereof), specialty pharmacy providers, governmental authorities, or their agencies or purchasers, reimbursers, or trade customers, as well as amounts owed to patients through co-pay assistance cards or similar forms of rebate to the extent the latter are directly related to the prescribing of the Licensed Product;
(e)outbound freight, shipment and insurance costs to the extent included in the price and separately itemized on the invoice price;
(f)retroactive price reductions, credits or allowances actually granted upon claims, rejections or returns of Licensed Product, including for recalls or damaged or expired  goods, billing errors and reserves for returns;

10
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

(g)any invoiced amounts which are not collected by the selling party or its Affiliates, including bad debts; and
(h)any deductions in the context of payments that are due or collected significantly after invoice issuance.

All aforementioned deductions will only be allowable to the extent they are commercially reasonable by Janssen and will be determined, on a country-by-country basis, as incurred in the ordinary course of business in type and amount verifiable based on Janssen’s and Affiliates’ reporting system.  All such discounts, allowances, credits, rebates, and other deductions will be fairly and equitably allocated to Licensed Product and other products of Janssen and its Affiliates and sublicensees such that Licensed Product does not bear a disproportionate portion of such deductions.
Sales of Licensed Product by and between Janssen and its Affiliates and sublicensees, in each case, unless the Affiliate, sublicensee, or Party is the end purchaser, are not sales to Third Parties and will be excluded from Net Sales calculations for all purposes; provided, however, that if such Licensed Product is subsequently resold to a Third-Party end user such resale shall be included in the determination of Net Sales.
Sales of Licensed Product for the use in conducting Clinical Studies of Licensed Product (including Included Medical Affairs Studies) in a country at or below cost, or in a ‘cost-plus a percentage’ scenario where the ‘percentage’ covers Janssen’s tax considerations, and in order to obtain the regulatory approval of the Licensed Product in such country will be excluded from Net Sales calculations for all purposes.
Compassionate use and “named patient sales” will be excluded from Net Sales calculations for all purposes.
Any disposition of the Licensed Product as free samples, donations, or patient assistance will be excluded from Net Sales calculations for all purposes.
If a Licensed Product is a Combination Product, the Parties will negotiate in good faith, at the latest [***] months before the expected launch of such Combination Product, an allocation of Net Sales of such Combination Product to the respective active pharmaceutical ingredient (“API”) components, as the case may be, based on the fair market value of such components for the purposes of determining a Licensed Product specific or licensed API specific allocated Net Sales. Payments related to such Combination Product under this Agreement, including royalty payments, will be calculated, due and payable based only on such allocated Net Sales.
Without limiting the foregoing and following negotiation, the Parties anticipate that allocated Net Sales will be calculated according to one of the following paradigms, with the calculation approach in clause (i) being more preferable:
(i)Net Sales for the determination of royalties of Combination Products will be calculated by multiplying Net Sales of such Combination Product by the fraction A/(A+B) where A is the average net selling price of the Licensed Product component contained in the Combination Product, if sold separately or subject to reasonable estimation, 

11
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

and B is the sum of the average net selling prices of any other API components included in the Combination Product, if sold separately or, if not sold separately, subject to reasonable estimation. 
(ii)Net Sales for the determination of royalties of Combination Products will be calculated by multiplying Net Sales of such Combination Product by the fraction A/C where A is the average net selling price of the Licensed Product component in the Combination Product, if sold separately or, if not sold separately, subject to reasonable estimation, and C is the average net selling Price of the entire Combination Product.
If the Parties do not agree on an allocation of Net Sales of such Combination Product to the respective API components or product components thereof before launch, then the calculation approach described in clause (i) above will be used.  Where the foregoing refers to “subject to reasonable estimation” such estimation shall be made by the selling Party and promptly provided to the other Party.  If the other Party disagrees with such estimation, it shall notify the other Party (“Component Allocation Notice”) and the JFC shall convene to reasonably determine the proper allocation between the applicable components.  If the JFC does not agree on such allocation within [***] days of the Component Allocation Notice, then [***].  For clarity, the selling Party may launch such Combination Product and use its reasonable estimation of the average net selling product of each component while such matter is being discussed and until it is resolved in accordance with this Section or Section 2.5.1.4.
1.64“Patents” means: (a) all original (priority establishing) patent applications claiming one or more inventions filed anywhere in the world, including provisionals and nonprovisionals; and (b) any patent or patent application that claims, or is entitled to claim, direct or indirect priority to the patent applications described in clause (a), including any continuations, continuations-in-part, divisions, or substitute applications, any patents issued or granted from any such patent applications, and any reissues, reexaminations, renewals or extensions (including by virtue of any supplementary protection certificates) of any such patents, and any confirmation patents or registration patents or patents of addition based on any such patents, and all foreign counterparts or equivalents of any of the foregoing.
1.65“Person” means any individual, firm, corporation, partnership, limited liability company, trust, business trust, joint venture, governmental authority, association or other entity.
1.66“Phase 1 Study” means a Clinical Study of a Licensed Product as a monotherapy or in combination with one or more other products, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as more fully defined in 21 C.F.R. § 312.21(a), or its successor regulation, or the equivalent in any foreign country.  
1.67“Phase 2 Study” means a Clinical Study of a Licensed Product as a monotherapy or in combination with one or more other products: (a) with the primary endpoint of evaluating its effectiveness for a particular Indication or Indications, its short term tolerance and safety, but is not intended to be pivotal to support Marketing Approval for such Licensed Product; or (b) that meets the definition in 21 C.F.R. §312.21(b) or any of its foreign equivalents.  

12
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

1.68“Phase 3 Study” means a Clinical Study of a Licensed Product as a monotherapy or in combination with one or more other products: (a) on a sufficient number of patients, which trial (i) is designed to establish that such Licensed Product is safe and efficacious for its intended use and (ii) is pivotal to support Marketing Approval for such Licensed Product; or (b) that meets the definition in 21 C.F.R. §312.21(c) or any of its foreign equivalents.  
1.69“PPACA” means the U.S. Patient Protection and Affordable Care Act.
1.70[***].  
1.71“Regulatory Authority” means any federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the marketing and sale of pharmaceutical products in a country, including FDA in the U.S. and EMA in the EU.  Regulatory Authority also includes any non-governmental group licensed by an entity described in the preceding sentence to perform inspections, audits and/or reviews.
1.72“Regulatory Exclusivity” means any exclusive marketing rights or data protection or other exclusivity rights conferred by any Regulatory Authority with respect to a drug or biological product that prevent (a) such Regulatory Authority from granting any regulatory approval of a Third Party product that has an amino acid sequence that is the same as or substantially identical to the amino acid sequence of such biological product; or (b) a Third Party from making a cross reference to data held by such Regulatory Authority, including orphan drug exclusivity, pediatric exclusivity, rights conferred in the U.S. under Section 351 of the Public Health Service Act, 42 U.S.C. §262 (such Act, the “PHSA”), the Drug Price Competition and Patent Term Restoration Act (21 U.S.C. §355), as amended (the “Hatch-Waxman Act”), the PPACA or in the European Union under Directive 2001/83/EC, as amended, and Regulation (EC) No. 1901/2006, as amended, or rights similar thereto in other countries or regulatory jurisdictions.  If a Regulatory Authority confers more than one type of exclusivity with respect to a biological product in a country or jurisdiction (e.g., the FDA grants both biologic drug reference product exclusivity and orphan drug exclusivity with respect to such biological product), Regulatory Exclusivity will be deemed to apply to such biological product in such country or jurisdiction so long as any exclusivity granted to such biological product prevents such Regulatory Authority from granting any regulatory approval of a Third Party product that has an amino acid sequence that is the same as or substantially identical to the amino acid sequence of such biological product or making any cross reference to data held by such Regulatory Authority.
1.73[***]. 
1.74“Research” means scientific investigation and non-clinical activities to discover, identify, characterize and optimize antibodies.
1.75“Specified Xencor Know-How” means [***].
1.76“Target Prostate Antigen” means [***].

13
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

1.77“Target Prostate Antigen Binding Domain” means a Binding Domain which binds any epitope of the Target Prostate Antigen. 
1.78“Tax” or “Taxes” means any present or future taxes, levies, imposts, duties, charges, assessments or fees of any nature (including any interest thereon).
1.79“Territory” means worldwide.
1.80“Third Party” means any Person other than a Party or any of its Affiliates.
1.81“U.S.” means the United States of America.  
1.82“Valid Claim” means a claim of: (a) of any issued, unexpired patent that has not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be taken, or with respect to which an appeal is not taken within the time allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise; or (b) of any patent application that has not been cancelled, withdrawn or abandoned, without being re-filed in another application in the applicable jurisdiction or has not been pending or filed more than seven years from the earliest possible priority date for said application, provided that if such claim is later issued, it will from the issuance date forward, be deemed to be a Valid Claim, subject to clause (a) of this Section 1.83.  
1.83“Variant” means [***].  
1.84“Variant Binding Domain” means[***].
1.85“Xencor Binding Domain” means (a) any Xencor proprietary CD28 Binding Domain or Target Prostate Antigen Binding Domain used by Xencor for incorporation into Licensed Antibodies, or (b) [***].
1.86“Xencor Intellectual Property” means, collectively, the Xencor Research Know-How and Xencor Patents.  
1.87“Xencor Patents” means all Patents Controlled by Xencor or its Affiliates as of the Effective Date or at any time during the Term that are necessary to Exploit ([***]) any Licensed Antibody or Licensed Product, but excluding [***].  
1.88“Xencor Platform Technology” means: (a) Patents Controlled by Xencor or its Affiliates Covering or (b) Know-How Controlled by Xencor or its Affiliates that is disclosed by Xencor to Janssen and describes, in either case ((a) or (b)), [***]. 
1.89“Xencor Research Intellectual Property” means, collectively, the Xencor Research Know-How and Xencor Research Patents.
1.90“Xencor Research Know-How” means:

14
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

(a)Know-How, but not Specified Xencor Know-How, Controlled by Xencor or its Affiliates (or an invention that, at a previous time, was such Know-How and is Covered in a Patent Controlled by Xencor or its Affiliates at the time the invention was applied or incorporated) that is first incorporated by Xencor (or by Janssen with the Consent of Xencor) into a Licensed Antibody or Licensed Product prior to [***];
(b)Specified Xencor Know-How; and 
(c)Know-How Controlled by Xencor or its Affiliates at any time prior to the end of the Term that is a composition of matter of a Xencor Binding Domain or Variant Binding Domain thereof,

in each case ((a), (b) and (c)), including those Inventions assigned to Xencor pursuant to Section 9.2.2.2(a) and Xencor’s interest in Joint Inventions.  
1.91“Xencor Research Patents” means [***]. 
1.92Additional Definitions.  Each of the following definitions is set forth in the Section of this Agreement indicated below:  

	Defined Term
	Section

	1974 Convention
	16.5

	Acquirer Competing Product
	8.4.5.1

	Acquirer Intellectual Property
	9.9.1

	Acquiring Party
	8.4.6

	Agreement
	the Introduction

	Alliance Manager
	2.7

	Anti-Corruption Laws
	11.8.1(a)

	API
	1.64

	Applied Janssen Technology
	13.6.2.1(a)

	Backup
	7.2.1

	Bankruptcy Code
	13.5.2

	Beneficial Owner
	1.11(e)

	Beneficial Ownership
	1.11(e)

	Biosimilar Application
	9.4.4

	Bispecific Competing Product
	8.4.1.1

	BLA
	1.29

	Breaching Party
	13.2.1

	Business Combination
	1.11(c)

	Candidate Selection
	3.7.3

	Candidate Selection Date
	3.7.3

	CDR
	1.4

	Claim Basis
	12.3.2

15
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

	Defined Term
	Section

	Clinical Reverted Product
	13.6.2.6

	CMC Development Activities
	1.26(b)

	Co-Chair
	2.4.2

	Co-Detailing Agreement
	6.3.3.5

	Co-Detailing Data Package
	6.3.1.2

	Co-Detailing Data Package Delivery Date
	6.3.1.3

	Co-Detailing Option
	6.1

	Co-Detailing Option Exercise Date
	6.3.2

	Co-Detailing Plan
	6.3.3.4

	Co-Funding Option
	6.1

	Co-Funding Option Exercise Date
	6.2.2

	Co-Funding Opt-Out
	6.2.4

	Co-Funding Opt-Out Effective Date
	6.2.4

	Co-Funding Opt-Out Notice
	6.2.4

	Co-Funding Sales Milestone Event
	7.3.2

	Co-Funding Sales Milestone Payment
	7.3.2

	Co-Funding Wind-down Period
	6.2.4(g)

	Committee Matters
	2.5.2

	Competing Product
	8.4.1.2

	[***]
	[***]

	Component Allocation Notice
	1.64

	Confidential Information
	10.1.2

	Contemplated Transactions
	14.2.1

	Cost Report
	6.2.3.4(c)(iii)

	Cost Variances
	6.2.3.1(a)(ii)

	CPR Mediation Procedure
	15.3.1

	CPR Rules
	15.4.1

	Create Act
	9.3.1.7

	Cure Period
	13.2.1

	Data Package
	3.7.1

	Data Package Delivery Date
	3.7.1

	Derived Competing Product
	8.4.1.3

	Detail
	6.3.3.6

	Detailing
	6.3.3.6

	Development Budget
	6.2.3.2(b)(iii)

	Development FTE
	6.2.3.1(b)

	Development FTE Costs
	6.2.3.1(c)

	Development FTE Rate
	6.2.3.1(d)

	Development Reconciliation Procedures
	6.2.3.4(c)(ii)

	Disclosing Party
	10.1.1

16
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

	Defined Term
	Section

	Dispute
	15.1

	Effective Royalty Rate
	7.4.3.4(b)

	Eligible Prostate Products
	5.1.1

	Execution Date
	the Introduction

	Executive Officers
	2.5.1.2

	Existing Xencor Intellectual Property
	11.5.2

	Expert
	2.5.1.4(a)

	Expert Panel
	2.5.1.4(a)

	First Exclusivity Period
	8.4.1.4

	First Licensed Product
	7.2.1

	Force Majeure
	16.14

	GDP
	6.2.3.2(a)

	Global Development Plan
	6.2.3.2(a)

	Hatch-Waxman Act
	1.73

	Included Medical Affairs Studies
	6.2.3.2(b)(iv)

	Included Medical Affairs Studies Costs
	6.2.3.1(e)

	Included Medical Affairs Studies Costs Limit
	6.2.3.1(g)(iv)

	Incumbent Board
	1.11(b)

	Indemnification Claim
	12.3.1

	Indemnitee
	12.3.2

	Indemnitor
	12.3.2

	Independent Prostate Combination Regimen Study
	5.1.2

	Infringement Action
	9.4.2.1

	Infringement Claim
	9.8

	Insolvency Event
	13.5.1

	Invalidity Claim
	9.7.1

	Inventions
	9.2.1

	Janssen
	the Introduction

	Janssen Assigned Inventions
	8.1.4

	Janssen Eligible Prostate Products
	5.1.1

	Janssen Indemnitees
	12.2

	[***]
	[***]

	[***]
	[***]

	JDC
	2.2.1

	JFC
	2.3

	Joint Inventions
	9.2.2.3

	Joint Patent Costs
	9.3.3.3(a)

	Joint Patents
	9.2.2.3

17
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

	Defined Term
	Section

	[***]
	[***]

	JRC
	2.1.1

	JRD
	10.6

	Losses
	12.1

	MAA
	1.29

	Manufacturing Cost of Clinical Supply
	6.2.3.1(a)

	Materials
	3.8

	Milestone Event
	7.2.1

	Milestone Payment
	7.2.1

	Non-breaching Party
	13.2.1

	Other Costs Not Included in Standard
	6.2.3.1(a)(iii)

	Out-of-Pocket Expenses
	6.2.3.1(f)

	Outstanding Common Stock
	1.11(a)

	Outstanding Voting Securities
	1.11(a)

	Party
	the Introduction

	Patent Representative
	9.1

	PDE
	6.3.3.5(b)

	Permitted Prostate Combination Regimen Study
	5.3

	Permitted Study Plan and Budget
	5.3.3

	PHSA
	1.73

	POC Data Package
	6.2.1.2

	POC Data Package Delivery Date
	6.2.1.3

	Primary Antibody
	1.56

	Product Infringement
	9.4.1

	Product Marks
	9.10

	Proof-of-Concept
	6.2.1.1

	Proof-of-Concept Date
	6.2.1.1

	Proposal Delivery Date
	5.2.1

	Proposal Review Period
	5.2.2

	Prosecute
	9.3.1.2

	Prosecution
	9.3.1.2

	Prostate Combination Regimen
	5.1.3

	Protocol
	15.4.6

	[***]
	[***]

	Public Official
	11.8.4

	Purple Book
	9.6

	Quarterly Net Sales
	7.4.3.4(a)

	Receiving Party
	10.1.1

	Regulatory Documentation and Filings
	13.6.2.4

18
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

	Defined Term
	Section

	Research Clone Banking
	13.6.2.1(b)

	Research License
	8.1.1.1

	Research Plan
	3.2.1

	Research Program
	3.1

	Research Program Results
	10.1.4

	Research Program Term
	3.1

	[***]
	13.6.2.3

	Reverted Antibody
	13.6.2.1(c)

	Reverted Derivative
	13.6.2.1(d)

	Reverted Product
	13.6.2.1(f)

	Reverted Product Derivative
	13.6.2.1(g)

	Reverted Variant
	13.6.2.1(e)

	Royalty Term
	7.4.2

	Royalty-Bearing Patent
	7.4.2

	Sales Milestone Event
	7.3.1

	Sales Milestone Payment
	7.3.1

	Scale-Up
	8.4.1.5

	Second Exclusivity Period
	8.4.1.6

	[***]
	[***]

	Shared Development Costs
	6.2.3.1(g)

	Specified Person
	1.11(a)

	Standard Cost of Goods Manufactured
	6.2.3.1(a)(i)

	Subcontract
	16.3

	Subcontractor
	16.3

	Supplemental Application
	1.29

	Target Criteria
	3.2.2

	Term
	13.1

	Third Party Compensation
	1.20

	Third Party Competitive Product
	9.4.1

	Third Party License
	7.4.3.2(a)

	Third Party Prostate Agreement
	5.1.4

	Unadjusted Quarterly Royalties
	7.4.3.4(c)

	Xencor
	the Introduction

	Xencor CD28 Inventions
	11.5.2

	Xencor Eligible Prostate Products
	5.1.1

	Xencor Indemnitees
	12.1

	[***]
	[***]

	Xencor Prostate Antigen xCD28 Patents
	9.3.1.2

​
​

19
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

ARTICLE 2​
GOVERNANCE
2.1Joint Research Committee.  ​
2.1.1JRC Formation; Composition.  The Parties will establish a joint research committee (the “JRC”) promptly after the Effective Date.  The Parties will use reasonable efforts to establish the JRC and hold the first meeting of the JRC within [***] days after the Effective Date.  The JRC will be composed of at least [***] employee representatives of each Party.  Each JRC member must have the appropriate capabilities and experience to carry out the responsibilities of the JRC and sufficient seniority within the applicable Party to make decisions arising within the scope of the JRC’s responsibilities.  Each Party may change its JRC representatives from time to time in its sole discretion, effective upon written notice to the other Party of such change.  The JRC will be disbanded after the completion of the Research Program.
2.1.2JRC Responsibilities.  The JRC will: (a) serve as a forum for and facilitate communications between the Parties with respect to the activities conducted under the Research Plan; (b) prepare, discuss, and approve amendments to the Research Plan in accordance with Section 3.2; and (c) perform the other functions that are expressly delegated to the JRC in this Agreement.
2.2Joint Development Committee.  ​
2.2.1JDC Formation; Composition.  The Parties will establish a joint development committee (the “JDC”) promptly after Candidate Selection.  The JDC will be composed of at least [***] employee representatives of each Party.  Each JDC member must have the appropriate capabilities and experience to carry out the responsibilities of the JDC and sufficient seniority within the applicable Party to make decisions arising within the scope of the JDC’s responsibilities.  Each Party may change its JDC representatives from time to time in its sole discretion, effective upon written notice to the other Party of such change.  If Xencor exercises the Co-Funding Option in accordance with Section 6.2, the JDC will be disbanded after the completion of the GDP activities.  If Xencor does not exercise the Co-Funding Option in accordance with Section 6.2, the JDC will be disbanded within [***]days after the POC Data Package Delivery Date except for purposes relating to Independent Prostate Combination Regimen Studies.  
2.2.2JDC Responsibilities.  ​
2.2.2.1The JDC will serve as a forum for and facilitate communications between the Parties with respect to: (a) the reports provided by Janssen under Section 4.4.2.1 prior to Xencor’s exercise of the Co-Funding Option; and (b) proposed Independent Prostate Combination Regimen Studies in accordance with Section 5.2.3.  Prior to Xencor’s exercise of the Co-Funding Option, the JDC will have no decision-making authority except as expressly described in Section 5.2.3.

20
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

2.2.2.2If Xencor exercises the Co-Funding Option in accordance with Section 6.2, the JDC will: (a) serve as a forum for and facilitate communications between the Parties with respect to the activities conducted under the GDP and CMC Development Activities; (b) discuss and approve amendments to the GDP in accordance with Section 6.2.3; and (c) perform the other functions that are expressly delegated to the JDC in this Agreement.  
2.3Joint Finance Committee.  If Xencor exercises the Co-Funding Option in accordance with Section 6.2, the Parties will establish a joint finance committee (the “JFC”) promptly after the Co-Funding Option Exercise Date.  The JFC will: (i) coordinate and conduct the budgeting, accounting, reporting, reconciliation and other financial activities with respect to the Development Budget and Shared Development Costs to the extent provided in Section 6.2; (ii) if requested by the JDC, develop and recommend to the JDC for approval a process for the development and approval of budgets contemplated by Section 6.2; and (iii) perform the other functions with respect to the Development Budget and Shared Development Costs that are expressly delegated to the JFC in this Agreement.  The JFC will be composed of employee representatives of each Party, each with reasonable expertise in the areas of accounting, cost allocation, budgeting and financial reporting and sufficient seniority within the applicable Party to make decisions arising with the scope of the JFC’s responsibilities.  The JFC will be disbanded after the completion of the GDP activities and reimbursement of all Shared Development Costs.
2.4Meetings and Minutes.  ​
2.4.1Frequency of Meetings.  Each Committee will hold meetings in accordance with a schedule established by mutual written agreement of the Parties.  Each Committee will meet at least once each Calendar Quarter, unless otherwise agreed by the Committee.  A Committee may meet in person or by means of teleconference, Internet conference, videoconference or other similar communications equipment, as agreed to by the Committee members.  Each Party’s Co-Chair may also call for special meetings to resolve particular matters requested by such Party upon [***]prior written notice to the other Party’s Committee members.  
2.4.2Co-Chairs.  For each Committee, each Party will designate one of its representatives to co-chair the meetings of the Committee (each, a “Co-Chair”).  The Co-Chairs will, with the assistance of the Alliance Managers, coordinate and prepare the agenda for, and ensure the orderly conduct of, the meetings of each Committee.
2.4.3Preparation and Attendance.  The Co-Chairs will, with the assistance of the Alliance Managers, solicit agenda items from Committee members and provide an agenda, along with appropriate information for such agenda, reasonably in advance of any meeting.  The agenda will include all agenda items requested by either Co-Chair.  Each Party will bear its own expenses related to its Committee representatives’ participation in and attendance at such meetings.
2.4.4Meeting Minutes.  Each Party, through its Co-Chair and Alliance Manager, will alternate responsibility for preparing written minutes of the meetings of each Committee and will provide the draft minutes to the Committee members for review no later than [***]after the date 

21
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

of the meeting to which the minutes pertain.  Draft minutes will become final and deemed to be approved if the Parties do not provide any comments to the minutes within [***]of receipt by the Committee members (or such additional period of time as mutually agreed by the Parties).  If a Party provides comments to the minutes within such period (or such additional period of time as mutually agreed by the Parties), the Committee members of each Party will discuss such comments in good faith to resolve any discrepancies within five Business Days after receipt of such comments.
2.5Decision-Making.  ​
2.5.1Committee Actions.  Each Committee will determine, approve or resolve Committee Matters within the authority of the Committee by unanimous vote, with each Party’s representatives on the Committee collectively having one vote.  If the Committee representatives of the Parties do not reach consensus as to a particular Committee Matter within [***]after such matter is first presented to the Committee (or [***]), then the following provisions of this Section 2.5.1 will apply.
2.5.1.1With respect to the JRC, neither Party will have final decision making authority with respect to Committee Matters of the JRC, and any such Committee Matter will be deemed not to have been approved by the JRC, unless and until the JRC reaches consensus, or the Parties agree, on such matter.
2.5.1.2With respect to the JDC, either Party may refer the Committee Matter to [***]and [***] for resolution.  Such Executive Officers shall endeavor to meet promptly to discuss the matter.  If the Executive Officers do not reach consensus on such Committee Matter within [***]after such matter is referred to them, then Janssen will have the final decision making authority with respect to the Committee Matter, except as otherwise specified in Section 5.2.3. 
2.5.1.3With respect to the JFC, either Party may refer a Committee Matter of the JFC (other than a [***]) for resolution by an independent Third Party accounting firm.  If either Party refers a matter for resolution by an independent Third Party accounting firm, the Parties will mutually select and engage an independent Third Party accounting firm that has no auditing or other financial relationship with either Party or any of its Affiliates to resolve the matter.  If the Parties are unable to agree on the identity of the Third Party accounting firm within [***] of the date on which a Party refers such matter for resolution pursuant to this Section, the Third Party accounting firm will be one of the “big four” accounting firms that is not the external auditor of either Party.  The accounting firm will, as soon as reasonably practicable after the firm is engaged and acting as expert and not an arbitrator, deliver a report to each Party with its analysis and determination of the Committee Matter.  The accounting firm’s determination will be final and binding on the Parties, and the amounts payable to the firm for these services will be shared equally by the Parties.  If, however, the Committee Matter relates to an amount less than [***], then Janssen will have the final decision making authority with respect to such Committee Matter instead of an independent Third Party accounting firm.

22
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

2.5.1.4With respect to the JFC, either Party may refer a Committee Matter that is a [***] for resolution by an Expert Panel according to the following procedures:
(a)Each Party will select one Third Party expert who is neutral, disinterested and impartial, and has experience relevant to the specific subject matter of the referred Committee Matter, within [***] after either Party requests resolution by an Expert Panel (each, an “Expert”).  The Experts selected by the Parties shall jointly select a third Expert within [***]thereafter (the three Experts together, the “Expert Panel”).  
(b)Within [***] after the Expert Panel has been selected, each Party will provide to the Expert Panel and the other Party a written report setting forth its position on the referred Committee Matter.  Each Party may update its own report within [***] after receiving the other Party’s report.  If requested by the Expert Panel, each Party will make oral submissions based on its written report and each Party will have the right to be present during any such oral submissions.
(c)Within [***] after receiving the last report or, if requested by the Expert Panel, the oral submissions, the Expert Panel will select one Party’s position on the referred Committee Matter as its final decision.  The Expert Panel will not have the authority to modify either Party’s position or to render any substantive decision other than to select one Party’s position on the referred Committee Matter as set forth in such Party’s written report most recently submitted to the Expert Panel.  The decision of the Expert Panel will be the Parties’ sole, exclusive and binding resolution of the referred Committee Matter, and the Expert Panel’s decision will become the decision of the JFC on the matter.
(d)The costs and fees of the Expert Panel will be shared equally by the Parties.  Each Party will bear its own costs of participating in the proceeding.
(e)The Parties will use, and will direct the Expert Panel to use, Diligent Efforts to resolve the referred Committee Matter within [***] after either Party requests such resolution.
(f)Unless otherwise mutually agreed upon by the Parties, the in-person portion (if any) of such proceedings shall be conducted in [***].
2.5.2Limitations of Committee Authority.  Each Committee will only have authority to determine, approve or resolve matters that such Committee is expressly authorized to determine, approve or resolve under this Agreement (“Committee Matters”).  No Committee has the authority to: (a) modify or amend the terms and conditions of this Agreement; (b) waive or determine either Party’s compliance with the terms and conditions of this Agreement; (c) decide any issue in a manner that would conflict with the express terms and conditions of this Agreement; (d) decide any issue for which this Agreement expressly requires a Party’s approval or consent; or (e) resolve any Dispute under this Agreement.
2.6Subcommittees.  From time to time, each Committee may establish subcommittees to perform particular tasks and oversee particular projects or activities within the Committee’s 

23
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

authority.  Each subcommittee will be constituted and will operate as the forming Committee determines, provided that no subcommittee will have any decision-making authority, but will instead make recommendations to the forming Committee with respect to matters within its authority.
2.7Alliance Managers.  Promptly after the Effective Date, each Party will appoint an individual to act as the alliance manager for such Party with respect to this Agreement (each, an “Alliance Manager”).  The Alliance Managers will not be members of any Committee, but will be permitted to attend meetings of any Committee as nonvoting observers.  The Alliance Managers will be the primary point of contact for the Parties regarding this Agreement and will facilitate communication regarding all activities under this Agreement.  Each Party may change its designated Alliance Manager from time to time upon notice to the other Party.
ARTICLE 3​
RESEARCH
3.1Overview.  The Parties will collaborate to conduct a program of research and development of Licensed Antibodies in accordance with the Research Plan, including antibody discovery and biology efforts through Candidate Selection (the “Research Program”), as further described in this ARTICLE 3.  The objective of the Research Program is to Research one or more Licensed Antibodies that meet the target criteria set forth in the Research Plan.  The time period beginning on the Effective Date and ending on the earlier of (a) the third anniversary of the Effective Date and (b) the date of Candidate Selection in accordance with Section 3.7 is referred to as the “Research Program Term.”
3.2Research Plan.  ​
3.2.1Initial Plan.  The Parties have agreed upon a draft of a written research plan describing the Research Program (the “Research Plan”).  The draft of the initial Research Plan is attached to this Agreement as Exhibit 3.2.  The Parties will use Diligent Efforts to finalize the initial Research Plan as soon as possible after the Execution Date.  The finalized initial Research Plan will be approved by the JRC in accordance with Section 3.2.3.
3.2.2Contents.  The initial Research Plan includes, and any amended Research Plan will include, the following elements: (a) descriptions of the key activities to Research Licensed Antibodies; (b) a target timeline for completing the activities; (c) Janssen’s target criteria for Licensed Antibodies (the “Target Criteria”); and (d) certain Materials that will be provided by Xencor and Janssen.
3.2.3Amendments.  Either Party may propose amendments to the Research Plan at any time during the Research Program Term.  All amendments require approval of the JRC.  If the JRC approves an amendment, the amendment becomes effective upon the date of JRC approval. A written copy of the amended Research Plan will be prepared by one of the Parties, as decided by the JRC, and provided to both Parties.
3.3Conduct of Research Program Activities.  Xencor will be responsible for conducting all Research Plan activities, except Janssen will be responsible for conducting the activities assigned to Janssen under the Research Plan.  Each Party will carry out the activities assigned to 

24
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

it in the Research Plan in accordance with the timeline set forth in the Research Plan.  Each Party will keep the other Party reasonably informed as to the progress of the conduct of such activities through meetings of the JRC.  Each Party will conduct its Research Program activities in good scientific manner and in compliance with all applicable Laws, including GLP.
3.4Binding Domains.​
3.4.1Janssen Binding Domains.  Janssen will designate and provide [***] proprietary Target Prostate Antigen Binding Domains to Xencor for the purpose of Researching Licensed Antibodies incorporating such binding domain in the Research Program.  Janssen may provide such binding domains to Xencor either by providing tangible materials containing the binding domain or by disclosing the amino acid sequence of the binding domain.
3.4.2Xencor Binding Domains.  Xencor will designate and use in the Research Program at least one of its proprietary CD28 Binding Domains and at least one of its Target Prostate Antigen Binding Domains for the purpose of Researching Licensed Antibodies incorporating such binding domains.
3.4.3Restrictions on Use of Binding Domains.  ​
3.4.3.1During and after the Term, neither Janssen nor any of its Affiliates will use, nor have any right to use, any Xencor Binding Domain except to the extent Janssen is granted a license to Exploit the Licensed Antibodies and Licensed Products under this Agreement.  For clarity, Xencor retains the right to use any Xencor Binding Domain in any product that is not a Licensed Antibody or Licensed Product during or after the Term.
3.4.3.2During and after the Term, neither Xencor nor any of its Affiliates will use, nor have any right to use, any Janssen Binding Domain except to the extent Xencor is granted a license to Research the Licensed Antibodies and Exploit the Reverted Products and Reverted Product Derivatives under this Agreement.  For clarity, Janssen retains the right to use any Janssen Binding Domain in any product that is not a Licensed Antibody or Licensed Product during or after the Term.
3.5Research Program Costs.  Xencor will bear all costs incurred by Xencor and its Affiliates in conducting the Research Program activities.  Janssen will bear all costs incurred by Janssen and its Affiliates in conducting the Research Program activities allocated to Janssen under the Research Plan.
3.6Records; Reports.​
3.6.1Records.  Xencor will maintain, consistent with its then-current internal policies and practices, and cause its employees and subcontractors to maintain, records and laboratory notebooks of its Research activities under the Research Plan in sufficient detail and in a good scientific manner appropriate for regulatory and intellectual property protection purposes.  If requested by Janssen, Xencor will provide Janssen with a copy of any such records to the extent specific to any Primary Antibody.

25
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

3.6.2Reports and Data Packages.  Xencor will provide periodic updates and reports regarding the Research Program activities and results to Janssen through the JRC, including summaries of the data and information generated and, if reasonably requested by Janssen, any raw data relating to such activities to the extent specific to any Primary Antibody.  During the Research Program Term, upon request of Janssen, Xencor will provide Janssen with information about the Xencor Platform Technology used by Xencor to Research any Licensed Antibody.  
3.7Candidate Selection.​
3.7.1Promptly after completing all Research Program activities, Xencor will prepare and deliver to Janssen in writing a complete package of all reasonably relevant data and results of the Research Program activities for all Licensed Antibodies (the “Data Package”).  If Janssen notifies Xencor within [***] following receipt that the Data Package is not complete, Xencor will provide the missing data and results as soon as possible.  The date on which Janssen is in receipt of a complete Data Package is deemed to be the “Data Package Delivery Date.”
3.7.2Within [***] after the Data Package Delivery Date, Janssen will decide whether any of the Licensed Antibodies that are the subject of the Data Package should be further Developed.  Janssen will notify Xencor of its decision within the [***]period.
3.7.3If Janssen decides that at least one of such Licensed Antibodies should be further Developed, the notice will identify which Licensed Antibody or Licensed Antibodies will be further Developed.  This decision to further Develop a Licensed Antibody is referred to as “Candidate Selection,” and the date on which Janssen gives such notice is referred to as the “Candidate Selection Date.”  
3.7.4If Janssen decides that none of the Licensed Antibodies that are the subject of the Data Package should be further Developed, Janssen’s notice will be deemed to be a notice to terminate this Agreement without cause in accordance with Section 13.3.  If Janssen does not notify Xencor of Candidate Selection within the [***] period after the Data Package Delivery Date, the provisions of Section 13.4 will apply.
3.8Materials.  In connection with the performance of activities under the Research Program, either Party may provide to the other Party for use as research tools certain proprietary biological materials or chemical compounds, such as control molecules (“Materials” of the supplying Party).  For clarity, Materials do not include precursors for manufacture of Antibodies or excipients to be used in formulations of Antibodies.  All Materials shall be used by the receiving Party solely to perform its activities under the Research Program, shall not be used or delivered by the receiving Party to or for the benefit of any Third Party without the prior written consent of the supplying Party, and shall not be used by the receiving Party in research or testing involving human subjects.  Any Materials supplied under this Section 3.8 are supplied “as is” and must be used with prudence and appropriate caution in any experimental work, since not all of their characteristics may be known.

26
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

ARTICLE 4​
DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION
4.1General.  Janssen will have the sole and exclusive right to Research, Develop (including conducting all regulatory matters with respect to), Manufacture, Commercialize and otherwise Exploit Licensed Antibodies and Licensed Products in the Territory at its sole cost and expense, except that Xencor will Research Licensed Antibodies during the Research Program Term in accordance with ARTICLE 3.  Without limiting the foregoing:  
(a)Development conducted by Janssen with respect to Licensed Antibodies generated by Xencor during the Research Program Term will include all activities following Candidate Selection, including IND-enabling activities.  Janssen’s authority over Development of the Licensed Antibodies will include the right to conduct Development of Combination Regimens that include the Licensed Products and other Janssen products or Third Party products in Janssen’s sole discretion.
(b)Janssen will have the sole and exclusive right to hold all regulatory filings for the Licensed Products, including INDs/CTAs and Drug Approval Applications.  
(c)Janssen will have sole decision-making authority over global Commercialization matters for the Licensed Products, including pricing and reimbursement.
4.2Xencor Assistance.  After Candidate Selection and until [***], Xencor will reasonably cooperate with Janssen to provide reasonable technical assistance, and to transfer to Janssen any Xencor Research Know-How licensed to Janssen under Section 8.1.1, as requested by Janssen to facilitate Janssen’s Research and Development efforts related to Licensed Antibodies and Licensed Products to Janssen.  Such cooperation will include providing Janssen with reasonable access by teleconference or in-person at Xencor’s facilities to any Xencor personnel involved in the performance of the Research Program.  [***].    
4.3Diligence.  ​
4.3.1Development Diligence.  After the Candidate Selection Date, Janssen will use Commercially Reasonable Efforts to Develop and seek Marketing Approval for one Licensed Product for one Indication in the U.S., each of the Major European Countries and Japan.  
4.3.2Commercialization Diligence.  Following receipt of Commercialization Approval of a Licensed Product in the U.S., a Major European Country or Japan, Janssen would use Commercially Reasonable Efforts to Commercialize the Licensed Product in such country. 
4.4Conduct of Activities.  ​
4.4.1Standards of Conduct; Records.  Janssen will conduct all Development of Licensed Antibodies and Licensed Products in good scientific manner and in compliance with all applicable Law, including GMP, GLP and GCP, as applicable.  Janssen will maintain, consistent with its then-current internal policies and practices, and cause its employees and subcontractors to maintain, records and laboratory notebooks of its Development activities under this Agreement in sufficient detail and in a good scientific manner appropriate for regulatory and 

27
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

intellectual property protection purposes.  Janssen will conduct all Commercialization activities under this Agreement in compliance with all applicable Laws.
4.4.2Reports.  ​
4.4.2.1Janssen will provide Xencor with periodic reports on its Development activities with respect to the Licensed Antibodies and Licensed Products for so long as Janssen is conducting Development activities.  Such reports will be provided on a [***] basis  after [***].  If Xencor exercises the Co-Funding Option in accordance with Section 6.2, Janssen will continue to provide [***] reports in accordance with 6.2.3.3(d).  Otherwise, Janssen will provide such reports on [***]  basis within [***] after [***].  Each such report will include results of Development since the previous report and Janssen’s anticipated Development activities for the subsequent four Calendar Quarters.
4.4.2.2On an [***] basis within [***] after the completion of each Calendar Year after the First Commercial Sale of any Licensed Product, Janssen will provide Xencor a high-level summary of its Commercialization launch status and performance for Licensed Products since the previous summary and a high-level summary of Janssen’s projected Commercialization activities for the subsequent Calendar Year.
ARTICLE 5​
PROSTATE COMBINATION REGIMEN STUDIES
5.1Definitions.  ​
5.1.1“Eligible Prostate Products” means: (a) with respect to Janssen, the Licensed Products and the Janssen products listed under the heading “Janssen Eligible Prostate Products” on Schedule 5.1.1 (the “Janssen Eligible Prostate Products”); and (b) with respect to Xencor, the Xencor products listed under the heading “Xencor Eligible Prostate Products” on Schedule 5.1.1 (the “Xencor Eligible Prostate Products”).
5.1.2“Independent Prostate Combination Regimen Study” means a Clinical Study of a Prostate Combination Regimen that meets all of the following criteria: 
(a)[***].  
5.1.3“Prostate Combination Regimen” means a Combination Regimen that includes one Janssen Eligible Prostate Product and one Xencor Eligible Prostate Product and may include [***].
5.1.4“Third Party Prostate Agreement” means, with respect to an Eligible Prostate Product, any agreement or arrangement between a Party and a Third Party relating to such Eligible Prostate Product that is in effect on the Execution Date.  
5.2Prostate Combination Regimen Study Proposals.  ​
5.2.1Study Proposals.  If a Party desires to conduct an Independent Prostate Combination Regimen Study, such Party must first submit a detailed proposal for such study to 

28
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

the other Party (with a copy to the other Party’s Alliance Manager).  The proposal will include a draft study protocol that includes at least the following information: [***]. The proposal will also include [***].  If the non-proposing Party notifies the proposing Party within [***] following receipt that the proposal is not complete, the proposing Party will provide the missing information as soon as possible.  The date on which the non-proposing Party is in receipt of a complete proposal is deemed to be the “Proposal Delivery Date.”
5.2.2Review of Proposals.  The other Party will consider the proposal in good faith and will notify the proposing Party in accordance with Section 16.7 within [***] after the Proposal Delivery Date (the “Proposal Review Period”) whether it objects to the proposed study.  If the non-proposing Party objects to the proposed study, such notice will state the reason for the objection.  [***]. 
5.2.3No Objection to Proposal.  If the non-proposing Party notifies the proposing Party that it objects to the proposed study for a reason set forth in Section 5.2.2 and the proposing Party does not agree that such reason applies to the proposed study, then the proposing Party may refer the matter to the JDC for further discussion.  Such matter will be a Committee Matter of the JDC, and the JDC will attempt to reach consensus on whether the reason applies or does not apply in accordance with Section 2.5.1.2.  If the JDC does not reach consensus on whether the reason applies (or if the Executive Officers do not reach consensus in accordance with Section 2.5.1.2, if the matter is submitted to the Executive Officers), then [***].  
5.2.4Third Party Prostate Agreements. Notwithstanding anything to the contrary in this ARTICLE 5:
5.2.4.1[***]
5.2.5Retained Rights. ​
5.2.5.1Nothing in this ARTICLE 5 is intended to prohibit or otherwise restrict a Party or its Affiliates from Exploiting, or entering into business relationships with one or more Third Parties to Exploit, its Eligible Prostate Products, subject to the terms and conditions of this Agreement with respect to the Licensed Antibodies and Licensed Products.   
5.2.5.2A Party or any of its Affiliates may, at any time during the Term and in its sole discretion, sell, assign, license, divest or otherwise transfer to a Third Party any of its rights or assets relating to any of its Eligible Prostate Products, subject to terms and conditions of this Agreement with respect to the Licensed Antibodies and Licensed Products.  If, as a result of such transfer, such Party no longer has the right to conduct (or such Party is restricted by contract from conducting) clinical studies of the applicable Eligible Prostate Product, then such Eligible Prostate Product will be deemed to be removed from Schedule 5.1.1 and will no longer be an “Eligible Prostate Product” for purposes of this Agreement.
5.2.5.3A Party or any of its Affiliates may, at any time during the Term and in its sole discretion, discontinue (temporarily or permanently) any of its Development, Manufacturing or Commercialization activities relating to its Eligible Prostate Products, subject to the terms and conditions of this Agreement with respect to the Licensed Antibodies and 

29
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

Licensed Products.  If a Party permanently discontinues all of such activities relating to one of its Eligible Prostate Products, then such Eligible Prostate Product will be deemed to be removed from Schedule 5.1.1 and will no longer be an “Eligible Prostate Product” for purposes of this Agreement.
5.3Conduct of Permitted Prostate Combination Regimen Studies.  If the non-proposing Party does not object to an Independent Prostate Combination Regimen Study for one or more of the reasons specified in Section 5.2.2 within the Proposal Review Period in accordance with Section 5.2, or does not respond to a proposal within the Proposal Review Period in accordance with Section 5.2, the proposing Party may conduct the study (a “Permitted Prostate Combination Regimen Study”) in accordance with the terms and conditions set forth in this Section 5.3.  
5.3.1Costs.  The conducting Party will be solely responsible for all costs and expenses of conducting the Permitted Prostate Combination Regimen Study, including drug supply costs.
5.3.2Anticipated Supply Requirements.  While actual supply requirements would be defined by a clinical trial supply agreement, the Parties anticipate [***].
5.3.3Studies that include a Licensed Product.  If the proposing Party is Xencor and the  Permitted Prostate Combination Regimen Study includes a Licensed Product, then Xencor will provide Janssen a plan and budget for its conduct of the study (the “Permitted Study Plan and Budget”).  Within [***] after the receipt of the Permitted Study Plan and Budget, Janssen will have the right to elect, by providing written notice to Xencor, to conduct the Permitted Prostate Combination Regimen Study itself in accordance with the Permitted Study Plan and Budget.  If Janssen elects to conduct the study, Janssen will use Diligent Efforts to perform the study and Xencor will reimburse the Out-of-Pocket Expenses and Development FTE Costs incurred by Janssen in performing the study (up to the budgeted amounts), all in accordance with the Permitted Study Plan and Budget.  If Janssen does not elect to conduct the study within [***] days after the receipt of the Permitted Study Plan and Budget, Xencor will have the right to conduct the study under the terms of this Section 5.3.
5.3.4Clinical Trial Agreement.  Before the commencement of the Permitted Prostate Combination Regimen Study, the Parties will enter into a clinical trial agreement with respect to the study.  The clinical trial agreement will include reasonable and customary terms for agreements of its type, as well as the following terms:
5.3.4.1[***].  
ARTICLE 6​
XENCOR OPTION RIGHTS
6.1General.  Janssen hereby grants to Xencor the right to elect to co-fund worldwide Development of Licensed Products in the Territory on the terms set forth in Section 6.2 (the “Co-Funding Option”).  If Xencor exercises the Co-Funding Option in accordance with 

30
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

Section 6.2, Janssen hereby grants to Xencor the right to elect to co-Detail Licensed Products in the U.S. on the terms set forth in Section 6.3 (the “Co-Detailing Option”).  
6.2Co-Funding Option.  ​
6.2.1POC Data Package.  ​
6.2.1.1Janssen will notify Xencor promptly following the Proof-of-Concept Date for the first Licensed Product to achieve Proof-of-Concept.  “Proof-of-Concept” means [***].  “Proof-of-Concept Date” means, with respect to a Licensed Product, the date on which Proof-of-Concept first occurs for such Licensed Product.
6.2.1.2Within [***] after the date of such notice, Xencor will notify Janssen of whether it requests Janssen to prepare and deliver a data package with respect to the Licensed Products (a “POC Data Package”).  The POC Data Package will include: [***]
6.2.1.3If Xencor requests the POC Data Package, Janssen will provide the POC Data Package to Xencor within [***]after the request.  If Xencor notifies Janssen within [***]after receipt of the POC Data Package that it is not complete, Janssen will provide any missing information, data or results as soon as practicable.  The date on which Xencor is in receipt of a complete POC Data Package is referred to as the “POC Data Package Delivery Date.”
6.2.2Exercise of Co-Funding Option.  Xencor may exercise the Co-Funding Option by providing notice to Janssen within [***]after the POC Data Package Delivery Date (the “Co-Funding Option Exercise Date”).  
6.2.3Effect of Co-Funding Option Exercise.  On and after the Co-Funding Option Exercise Date, the terms and conditions set forth in this Section 6.2.3 will apply with respect to the Development of Licensed Products worldwide:
6.2.3.1Definitions.  ​
(a)“Manufacturing Cost of Clinical Supply” means a Party’s reasonable internal and Third Party costs incurred in manufacturing or acquisition of (and to the extent directly attributable to) Licensed Product, determined in accordance with such Party’s standard cost accounting policies that are in accordance with GAAP and consistently applied across all of such Party’s manufacturing network to other products that the Party manufactures.  Manufacturing Cost of Clinical Supply does not include any costs of CMC Development Activities. “Manufacturing Cost of Clinical Supply” is comprised of Standard Cost of Goods Manufactured, Cost Variances, and Other Costs Not Included in Standard, where:
(i)“Standard Cost of Goods Manufactured” are budgeted unit costs established to facilitate inventory evaluation, planning and budgetary control, including direct materials, direct labor, product testing, transportation, depreciation and overhead (including Third Party costs for manufacturing or acquisition of product or materials used in such 

31
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

manufacture), in each case, to the extent directly attributable to Licensed Products Manufactured by a Party under this Agreement or under a supply agreement between the Parties;
(ii)“Cost Variances” are actual costs of manufacturing versus Standard Cost of Goods Manufactured and include direct materials variances (including material usage variances and purchase price variances), direct labor variances and overhead variances (including but not limited to volume variances, variable overhead spending variances and fixed overhead spending variances) in each case to the extent directly attributable to Licensed Products Manufactured by a Party under this Agreement or under a supply agreement between the Parties; and
(iii)“Other Costs Not Included in Standard” are actual costs of manufacturing which are incurred in the normal course of business but are not included in the Standard Cost of Goods Manufactured, including, but not limited to: cash discounts on raw material purchases, transportation expenses, manufacturing trial runs, manufacturing development expenses, start-up costs, appropriation expenses, abnormal capacity or idle facility costs (to the extent such capacity or portion of a facility is reserved for Manufacturing Licensed Antibodies or Licensed Products under this Agreement or a supply agreement between the Parties), shut-down costs, material scrapped in the normal course of business (including failed commercial batches), rework, obsolete facility and machinery, impairment expenses, full absorption adjustments, inventory revaluation adjustments, lower of cost or market inventory adjustments, inventory write-downs and write-offs, physical inventory adjustments, depreciation of equipment or instruments placed at customer or other Third Party sites, new product introduction costs, technical operations, internal inventory supply management, returned goods, royalty expense, and product liability insurance, in each case to the extent directly attributable to Licensed Products Manufactured by a Party under this Agreement or under a supply agreement between the Parties.  [***].  
(b)“Development FTE” means [***] hours of work in direct support of the Development of the Licensed Products that is carried out by one or more qualified employees or contractors or consultants of a Party or its Affiliates, provided that one individual conducting more than [***] of work in any Calendar Year will not be considered more than one Development FTE and, in the case of work by an individual that is less than [***], will be pro-rated based on the actual number of hours expended by such individual.  Development FTE includes scientific, medical, technical and other personnel directly engaged in performing Development activities with respect to the Licensed Products (including the project management teams that support the Licensed Products).  Development FTE will not include work performed by personnel performing administrative and corporate functions (including human resources, finance, legal and investor relations).
(c)“Development FTE Costs” means, with respect to any period, the amount calculated by multiplying the Development FTE Rate by the number of Development FTEs expended by a Party during such period.

32
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

(d)“Development FTE Rate” means a rate of [***]per full-time Development FTE per Calendar Year; provided, however, that such rate will be increased or decreased annually beginning on January 1, 2022 by the percentage increase or decrease in the CPI between the last day of the most recently completed Calendar Year and December 31, 2020, or an alternative methodology that is mutually agreed to by both Parties.  The Development FTE Rate is “fully burdened” and will cover employee salaries (excluding stock-based compensation), benefits, utilities, facilities, and travel expenses.
(e)“Included Medical Affairs Studies Costs” means, with respect to a particular Licensed Product, all Development FTE Costs and Out-of-Pocket Expenses incurred by the Parties and their Affiliates for Included Medical Affairs Studies specified in the GDP with respect to such Licensed Product.
(f)“Out-of-Pocket Expenses” means amounts paid by or on account of a Party to Third Party vendors or contractors for supplies and materials for use, or for services provided by them, directly in the performance of Development activities relating to the Licensed Antibodies and Licensed Products under this Agreement (or other activities for which sharing of Out-of-Pocket Expenses is otherwise specified in this Agreement).  For clarity, Out-of-Pocket Expenses do not include: (a) payments for the Parties’ or their Affiliates’ salaries or benefits, benefits, utilities, travel expenses, general office supplies, insurance, information technology, capital expenditures (or related depreciation), or the like; or (b) amounts paid relating to activities that were not performed under this Agreement.
(g)“Shared Development Costs” means Development FTE Costs and Out-of-Pocket Expenses incurred by the Parties and their Affiliates in conducting Development activities with respect to Licensed Products under the GDP, including:
(i)all Development FTE Costs and Out-of-Pocket Expenses incurred for activities specified in the GDP, including for Included Medical Affairs Studies up to the Included Medical Affairs Studies Costs Limit (as defined below), and all Development FTE Costs and Out-of-Pocket Expenses incurred for CMC Development Activities, even if not specified in the GDP; 
(ii)with respect to non-clinical and clinical research and drug development activities for the Licensed Products (including Clinical Studies), the Manufacturing Cost of Clinical Supply for Licensed Products and other drugs, biological products or devices used in such Clinical Studies (including Development FTE Costs and Out-of-Pocket Expenses to purchase or package Third Party drugs, biological products and devices) and Development FTE Costs and Out-of-Pocket Expenses for disposal of clinical samples;
(iii)with respect to regulatory activities for the Licensed Products, Development FTE Costs and Out-of-Pocket Expenses for fees incurred in connection with regulatory filings (including INDs/CTAs and Drug Approval Applications) and regulatory approvals and for meetings with Regulatory Authorities; and

33
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

(iv)any other Development FTE Costs and Out-of-Pocket Expenses incurred that are expressly included in the Development Budget.
Notwithstanding anything to the contrary, Shared Development Costs do not include [***] (the “Included Medical Affairs Studies Costs Limit”). 
6.2.3.2Global Development Plan and Budget.  ​
(a)General.  Janssen will conduct Development of Licensed Products in accordance with the Global Development Plan.  “Global Development Plan” or “GDP” means the written plan for Janssen’s Development of Licensed Products in the Territory containing the information set forth in Section 6.2.3.2(b) below, as it may be amended from time to time in accordance with the terms of Section 6.2.3.2(c).  The GDP will include the Development Budget, as described in Section 6.2.3.2(b)(iii) below.  
(b)GDP Contents.  
(i)The GDP will include all Development activities that are reasonably necessary to seek, obtain and maintain Commercialization Approval, and to support and sustain Commercialization, of the Licensed Products in the Territory.
(ii)The GDP will at all times reflect Commercially Reasonable Efforts to Develop and seek Marketing Approval for one Licensed Product for one Indication in the U.S., each of the Major European Countries and Japan.
(iii)The GDP will include a [***] budget for Shared Development Costs to be incurred by Janssen in conducting the Development activities described in the GDP that are scheduled to be commenced or conducted during the then-current Calendar Year and the succeeding Calendar Year (with respect to such Calendar Years, the “Development Budget”).  The [***]of each Development Budget will be binding on the Parties to the extent provided in Section 6.2.3.4(d), and [***] of such Development Budget will serve as non-binding guidance for the Parties.
(iv)The GDP will also describe Included Medical Affairs Studies.  “Included Medical Affairs Studies” means post-marketing commitments and other post-approval Clinical Studies conducted in support of obtaining Marketing Approval of a Licensed Product (e.g., IISs, cooperative group studies, or studies conducted by Janssen for an additional Indication or label expansion).  Each Development Budget will include an amount for Included Medical Affairs Studies for each Calendar Year covered by such budget.
(c)Initial GDP; Updates and Amendments.  
(i)The clinical development plan and budget included in the POC Data Package delivered by Janssen to Xencor under Section 6.2.1 will be the initial GDP and Development Budget for the Licensed Products.  The GDP (including the Development 

34
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

Budget) may be updated and amended from time to time only with the approval of the JDC (or Janssen, under Section 2.5), as described below in this Section 6.2.3.2(c).
(ii)The JDC will review the GDP annually.  Janssen will prepare, and submit to the JDC for review, an updated GDP (excluding the Development Budget) on or before [***] of the then-current Calendar Year.  When Janssen is preparing the updated GDP, Janssen will reasonably consider Xencor’s input into the Clinical Study design and key Development activities in the GDP.  Janssen will prepare, and submit to the JDC for review, an updated Development Budget covering each of [***] Calendar Years on or before [***] of the then-current Calendar Year.
(iii)The JDC will use reasonable efforts to grant preliminary approval of such updates no later than [***] of each Calendar Year.
(iv)Promptly after the JDC’s preliminary approval, such updates will be submitted to each Party for its internal budgeting process.
(v)After each Party performs its internal budgeting process, the JDC will use reasonable efforts to grant final approval of such updates no later than [***] of each Calendar Year, at which time any approved updates will be set forth in writing in an amended version of the GDP.
(vi)Either Party may submit a proposed update or amendment to the GDP to the JDC from time to time.  The JDC will discuss such proposal at its next meeting and decide whether to approve such update or amendment.
(d)If the JDC approves an update or amendment to the GDP (including any corresponding update or amendment to the Development Budget), the GDP (including the Development Budget) will be deemed to be amended accordingly on the date of such approval.  No update or amendment to the GDP will become effective unless and until the JDC (or Janssen, under Section 2.5) approves a corresponding update or amendment to the Development Budget.
6.2.3.3Conduct of Development Activities.  ​
(a)General.  Section 4.3.1 will no longer apply to any Licensed Products on and after the Co-Funding Option Exercise Date.  Janssen will use Diligent Efforts to execute and to perform, or cause to be performed, the Development activities in the GDP for the Licensed Products, in accordance with the timetables in the GDP.
(b)Responsibility for Development Activities. Janssen will be solely responsible for conducting all Clinical Studies and all other Development activities in the GDP and CMC Development Activities for the Licensed Products.
(c)Safety Concerns.  

35
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

(i)Notwithstanding anything to the contrary in this Agreement or the GDP, Janssen will not be obligated to commence or continue a Clinical Study of a Licensed Product if Janssen reasonably determines that such Clinical Study would pose an unacceptable safety or tolerability risk for the study subjects.  Janssen will so notify Xencor of its determination and the Parties will discuss the concerns in good faith to determine whether to terminate, suspend, modify or continue such Clinical Study.
(ii)If Xencor believes in good faith that termination or suspension of a Clinical Study of the Licensed Products is warranted because of safety or tolerability risks to the study subjects, then Xencor will so notify Janssen and the Parties will discuss Xencor’s concerns in good faith to determine whether to terminate, suspend, modify or continue such Clinical Study.
(d)Development Reports.  Section 4.4.2.1 will cease to apply to the Licensed Products after Xencor exercises the Co-Funding Option in accordance with Section 6.2 but shall continue to apply after the Co-Funding Opt-Out Effective Date if Xencor provides Co-Funding Opt-Out Notice.  In advance of each meeting of the JDC, Janssen will provide to the JDC a high-level summary report summarizing (a) its Development activities with respect to the Licensed Products that Janssen and its Affiliates has performed or caused to be performed since the last meeting of the JDC, including an evaluation of the work performed, and the results thereof, in relation to the goals of the GDP, and (b) its anticipated Development activities with respect to the Licensed Products for the subsequent Calendar Quarter.
(e)Day-to-Day Responsibility.  Janssen will be responsible for day-to-day implementation of the Development activities with respect to the Licensed Products and will have the right to make operational and administrative decisions with respect to how to implement such Development activities (e.g., with respect to a Clinical Study, Janssen will have the right to select and engage clinical trial sites), as long as such decisions do not conflict with the GDP or any decision of the JDC with respect to such Development activity.
6.2.3.4Shared Development Costs. 
(a)Cost Sharing.  Shared Development Costs incurred on or after the Co-Funding Option Exercise Date by the Parties and their Affiliates will be borne 80% by Janssen and 20% by Xencor, except as provided in Section 6.2.3.4(b).
(b)Medical Affairs Study Costs.   Included Medical Affairs Studies Costs for Licensed Products will be included in Shared Development Costs up to the Included Medical Affairs Studies Costs Limit.  Development FTE Costs and Out-of-Pocket Expenses costs incurred to conduct studies to support reimbursement and other types of medical affairs studies that are not Included Medical Affairs Studies will not be included in Shared Development Costs or shared by Janssen and Xencor and will be borne entirely by Janssen.  Janssen shall bear all Included Medical Affairs Studies Costs in excess of the Included Medical Affairs Studies Costs Limit.
(c)Cost Reports.

36
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

(i)Shared Development Costs will initially be borne by the Party incurring the cost or expense, subject to reimbursement as provided in Section 6.2.3.4(d).  Each Party will calculate and maintain records of Shared Development Costs incurred by it and its Affiliates in accordance with procedures to be established by the JFC in coordination with the JDC.
(ii)The procedures for quarterly reporting of actual results, quarterly review and discussion of potential discrepancies, quarterly reconciliation, reasonable cost forecasting, and other finance and accounting matters related to Shared Development Costs will be prepared by Janssen and approved by the JFC (the “Development Reconciliation Procedures”).  When Janssen is preparing the Development Reconciliation Procedures, Janssen will reasonably consider Xencor’s input.
(iii)The Development Reconciliation Procedures will provide that, within [***] after the end of each Calendar Quarter, each Party will submit to the JFC a report, in a format established by the JFC, of all Shared Development Costs incurred by such Party and its Affiliates during such Calendar Quarter (each, a “Cost Report”).  Within [***] following the receipt of each Cost Report, each Party will have the right to request reasonable additional information (as determined by the JFC) related to the other Party’s and its Affiliates’ Shared Development Costs during such Calendar Quarter in order to confirm that such other Party’s spending is in conformance with the approved Development Budget.  
(iv)Janssen will prepare and the JFC will approve reasonable procedures for the Parties to share estimated Shared Development Costs for each Calendar Quarter before the end of such Calendar Quarter, to enable each Party to appropriately accrue its share of Shared Development Costs for financial reporting purposes.  Janssen’s representatives on the JFC will have the primary responsibility for performing the reconciliation in accordance with the Development Reconciliation Procedures.
(d)Reimbursement of Shared Development Costs.
(i)The Party (with its Affiliates) that incurs more than its share of the total actual Shared Development Costs with respect to a Calendar Quarter will be paid by the other Party an amount of cash sufficient to reconcile to its agreed percentage of actual Shared Development Costs in such Calendar Quarter under Section 6.2.3.4(a).  Notwithstanding the foregoing, on a Calendar Year-to-date basis, the Parties will not share any Shared Development Costs in excess of the amounts allocated for such Calendar Year-to-date period in the Development Budget, except as follows:
(1)Shared Development Costs in excess of the Development Budget will be included in the calculation of Shared Development Costs to be shared by the Parties to the extent such excess Shared Development Costs do not exceed [***] of the total Shared Development Costs allocated to be incurred by such Party and its Affiliates in the applicable Calendar Year-to-date period in accordance with the Development Budget for such Calendar Year; and

37
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

(2)the Parties will share any and all Shared Development Costs in excess of the Development Budget to the extent attributable to: (A) a change in applicable Law; (B) Force Majeure; (C) a variation in actual patient enrollment from projected patient enrollment; (D) a change to a clinical trial protocol required or requested by any Governmental Authority; (E) increases in the costs of comparator drugs; or (F) increases to Manufacturing Cost of Clinical Supply of a Licensed Product.
(ii) If any excess Shared Development Costs are excluded from sharing by the Parties for a particular Calendar Year-to-date period pursuant to Section 6.2.3.4(d)(i)(1), such excess Shared Development Costs will be carried forward to the subsequent Calendar Quarters (provided that such Calendar Quarters fall within the same Calendar Year) and, to the extent the total Shared Development Costs incurred by such Party and its Affiliates for the Calendar Year-to-date as of the end of such subsequent Calendar Quarter are less than [***] of the aggregate Shared Development Costs allocated to such Party under the Development Budget for such Calendar Year-to-date period, such carried forward amounts will be included in Shared Development Costs to be shared by the Parties for such Calendar Year-to-date-period (i.e., so that the total Shared Development Costs incurred by such Party and its Affiliates that are shared pursuant to this Section during any Calendar Year do not exceed [***] of the Shared Development Costs allocated to such Party under the Development Budget for such Calendar Year, unless otherwise approved by the JDC).  For clarity, at the end of the Calendar Year, any amounts in excess of [***] of the aggregate Shared Development Costs allocated to such Party under the Development Budget for such Calendar Year will be borne solely by such Party and will not be shared by the other Party.
(iii) The Development Reconciliation Procedures will require the JFC to develop a written report setting out the calculation of any net amount owed by Xencor to Janssen or by Janssen to Xencor, as the case may be, as necessary to accomplish the sharing of Shared Development Costs set forth in this Section, and to prepare such report promptly following delivery of the Cost Reports and in a reasonable time (to be defined in the Development Reconciliation Procedures) in advance of payment.
(iv)The net amount payable to accomplish the sharing of Shared Development Costs as provided under this Section will be paid by Janssen or Xencor, as the case may be, [***] after the end of the applicable Calendar Quarter.
6.2.4Co-Funding Opt-Out.  Xencor may elect to terminate its rights and obligations set forth in this ARTICLE 6 (“Co-Funding Opt-Out”), including its obligation to co-fund worldwide Development of Licensed Products in the Territory, by giving notice to Janssen (the “Co-Funding Opt-Out Notice”) at any time after the Co-Funding Option Exercise Date.  Such Co-Funding Opt-Out shall become effective on the last day of the second full Calendar Quarter after Xencor gives the Co-Funding Opt-Out Notice (the “Co-Funding Opt-Out Effective Date”).  For example, if Xencor gives the Co-Funding Opt-Out Notice in the first Calendar Quarter of a Calendar Year, then the Co-Funding Opt-Out would be effective as of the last day of the third Calendar Quarter of such Calendar Year.  After the Co-Funding Opt-Out Effective Date, the following will apply:

38
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

(a) Xencor will have no further rights or obligations under Section 6.2.3, including no obligation to pay any portion of Shared Development Costs incurred or attributable to Development activities after the Co-Funding Opt-Out Effective Date, except for reporting and reimbursement of Shared Development Costs incurred on or prior to the Co-Funding Opt-Out Effective Date. 
(b)Janssen will have no further rights or obligations under Section 6.2.3 except for reporting and reimbursement of Shared Development Costs incurred on or prior to the Co-Funding Opt-Out Effective Date. 
(c)The JDC and JFC will disband automatically, except as necessary to resolve matters within their authority relating to Development prior to the Co-Funding Opt-Out Effective Date. 
(d)For all purposes of Sections 2.2.2, 4.4.2.1 and 11.8, Xencor will be deemed to have never exercised the Co-Funding Option. 
(e)For purposes of Section 7.3, after the Co-Funding Opt-Out Effective Date all future Sales Milestone Payments will be calculated in accordance with the table in Section 7.3.1.  If a Co-Funding Sales Milestone Event has previously occurred under Section 7.3.2, no Sales Milestone Payment (nor the difference between the corresponding Co-Funding Sales Milestone Payment and Sales Milestone Payment amounts) will be payable under Section 7.3.1 for the corresponding Sales Milestone Event.  For example, [***]. 
(f)For purposes of Section 7.4, after the Co-Funding Opt-Out Effective Date royalties will be calculated and payable on the terms set forth in Section 7.4.1.1.  If the Co-Funding Opt-Out Effective Date is not the last day of a Calendar Year, the royalty calculations will continue to be based on cumulative Net Sales in the Calendar Year in which the Co-Funding Opt-Out Effective Date occurred, but the royalty calculations will be made using the royalty rates in Section 7.4.1.1 beginning in the Calendar Quarter immediately following the Co-Funding Opt-Out Effective Date.
(g)The Shared Development Costs incurred [***] (the “Co-Funding Wind-down Period”) shall continue to be shared by the Parties on the terms set forth in Section 6.2.3, provided, however, that if Janssen amends the GDP to increase the aggregate amount of the Development Budget for such Calendar Quarters, then the incremental amount of the increase approved by Janssen shall be excluded from Shared Development Costs for purposes of Section 6.2.3 during the Co-Funding Wind-down Period. 
(h)If Xencor exercised the Co-Detailing Option before giving the Co-Funding Opt-Out Notice, then Xencor will be obligated to continue conducting Detailing activities in accordance with Section 6.3.3 until [***]. 
(i)The first two sentences of Section 4.4.2.1 will apply. 
(j)Section 4.3.1 will apply.  

39
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

For clarity, Xencor’s exercise of the Co-Funding Opt-Out is irrevocable as of the date of the Co-Funding Opt-Out Notice.  Except as provided in this Section 6.2.4, this ARTICLE 6, Section 7.3.2 and Section 7.4.1.2 will be of no further force and effect after the Co-Funding Opt-Out Effective Date.
6.3Co-Detailing Option.  If Xencor exercises the Co-Funding Option in accordance with Section 6.2, Xencor may exercise the Co-Detailing Option on the terms set forth in this Section 6.3.
6.3.1Co-Detailing Data Package.  ​
6.3.1.1Janssen will notify Xencor of the expected date of the first Marketing Approval of the first Licensed Product in the U.S. (as reasonably determined by Janssen) at least [***]. 
6.3.1.2Within [***] of such notice, Xencor will notify Janssen of whether it requests Janssen to prepare and deliver a data package with respect to such Licensed Product (a “Co-Detailing Data Package”).  The Co-Detailing Data Package will include the following information relating to the Detailing in the U.S. of such Licensed Product, to the extent it is in Janssen’s possession: [***].
6.3.1.3If Xencor requests the Co-Detailing Data Package, Janssen will provide the Co-Detailing Data Package to Xencor within [***].  If Xencor notifies Janssen within [***] after receipt of the Co-Detailing Data Package that it is not complete, Janssen will provide any missing information as soon as practicable.  The date on which Xencor is in receipt of a complete Co-Detailing Data Package is referred to as the “Co-Detailing Data Package Delivery Date.”
6.3.2Exercise of Co-Detailing Option.  Xencor may exercise the Co-Detailing Option by providing notice to Janssen on or before the date that is [***] before the expected date of the first Marketing Approval of the first Licensed Product in the U.S. (as reasonably determined by Janssen and communicated to Xencor) or, if later, [***] after the Co-Detailing Data Package Delivery Date.  The date of such notice is referred to as the “Co-Detailing Option Exercise Date.”  If Xencor does not exercise the Co-Detailing Option before such date, the Co-Detailing Option will not apply to any Licensed Products and the Co-Detailing Option will terminate. 
6.3.3Effect of Exercise of Co-Detailing Option.  On and after the Co-Detailing Option Exercise Date, the terms and conditions set forth in this Section 6.3.3 will apply with respect to the Detailing of Licensed Products in the U.S.:
6.3.3.1Xencor will have the right to perform up to thirty percent (30%) of the Detailing efforts for each Licensed Product in the U.S. for all approved Indications.  Janssen will be responsible for performing the remainder of the Detailing efforts.  Janssen will otherwise continue to have sole responsibility for and authority over all Commercialization activities in the U.S., including pricing and reimbursement matters.

40
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

6.3.3.2Xencor will select its Detailing effort percentage and specify it in its Co-Detailing Option notice provided to Janssen under Section 6.3.1.  Xencor will be required to demonstrate to Janssen its capabilities to provide the selected level of Detailing efforts, including employing an appropriate number of individuals with the appropriate qualifications (meeting the same criteria and standards that apply to Janssen’s own personnel).  Xencor’s capabilities will be evaluated and reasonably determined by Janssen.  Janssen will notify Xencor if, after its evaluation, Janssen determines that Xencor is not capable of providing the selected level of Detailing efforts and shall explain Xencor’s deficiencies in reasonable detail.  Xencor shall have [***] days to remedy such deficiencies.  Xencor will be responsible for performing its elected percentage of Detailing efforts.
6.3.3.3Janssen may terminate the Co-Detailing Option and Xencor’s rights under this Section 6.3.3 and under the Co-Detailing Agreement in the event of the occurrence of a Change of Control of Xencor or an assignment of this Agreement in its entirety by Xencor (other than an assignment to an Affiliate of Xencor) by giving Xencor [***] notice at any time after the occurrence of such event.
6.3.3.4After the Co-Detailing Option Exercise Date, and on an annual basis after such date, Janssen will prepare and provide to Xencor for its review and comment Janssen’s written plan for the Detailing of and allocation of calls for Licensed Products in the U.S. (the “Co-Detailing Plan”).  The Parties will discuss, and Janssen will consider in good faith Xencor’s comments on, the Co-Detailing Plan before Janssen finalizes the plan.  Janssen will use the Co-Detailing Plan to allocate the Parties’ responsibilities for Details.
6.3.3.5Promptly after the Co-Detailing Option Exercise Date, the Parties will negotiate in good faith to enter into a separate co-detailing agreement with respect to the co-Detailing of Licensed Products in the U.S. on commercially reasonable terms (the “Co-Detailing Agreement”).  In addition to such usual and customary terms that are typically found within co-detailing agreements, the Co-Detailing Agreement will include the terms set forth below in this Section 6.3.3.5:  [***]
6.3.3.6 “Detail” means an interactive face-to-face visit by a sales representative with a medical professional having prescribing authority or who is able to influence prescribing decisions, within the target audience during which approved uses, safety, effectiveness, contraindications, side effects, warnings or other relevant characteristics of a pharmaceutical product are discussed in an effort to increase prescribing preferences of a pharmaceutical product for its approved uses. Activities conducted by medical support staff (such as medical science liaisons), key account managers, thought leader liaisons and managed markets/reimbursement team will not constitute Details.  E-details, activities conducted at conventions or similar gatherings and activities performed by market development specialists, managed care account directors and other personnel not performing face-to-face sales calls or not specifically trained with respect to a pharmaceutical product will not constitute Details. “Detailing” means the act of performing Details and to “Detail” mean to perform Details.

41
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

ARTICLE 7​
FINANCIAL PROVISIONS
7.1Upfront Payment.  Janssen will make a non-refundable, non-creditable payment of US$50 million to Xencor within [***] Business Days after the Effective Date. 
7.2Development and Regulatory Milestones. ​
7.2.1Milestone Payments and Events.  Janssen will make the payments set forth in the table below (each, a “Milestone Payment”) to Xencor within [***] after Xencor delivers an invoice to Janssen upon the first occurrence of the corresponding milestone event set forth below (each, a “Milestone Event”).  Janssen will notify Xencor within [***] Business Days after the first occurrence of any of the Milestone Events.   
[***] 
​
7.2.2Rules regarding Determination of Milestone Payments and Events.  [***]
7.2.2.1The Milestone Payments under this Section 7.2 will be non-refundable and non-creditable.  Each Milestone Payment shall be payable only once upon the first occurrence of the relevant Milestone Event by a Licensed Product, even if the Milestone Event occurs with respect to more than one Licensed Product, with respect to more than one Indication, multiple times with respect to the same Licensed Product or multiple times with respect to the same Indication.
7.3Sales Milestones.  ​
7.3.1Sales Milestones if Xencor does not Exercise Co-Funding Option.  If Xencor does not exercise the Co-Funding Option in accordance with Section 6.2, then this Section 7.3.1 will apply and Section 7.3.2 will not apply.  Janssen will notify Xencor in the applicable royalty report delivered pursuant to Section 7.4.5 the first time the aggregate Net Sales of all Licensed Products in any Calendar Year by Janssen, its Affiliates and its sublicensees in the Territory exceed the amounts set forth in the table set forth below in this Section 7.3.1 (each, a “Sales Milestone Event”); provided, however, that Net Sales of a particular Licensed Product in a particular country occurring after expiration of the Royalty Term for such Licensed Product in such country will be disregarded in the calculation of Net Sales for purposes of this Section 7.3.1.  Janssen will pay to Xencor the applicable milestone payments set forth in the table below (each, a “Sales Milestone Payment”) within [***] after receipt of an invoice from Xencor with respect to achievement of each Sales Milestone Event.  
	Sales Milestone Event
	Sales Milestone Payment

	[***]
	[***]

	[***]
	[***]

42
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

	[***]
	[***]

	[***]
	[***]

​
7.3.2Sales Milestones if Xencor Exercises Co-Funding Option.  If Xencor exercises the Co-Funding Option in accordance with Section 6.2, Section 7.3.1 will not apply and instead this Section 7.3.2 will apply.  Janssen will notify Xencor in the applicable royalty report delivered pursuant to Section 7.4.5 the first time the aggregate Net Sales of all Licensed Products in any Calendar Year by Janssen, its Affiliates and its sublicensees in the Territory exceed the amounts set forth in the table set forth below in this Section 7.3.2 (each, a “Co-Funding Sales Milestone Event”); provided, however, that Net Sales of a particular Licensed Product in a particular country occurring after expiration of the Royalty Term for such Licensed Product in such country will be disregarded in the calculation of Net Sales for purposes of this Section 7.3.2.  Janssen will pay to Xencor the applicable milestone payments set forth in the table below (each, a “Co-Funding Sales Milestone Payment”) within [***] days after receipt of an invoice from Xencor with respect to achievement of each Co-Funding Sales Milestone Event.  
	Co-Funding Sales Milestone Event
	Co-Funding Sales Milestone Payment

	[***]
	[***]

	[***]
	[***]

	[***]
	[***]

	[***]
	[***]

​
7.3.3Rules regarding Determination of Sales Milestone Payments and Events.  [***]
7.4Royalties.  ​
7.4.1Royalty Rates.  ​
7.4.1.1Royalty Rates if Xencor does not Exercise Co-Funding Option.  If Xencor does not exercise the Co-Funding Option in accordance with Section 6.2, this Section 7.4.1.1 will apply and Section 7.4.1.2 will not apply.  Subject to Section 7.4.2 through Section 7.4.6, Janssen will pay to Xencor royalties on the aggregate Net Sales of Licensed Products by Janssen, its Affiliates and sublicensees during the applicable Royalty Term in the Territory during each Calendar Year at the rates set forth in the table below in this Section 7.4.1.1.  For clarity, Net Sales of all Licensed Products will be aggregated for purposes of calculation of royalties pursuant to this Section 7.4.1.1; provided, however, that Net Sales of a particular Licensed Product in a particular country occurring after expiration of the Royalty Term for such 

43
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

Licensed Product in such country will be disregarded in the calculation of royalties pursuant to this Section  7.4.1.1.
	Annual Aggregate Net Sales of Licensed Products in the Territory
	Royalty Rate

	For that portion of annual Net Sales of Licensed Products in the Territory in such Calendar Year less than US$[***]
	[***]

	For that portion of annual Net Sales of Licensed Products in the Territory in such Calendar Year greater than or equal to US$[***] and less than US$[***]
	[***]

	For that portion of annual Net Sales of Licensed Products in the Territory in such Calendar Year greater than or equal to US$[***]
	[***]

​
[***]  
7.4.1.2Royalty Rates if Xencor Exercises Option.  If Xencor exercises the Co-Funding Option in accordance with Section 6.2, this Section 7.4.1.2 will apply and Section 7.4.1.1 will not apply.  Subject to Section 7.4.2 through Section 7.4.6, Janssen will pay to Xencor royalties on the aggregate Net Sales of Licensed Products by Janssen, its Affiliates and sublicensees during the applicable Royalty Term in the Territory during each Calendar Year at the rates set forth in the table below in this Section 7.4.1.2.  For clarity, Net Sales of all Licensed Products will be aggregated for purposes of calculation of royalties pursuant to this Section 7.4.1.2; provided, however, that Net Sales of a particular Licensed Product in a particular country occurring after expiration of the Royalty Term for such Licensed Product in such country will be disregarded in the calculation of royalties pursuant to this Section 7.4.1.2.
	Annual Aggregate Net Sales of Licensed Products in the Territory
	Co-Funding Royalty Rate

	For that portion of annual Net Sales of Licensed Products in the Territory in such Calendar Year less than US$[***]
	[***]

	For that portion of annual Net Sales of Licensed Products in the Territory in such Calendar Year greater than or equal to US$[***] and less than US$[***]
	[***]

	For that portion of annual Net Sales of Licensed Products in the Territory in such Calendar Year greater than or equal to US$[***]
	[***]

​
[***]  

44
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

7.4.2Royalty Term.  Royalties will be paid on a Licensed Product-by-Licensed Product and country-by-country basis, beginning with the First Commercial Sale of a Licensed Product in a country and ending on the later of: (a) the expiration of the last-to-expire Valid Claim of a Royalty-Bearing Patent with respect to the Licensed Product in the country; (b) the expiration of Regulatory Exclusivity for the Licensed Product in the country, if any; or (c) the 12th anniversary of the First Commercial Sale of such Licensed Product in such country (the “Royalty Term”).  “Royalty-Bearing Patent” means, with respect to a Licensed Product: (i) a Xencor Patent or Joint Patent that Covers the composition of matter or any method of use of such Licensed Product; or (ii) a Patent [***] Controlled by Janssen or any of its Affiliates during the Term that Covers the composition of matter of the Licensed Antibody contained in such Licensed Product.  [***]     
7.4.3Royalty Reductions; Third Party Royalty Payments.  ​
7.4.3.1Reductions for Loss of Exclusivity.  On a country-by-country and Licensed Product-by-Licensed Product basis, the royalties due to Xencor under Section 7.4.1.1 or 7.4.1.2, as applicable, will be reduced during the Royalty Term to an amount equal to [***] of the amount otherwise payable on Net Sales of such Licensed Product in such country from and after the later of (i) the date that there is no Valid Claim of a Xencor Patent or Joint Patent in such country that Covers the composition of matter or any method of use of such Licensed Product or (ii) if any Regulatory Exclusivity is granted with respect to such Licensed Product in such country, the date on which all such Regulatory Exclusivity expires.  Such reduction will be subject to Section 7.4.3.3 and applied in accordance with Section 7.4.3.4.
7.4.3.2Third Party Royalty Payments.  ​
(a)Subject to Section 7.4.3.2(b) and Section 7.4.3.2(c), if Janssen (or its Affiliate) [***] licenses under any Patents or Know-How of any Third Party for the manufacture, use or sale of a Licensed Antibody or Licensed Product (other than with respect to any active ingredient that is not a Licensed Antibody) in a country (each, a “Third Party License”), Janssen will have the sole right (but not the obligation) to negotiate and obtain any such license with respect to the applicable Licensed Antibody or Licensed Product.  For clarity, Xencor retains a right to negotiate and obtain licenses under any Patents or Know-How of any Third Party with respect to Antibodies and products of Xencor that are not Licensed Antibodies or Licensed Products. 
(i)With respect to such Patents or Know-How [***] for the manufacture, use or sale of a Licensed Antibody or Licensed Product, Janssen will have the right to deduct [***] of the royalties actually paid to such Third Party(ies) under the applicable Third Party License(s) by Janssen (or by such Affiliate or, to the extent offset against royalties paid to Janssen, its sublicensee, as applicable) with respect to sales of the applicable Licensed Product in such country in a Calendar Quarter from the royalty payments payable by Janssen to Xencor with respect to Net Sales of such Licensed Product in such country in such Calendar Quarter.
(ii)With respect to such Patents or Know-How [***] for the manufacture, use or sale of a Licensed Antibody or Licensed Product (e.g. formulation 

45
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

technology or for ease of administration), Janssen will have the right to deduct [***] of the royalties actually paid to such Third Party(ies) under the applicable Third Party License(s) by Janssen (or by such Affiliate or, to the extent offset against royalties paid to Janssen, its sublicensee, as applicable) with respect to sales of the applicable Licensed Product in such country in a Calendar Quarter from the royalty payments payable by Janssen to Xencor with respect to Net Sales of such Licensed Product in such country in such Calendar Quarter.  
(iii)Such deductions will be subject to Section 7.4.3.3 and applied in accordance with Section 7.4.3.4.
(b)If a Party becomes aware that it is necessary to obtain one or more licenses under any Patents or Know-How of any Third Party in order to practice any Xencor Binding Domain for a Licensed Antibody (including for a Licensed Antibody contained in a Licensed Product) in a country, such Party will promptly notify the other Party.  Xencor will have the sole responsibility and right to negotiate and obtain such license, provided that such license does not impose any liability, restriction or obligation on Janssen (beyond the terms and conditions in connection with the practice of such license) without Janssen’s consent.  Such Third Party’s Patents or Know-How, as applicable, will be included in the Xencor Research Patents, Xencor Patents or Xencor Research Know-How, as applicable.  Xencor will be responsible for all payments under such license.
(c)If a Party becomes aware that it is necessary to obtain one or more licenses under any Patents or Know-How of any Third Party in order to practice any Janssen Binding Domain for a Licensed Antibody (including for a Licensed Antibody contained in a Licensed Product) in a country, such Party will promptly notify the other Party.  Janssen will have the sole responsibility and right to negotiate and obtain such license, provided that such license does not impose any liability, restriction or obligation on Xencor (beyond the terms and conditions in connection with the practice of such license) without Xencor’s consent.  Such Third Party’s Patents or Know-How, as applicable, will be included in the Janssen Research Patents or Janssen Research Know-How, as applicable.  Janssen will be responsible for all payments under such license.
7.4.3.3Royalty Floor.  In no event will the total reductions and deductions under Sections 7.4.3.1 and 7.4.3.2 reduce the royalties payable to Xencor under Section 7.4.1.1 or 7.4.1.2, as applicable, with respect to a given Licensed Product in a given country in any Calendar Quarter by more than [***] of the amount that would otherwise be payable if such reductions and deductions were not made.
7.4.3.4Royalty Calculation.  If the royalties payable with respect to Net Sales of a Licensed Product in a country in a Calendar Quarter are subject to reduction under Section 7.4.3.1 or deductions under Section 7.4.3.2, the royalties payable with respect to such Net Sales will be calculated as follows:
(a)First, determine the aggregate Net Sales of such Licensed Product in such country during such Calendar Quarter that occurred during the applicable Royalty Term (the “Quarterly Net Sales”).

46
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

(b)Second, determine the Effective Royalty Rate for the applicable Calendar Quarter.  The “Effective Royalty Rate” means, with respect to a particular Calendar Quarter, the amount (expressed as a percentage) equal to A ÷ B (i.e., A divided by B), where:
(i)A = Aggregate amount of royalties payable under Section 7.4.1.1 or 7.4.1.2, as applicable, applying the relevant royalty tiers, on aggregate annual Net Sales of Licensed Products in the Territory during such Calendar Quarter before applying any reductions under Section 7.4.3.1 or deductions under Section 7.4.3.2; and
(ii)B = Aggregate annual Net Sales of Licensed Products in the Territory during such Calendar Quarter (excluding any Net Sales of such Licensed Products that occurred after the expiration of the applicable Royalty Term).
(c)Third, multiply the Effective Royalty Rate by the Net Sales of such Licensed Product in such country in such Calendar Quarter that occurred during the applicable Royalty Term to determine the royalties that would have been payable on the Quarterly Net Sales under Section 7.4.1.1 or 7.4.1.2, as applicable, if no reduction or deduction applied under Section 7.4.3.1 or 7.4.3.2 (the “Unadjusted Quarterly Royalties” for such country).
(d)Last, reduce the Unadjusted Quarterly Royalties for such country to the amount specified in Section 7.4.3.1 and by the amount(s) specified in Section 7.4.3.2, as applicable, in each case, to the extent allowable by Section 7.4.3.3.
7.4.4Expiration of Royalty Term.  Upon the expiration of the Royalty Term with respect to a Licensed Product in a country, Xencor hereby grants to Janssen a perpetual, irrevocable, non-exclusive, fully-paid and royalty-free right and license, with the right to grant sublicenses, under the Xencor Intellectual Property to Exploit such Licensed Product in the Field in such country.  For clarity, after the Royalty Term expires with respect to a Licensed Product in a country, the calculation of annual aggregate Net Sales of such Licensed Product in the Territory will exclude sales of such Licensed Product in such country.
7.4.5Royalty Reports and Payments.  Commencing with the First Commercial Sale of a Licensed Product by Janssen or its Affiliates or sublicensees in the Territory, royalty payments are due and payable [***] after the end of each Calendar Quarter in which royalties are applicable.  Each payment of royalties under this Agreement will be accompanied with a report setting forth, by region (which regions will be the U.S., Canada, Japan, China, each of the Major European Countries and all other countries in the Territory), the Net Sales, the applicable royalty rate and the amount of royalty payment due on such Net Sales.  Additionally, Janssen will provide Xencor with a non-binding estimate of each royalty payment for each Calendar Quarter within [***] after the end of such Calendar Quarter. All reports delivered by Janssen under this Section will be Confidential Information of Janssen.  
7.4.6Royalty Conditions.  All royalties due to Xencor under this Section 7.4 are subject to the following conditions: (a) only one royalty will be due with respect to the same unit of Licensed Product; and (b) no royalties will be due upon the sale or other transfer among Janssen or its Affiliates, but in such cases the royalty will be due and calculated upon Janssen’s or its 

47
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

Affiliate’s Net Sales to the first independent Third Party, and distributors of Janssen selling Licensed Product that are not otherwise sublicensees will not, for this purpose, be deemed to be sublicensees of Janssen and will instead be considered as independent Third Parties.
7.5Payment Terms.  ​
7.5.1Payment Instruction.  All payments to be made by a Party hereunder will be made in Dollars by electronic funds transfer to the bank account as will be designated by the Party receiving the payment.
7.5.2Exchange Rate.  If any amounts that are relevant to the determination of amounts to be paid under this Agreement or any calculations to be performed under this Agreement are received or paid or initially reported in a currency other than U.S. Dollars, then such amounts will be converted to their U.S. Dollar equivalent as follows:   ​
7.5.2.1Janssen will notify Xencor in writing of Johnson & Johnson’s Currency Hedge Rate for a given Calendar Year in advance of such Calendar Year, within [***] after the Currency Hedge Rate(s) are available from the GTSC or its Affiliates, which is customarily at the end of November of the preceding Calendar Year.
7.5.2.2Then: (i) the Currency Hedge Rate(s) as provided in the notice to Xencor will remain constant throughout the applicable Calendar Year; and (ii) Janssen will use such Currency Hedge Rate(s) to convert non-U.S. Dollar amounts to U.S. Dollars for the purpose of calculating Net Sales, royalties and the achievement of Sales Milestone Events or Co-Funding Sales Milestone Events, as applicable, for each Calendar Quarter in the applicable Calendar Year.
7.6Records; Audits.
7.6.1Records.  Each Party will keep, and cause its Affiliates and sublicensees to keep, complete and accurate records of the items underlying Shared Development Costs, Net Sales and any other elements required to prepare the reports or calculate payments required by under this Agreement.  Such records must be retained for a period of [***] following the relevant reporting period.
7.6.2Audits.  ​
7.6.2.1Each Party will have the right at its own expense to have an independent, certified public accountant of nationally recognized standing, selected by such Party and reasonably acceptable to the other Party, review any records of the other Party and its Affiliates that are required to be kept pursuant to Section 7.6.1 in the location(s) where such records are maintained by the other Party or its Affiliates upon prior written notice and during normal business hours and under obligations of confidence, for the sole purpose of verifying the basis and accuracy of payments made under this Agreement, within the prior [***] period.  Audits may not be conducted by a Party under this Section more than once every [***], and an audit of the records relating to a particular Calendar Year may be conducted not more than once.

48
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

7.6.2.2The report of the independent certified public accountant will be shared with the audited Party before distribution to the auditing Party so that the audited Party can provide the independent public accountant with justifying remarks for inclusion in the report before sharing the conclusions of such independent public audit with the auditing Party.  The final audit report will be shared with the auditing and audited Party at the same time and will specify whether the amounts paid to the auditing Party during the audited period were correct or, if incorrect, the amount of any underpayment or overpayment.  The audit report will only contain the information relevant to support the statement as to whether the amounts due under this Agreement were calculated and paid accurately and will not include any other confidential information (or other additional information that is ordinarily not included in the reports to the auditing Party) disclosed to the auditor during the course of the audit.
7.6.2.3If the review of such records reveals that the audited Party has failed to accurately report information pursuant to the relevant provisions of this Agreement or make any payment (or portion thereof) required under this Agreement, then the audited Party will pay, within [***] days after receipt of the final audit report by the audited Party, to the auditing Party any underpaid amounts due under this Agreement.  If any such discrepancies resulted in an underpayment of amounts due under this Agreement greater than [***] of the amounts actually due for the applicable audit period, the audited Party will pay all reasonable costs incurred in conducting such review.  If the audited Party disagrees with the findings of the audit report, the Parties will first seek to resolve the matter between themselves, and in the event they fail to reach agreement, the dispute resolution provisions set forth in ARTICLE 15 will apply.
7.7Taxes.  ​
7.7.1Withholding.
7.7.1.1Janssen will make all payments to Xencor under this Agreement without deduction or withholding for Taxes except to the extent that any such deduction or withholding is required by law in effect at the time of payment.
7.7.1.2Any Tax required to be withheld on amounts payable under this Agreement will be paid by Janssen on behalf of Xencor to the appropriate Governmental Authority, and Janssen will furnish Xencor with proof of payment of such Tax. Any such Tax required to be withheld will be an expense of and borne by Xencor. If any such Tax is assessed against and paid by Janssen, then Xencor will indemnify and hold harmless Janssen from and against such Tax.
7.7.1.3Janssen and Xencor will cooperate with respect to all documentation required by any taxing authority or reasonably requested by Janssen to secure a reduction in the rate of applicable withholding Taxes.  On the date of execution of this Agreement, Xencor will deliver to Janssen an accurate and complete Internal Revenue Service Form W-9.

49
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

7.7.2Indirect Taxes.  Amounts payable under this Agreement do not include any sales, use, excise, value added or other applicable taxes, tariffs or duties.  If any taxing authority imposes a VAT, GST, sales, use, service, consumption, business or similar Tax with respect to the work undertaken under this Agreement, then Janssen agrees to pay that amount if specified in a valid invoice or supply exemption documentation.  For avoidance of doubt, Xencor will not be entitled to pass on to Janssen, and Janssen will not be obligated to pay or bear, any Tax that is based on Xencor’s real, personal or intangible property (whether owned or leased), corporate structure, franchise, continuing business operations, income, gross receipts, capital stock, net worth or imposed with respect to Xencor’s engagement of employees or independent contractors or that Xencor incurs upon subcontracting any work hereunder, in whole or in part, to any affiliated or non-affiliated third party.  Xencor is solely responsible, to the extent required by applicable law, for identifying, billing, and collecting the Taxes payable by Janssen in all relevant federal, state, county, municipal and other taxing jurisdictions and for filing all required tax returns in a timely manner.  To the extent that Xencor does not provide Janssen a valid invoice (i.e., an invoice compliant with this Agreement and the rules and regulations of the jurisdiction of both Xencor and Janssen, including separate identification of the Tax where legally required), Xencor shall be responsible for any penalty resulting directly from such noncompliance.  The Parties will cooperate in good faith to minimize Taxes to the extent legally permissible.
ARTICLE 8​
LICENSE GRANTS; EXCLUSIVITY
8.1Grants.  ​
8.1.1Licenses to Janssen.  ​
8.1.1.1Research License.  Subject to the terms and conditions of this Agreement, Xencor hereby grants, on behalf of itself and its Affiliates, to Janssen during the Term an exclusive (even as to Xencor and its Affiliates, except with respect to performance of its obligations under this Agreement), royalty-bearing, non-transferable (except as provided in Section 16.1), sublicenseable (solely as provided in Section 8.2) license, under the Xencor Research Intellectual Property, to Research Licensed Antibodies in the Field in the Territory (the “Research License”).
8.1.1.2Commercial License.  Subject to the terms and conditions of this Agreement, Xencor hereby grants, on behalf of itself and its Affiliates, to Janssen during the Term an exclusive (even as to Xencor), royalty-bearing, non-transferable (except as provided in Section 16.1), sublicenseable (solely as provided in Section 8.2) license, under the Xencor Intellectual Property, to Exploit (but not to Research) Licensed Antibodies and Licensed Products in the Field in the Territory.  Janssen shall not Develop, Manufacture or Commercialize during the Term (i) any Licensed Antibody that is Researched using Know-How or Patents Controlled by Xencor or its Affiliates that are not licensed to Janssen pursuant to the Research License or (ii) any Licensed Product containing a Licensed Antibody described in clause (i).

50
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

8.1.1.3Other Antibodies and APIs.  Notwithstanding anything to the contrary, the licenses granted by Xencor to Janssen under this Section 8.1.1 with respect to Licensed Products do not grant any right or license under any Patent that Covers any composition of matter of any Antibodies or other active ingredients other than Licensed Antibodies.
8.1.2License to Xencor.  Subject to the terms and conditions of this Agreement, Janssen, on behalf of itself and its Affiliates, hereby grants to Xencor, during the Research Program Term, a non-exclusive, royalty-free, non-transferable (except as permitted under in Section 16.1), sublicensable (solely as provided in Section 8.2) license under (a) the Xencor Intellectual Property licensed to Janssen under Section 8.1.1 and (b) the Janssen Research Intellectual Property, in each case ((a) and (b)), solely to the extent necessary for Xencor to perform its obligations under this Agreement with respect to the Research Program.
8.1.3Cross-License.  ​
8.1.3.1Subject to the terms and conditions of this Agreement (including the restrictions set forth in Section 3.4.3 and Section 8.4 and the confidentiality obligations under ARTICLE 10), Xencor hereby grants to Janssen a non-exclusive, worldwide, irrevocable, royalty-free, perpetual license to use for all purposes any technical Know-How Controlled by Xencor and disclosed to Janssen pursuant to this Agreement; provided, however, that such license does not include (i) a grant of any rights to Janssen for any Exploitation of any Licensed Antibody or Licensed Product, (ii) a right to practice any Patents owned or Controlled by Xencor or its Affiliates, (iii) a right to practice any Xencor Platform Technology, (iv) a right to practice Know-How embodied by Materials supplied by Xencor to Janssen, or (v) a right to use any Materials provided by Xencor.  For clarity, this does not give Janssen the right to disclose any Confidential Information of Xencor.
8.1.3.2Subject to the terms and conditions of this Agreement (including the restrictions set forth in Section 3.4.3 and Section 8.4 and the confidentiality obligations under ARTICLE 10), Janssen hereby grants to Xencor a non-exclusive, worldwide, irrevocable, royalty-free, perpetual license to use for all purposes any technical Know-How Controlled by Janssen and disclosed to Xencor pursuant to this Agreement; provided, however, that such license does not include (i) a grant of any rights to Xencor for any Exploitation of any Licensed Antibody or Licensed Product, (ii) a right to practice any Patents owned or Controlled by Janssen or its Affiliates, (iii) a right to practice Know-How embodied by Materials supplied by Janssen to Xencor, or (iv) a right to use any Materials provided by Janssen.  For clarity, this does not give Xencor the right to disclose any Confidential Information of Janssen.
8.1.4License to Assigned Inventions.  Subject to the terms and conditions of this Agreement (including the restrictions set forth in Section 3.4.3 and Section 8.4 and the confidentiality obligations under ARTICLE 10), Xencor hereby grants to Janssen a non-exclusive, worldwide, irrevocable, royalty-free, perpetual license to use for all purposes any Janssen Assigned Invention; provided, however, that such license does not include (i) a grant of any rights to Janssen for the Exploitation of any Licensed Antibody or Licensed Product or (ii) a grant of any rights to practice, other than Janssen Assigned Inventions, any Patents or Know-

51
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

How owned or Controlled by Xencor or its Affiliates.  “Janssen Assigned Inventions” means the Inventions (and Patents filed thereon) that are assigned by Janssen to Xencor pursuant to Section 9.2.2.2(a) but not including those Inventions (and Patents filed thereon) primarily directed to an improvement of a Xencor Binding Domain.  
8.1.5Affiliates.  If any of the Patents or Know-How licensed by one Party to the other Party pursuant to this Section 8.1 is Controlled by an Affiliate of the licensing Party, the licensing Party will procure that such Affiliate grants the licenses to the other Party in accordance with this Section 8.1.
8.2Sublicensing.  ​
8.2.1Sublicenses by Janssen.  Janssen may grant and authorize sublicenses of any of the rights granted to it by Xencor under Section 8.1.1 and Section 8.1.3.2 without the consent of Xencor to one or more of its Affiliates or to one or more Third Parties through multiple tiers.  Janssen may grant and authorize sublicenses of any of the rights granted to it by Xencor under Section 8.1.3.1 without the consent of Xencor to one or more of its Affiliates.  Janssen may not grant or authorize sublicenses of any of the rights granted to it by Xencor under Section 8.1.3.1 to any Third Party without the prior written consent of Xencor, which will not be unreasonably withheld, delayed or conditioned. 
8.2.2Sublicenses by Xencor.  Xencor may grant and authorize sublicenses of any of the rights granted to it by Janssen under Section 8.1 without the consent of Janssen to one or more of its Affiliates.  Xencor may not grant or authorize sublicenses of any of the rights granted to it by Janssen under Section 8.1 to any Third Party without the prior written consent of Janssen, which will not be unreasonably withheld, delayed or conditioned.
8.2.3Sublicense Requirements.  Each sublicense will be pursuant to a written agreement that is subject to and consistent with the terms and conditions of this Agreement.  The sublicensing Party will remain directly responsible and fully liable to the other Party for the performance of the sublicensee in accordance with this Agreement.  The sublicensing Party will provide to the other Party a copy of each sublicense agreement within [***] following the execution thereof, provided that the sublicensing Party will be permitted to redact commercially sensitive terms to the extent such terms are not necessary for the other Party to confirm compliance with this Agreement.
8.3No Implied Licenses.  Neither Party grants to the other Party any rights or licenses in or to any Know-How, Patents or other intellectual property rights, whether by implication, estoppel, or otherwise, other than the rights and licenses that are expressly granted under this Agreement.
8.4Exclusivity.  ​
8.4.1Definitions.
8.4.1.1“Bispecific Competing Product” means [***]. 
8.4.1.2“Competing Product” means [***].

52
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

8.4.1.3“Derived Competing Product” means [***].  
8.4.1.4“First Exclusivity Period” means the period beginning on the Effective Date and ending on the earlier of (i) the last day of the Term or (ii) [***].
8.4.1.5“Scale-Up” means, with respect to a Licensed Product, that such Licensed Product has been successfully produced by or on behalf of Janssen or its Affiliates in a [***] that is at least [***] in volume.  
8.4.1.6“Second Exclusivity Period” means the period beginning [***] and ending on the earlier of (i) the last day of the Term or (ii) [***].
8.4.1.7[***].
8.4.2First Exclusivity Period.  During the First Exclusivity Period, neither Party nor any of its Affiliates will conduct, directly or indirectly, or collaborate with, license or otherwise grant any rights to any Third Party to conduct, any Research, non-clinical or clinical Development, Manufacture or Commercialization of any Competing Product in the Field in the Territory, except for use of Competing Products as research tools.
8.4.3Second Exclusivity Period. During the Second Exclusivity Period, neither Party nor any of its Affiliates will conduct, directly or indirectly, or collaborate with, license or otherwise grant any rights to any Third Party to conduct, any clinical Development (or activities to scale-up for clinical Development), Manufacture or Commercialization of any Bispecific Competing Product in the Field in the Territory.  For clarity, for all purposes of this Section 8.4.3, “clinical Development” excludes Research.
8.4.4Derived Competing Products.  During the Term, neither Xencor nor any of its Affiliates will conduct, directly or indirectly, or collaborate with, license or otherwise grant any rights to any Third Party to conduct, any Research, non-clinical or clinical Development, Manufacture or Commercialization of any Derived Competing Product in the Field in the Territory.  
8.4.5Effect of Xencor Change of Control.   ​
8.4.5.1If, on the date of consummation of a Change of Control of Xencor, the Acquirer of Xencor in such Change of Control transaction is conducting Research, Development, Manufacture or Commercialization activities with respect to a Competing Product that would otherwise be prohibited under Section 8.4.2 (an “Acquirer Competing Product”), [***]. 
​
8.4.5.2[***].  
​
8.4.5.3

53
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

(a)Except as provided in Section 8.4.5.3(b), the restrictions in Section 3.4.3.2 will apply to an Acquirer of Xencor and its Affiliates, and will continue to apply to Xencor and its other Affiliates, after the consummation of a Change of Control of Xencor.
​
(b)After the consummation of a Change of Control of Xencor, the restrictions in Section 3.4.3.2 will not apply to the Research, Development, Manufacture or Commercialization by the Acquirer of an Acquirer Competing Product containing a Janssen Binding Domain so long as (i) neither Xencor (nor any Affiliate of Xencor that was an Affiliate of Xencor immediately prior to such Change of Control) disclosed or otherwise provided the Janssen Binding Domain to the Acquirer and (ii) [***].
​
8.4.5.4For clarity, the restrictions in Section 8.4.4 will apply to an Acquirer of Xencor and its Affiliates, and will continue to apply to Xencor and its other Affiliates, after the consummation of a Change of Control of Xencor.

8.4.6Acquisition of Competing Products.
  If either Party or any of its Affiliates acquires rights to any Competing Product as the result of a merger, acquisition, combination or similar transaction with, of or by a Third Party, and as of the date of consummation of such transaction, there are on-going activities with respect to such Competing Product that are prohibited under Section 8.4.2 or Section 8.4.3 (in each case, after giving effect to Section 8.4.5), then the Party who acquired (or whose Affiliate acquired) such rights to such Competing Product (“Acquiring Party”) will, within [***] after the date of consummation of such transaction, notify the other Party in writing whether it (or its Affiliate) will:  
(a)enter into a definitive agreement with a Third Party to divest such Competing Product within [***] after the consummation of such transaction; or
(b)discontinue or terminate its activities with respect to such Competing Product no later than [***] after the closing of such transaction, until the expiration of the First Exclusivity Period or Second Exclusivity Period, as applicable.
During any period in which the Acquiring Party is permitted to continue Researching, Developing, Manufacturing or Commercializing such Competing Product in accordance with clause (a) or (b) above, the applicable prohibition under Section 8.4.2 or Section 8.4.3 will not apply with respect to such Competing Product and the Acquiring Party will [***].
8.4.7Effect of Transfer of Xencor Intellectual Property.  Neither Xencor nor any of its Affiliates will sell or otherwise transfer the ownership of any Xencor Intellectual Property to any Third Party (including through a sale or ownership transfer by an Affiliate of Xencor that Controls such intellectual property) without imposing on such Third Party the restrictions set forth in Section 8.4.2 solely with respect to its use of such Xencor Intellectual Property.  A Change of Control of Xencor or its Affiliates is not deemed to constitute, by itself, a sale or transfer of Xencor Intellectual Property under this Section 8.4.7.  

54
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

ARTICLE 9​
INTELLECTUAL PROPERTY
9.1Patent Representatives.  Each Party will designate a patent attorney or agent as its contact to coordinate with the other Party the filing, prosecution and maintenance of Patents as provided in this Article (the “Patent Representative”).
9.2Inventions.  ​
9.2.1Inventorship.  The Parties agree that ownership of inventions conceived or first reduced to practice in the course of activities performed under this Agreement, together with all intellectual property rights therein (collectively, “Inventions”) will be consistent in the Territory with ownership as determined by application of U.S. patent Laws pertaining to inventorship.  In no event will either Party be liable to the other Party for compensation to any inventors for Inventions conceived or first reduced to practice by director(s), officer(s) or employee(s) of the other Party regardless of which Party has ownership rights to such Inventions pursuant to this Section.
9.2.2Ownership.  ​
9.2.2.1Subject to Section 9.2.2.2, all Inventions conceived or first reduced to practice solely by or on behalf of Janssen will be solely owned by Janssen, all Inventions conceived or first reduced to practice solely by or on behalf of Xencor will be solely owned by Xencor, and all Inventions conceived or first reduced to practice jointly by or on behalf of Janssen and Xencor will be jointly owned by Janssen and Xencor.
9.2.2.2Notwithstanding Section 9.2.2.1, the ownership of the following Inventions will be as follows, regardless of the inventorship of such Inventions between the Parties: 
(a)Xencor will solely own any Invention that would otherwise be owned or jointly owned by Janssen that: [***]. 
(b)Janssen will solely own any Invention that would otherwise be owned or jointly owned by Xencor that: [***]. 
Each Party hereby makes all assignments necessary to accomplish the foregoing ownership.     
9.2.2.3In the case of Inventions jointly owned by Janssen and Xencor (“Joint Inventions”), and any Patents that claim or disclose such Joint Inventions (“Joint Patents”), each Party will own an equal and undivided interest in the Joint Inventions and Joint Patents, with the right to practice, license and exploit the Joint Inventions and Joint Patents, without the duty or accounting or seeking consent from the other Party, subject to any exclusive licenses granted herein and in a manner not inconsistent with this Agreement. 
9.2.3Disclosure.  Each Party will, and will cause its Affiliates to, promptly disclose to the other Party in writing, the conception, development or reduction to practice of: (a) any 

55
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

Invention that is conceived or first reduced to practice during the Research Program Term; and (b) any Invention that is conceived or first reduced to practice during the Term that would be the subject of a [***].  Each Party will cause its Affiliates, employees, directors and officers to assign to such Party, such Person’s right, title and interest in and to any such Inventions, and intellectual property rights therein, as is necessary to enable such Party to fully effect the ownership of such Inventions, and intellectual property rights therein, as provided for in Section 9.2.2.  Each Party will include provisions that effect the intent of this ARTICLE 9 in its relevant agreements with Third Party sublicensees and Third Party contractors performing obligations on its behalf pursuant to this Agreement.  Each Party will, and will cause its Affiliates, employees, directors, and officers, Third Party contractors and Third Party sublicensees, in each case to cooperate with the other Party and take all reasonable additional actions and execute such agreements, instruments and documents as may be reasonably required to perfect the other Party’s right, title and interest in and to Inventions, and intellectual property rights therein, as set forth in this Section 9.2.  Regardless of the foregoing and any provision of this Section 9.2, a Party engaging a CRO (or clinical trial site) for the conduct of Clinical Studies or a CMO may agree to such terms as to the ownership of intellectual property, including Patents, as is reasonable under the circumstances and/or customary.
9.3Prosecution of Patents.  ​
9.3.1Xencor Patents.  ​
9.3.1.1The Parties recognize that it is their shared goal to obtain the broadest patent coverage available with regard to the Xencor Patents and Xencor Research Patents, consistent with the goal of obtaining patents that are valid and enforceable as against Third Parties.  Janssen acknowledges that there may be multiple licensees of certain Xencor Patents or Xencor Research Patents which are included in Xencor Platform Technology and that Xencor has the right to determine how best to conduct patent prosecution of such Xencor Patents or Xencor Research Patents, as applicable, considering in good faith the interests of all such licensees to the extent obligated to do so. 
9.3.1.2Xencor has the right using patent counsel selected by Xencor to prepare, file, prosecute (including any interferences, oppositions, reissue proceedings, reexaminations and similar proceedings) and maintain (collectively, “Prosecution” or to “Prosecute”) [***]  Xencor will take such reasonable acts in connection therewith as Xencor deems appropriate, provided Xencor considers in good faith any comments of Janssen and is acting in good faith to obtain and maintain [***] effective for market exclusivity of Licensed Products.  As of the Effective Date, Xencor uses certain external patent counsel to Prosecute [***].  In the event that such external patent counsel are effectively replaced by Xencor, the replacement patent counsel must be reasonably acceptable to Janssen.   
9.3.1.3Section 9.3.1.2 notwithstanding, with respect to [***], Xencor will promptly provide Janssen with copies of all correspondence to or from the USPTO, EPO and equivalent patent offices in foreign jurisdictions, relating to such [***].  Xencor will reasonably cooperate with Janssen in Prosecuting the [***], and in such case, in the event of any disagreement between Xencor and Janssen regarding the Prosecution of [***] under this Section: 

56
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

(a) after the earliest Candidate Selection Date, Janssen will have final decision-making authority and Xencor will (and will cause its outside counsel to) Prosecute [***] as instructed by Janssen, including in countries requested by Janssen to the extent permitted by applicable Law; and (b) prior to [***], Xencor will have final decision-making authority.  
9.3.1.4If Xencor, prior or subsequent to filing any Patent that would constitute [***], elects not to Prosecute such Patent, Xencor will give Janssen notice thereof within a reasonable period prior to allowing such Patent to lapse or become abandoned or unenforceable, and Janssen will thereafter have the right, but not the obligation, to Prosecute such [***].  If Janssen assumes responsibility for such [***] pursuant to this Section, Xencor will reasonably cooperate with Janssen in Prosecuting such Patents and, in such case, in the event of any disagreement between Xencor and Janssen regarding the Prosecution of [***] under this Section, Janssen will have final decision-making authority and Xencor will (and will cause its outside counsel to) Prosecute [***] as instructed by Janssen, including in countries requested by Janssen to the extent permitted by applicable Law. 
9.3.1.5As between the Parties, Xencor will be solely responsible for all costs and expenses Xencor incurs in connection with the Prosecution of [***].  Janssen will reimburse Xencor for all reasonable out-of-pocket costs incurred by Xencor in connection with the Prosecution of the [***]; provided, however, that at any time Janssen may elect not to be responsible for such costs, in which case such applicable [***] will no longer be included in any licenses granted to Janssen hereunder.
9.3.1.6The Parties understand that certain grounds for rejection in the United States may be cured or remedied by assignment of a Patent from one Party to another to allow for the filing of terminal disclaimers.  In the case of [***] Controlled by Janssen for which such assignment can provide such remedy, the Parties agree to discuss in good faith the best course of action, including the assignment of [***] Controlled by Janssen to vest ownership in one or both Parties to remedy such rejection.  If, after discussion, the Parties do not agree on the course of action to take, either Party may refer the matter to the Executive Officers for resolution.  Such Executive Officers shall endeavor to meet promptly to discuss the matter.  If the Executive Officers do not reach consensus on such matter within [***] after such matter is referred to them, then (i) in the case of assignment of a [***], Xencor will have final say, and (ii) in the case of assignment of a [***] Controlled by Janssen, Janssen will have the final say. 
9.3.1.7It is the intention of the Parties that this Agreement is a “joint research agreement” as that phrase is defined in Public Law 108-53 (the “Create Act”). If Janssen or Xencor intends to overcome a rejection of a claimed invention in a [***] Controlled by Janssen pursuant to the provisions of the Create Act under this Agreement, such Party shall first obtain the prior written consent of the other Party. Following receipt of such written consent, Xencor and Janssen shall limit any amendment to the specification or statement to the patent office with respect to this Agreement to that which is strictly required by 35 USC § 102(c) and the rules and regulations promulgated thereunder and which is consistent with the terms and conditions of this Agreement. 

57
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

9.3.2Janssen Patents. Janssen will be solely responsible for the Prosecution of and the cost for [***].
9.3.3Joint Patents.​
9.3.3.1[***]
9.3.3.2[***]  
9.3.3.3Joint Patent Costs. [***]
9.3.4Cooperation.  Each Party agrees to reasonably cooperate with the other with respect to the Prosecution of Patents pursuant to this Section 9.3.  At the request of the other Party, the Party responsible for Prosecuting a Patent will make reasonable efforts to separately prosecute subject matter solely related to [***] separate from other subject matter which may be disclosed or claimed in any Patent hereunder, to the extent it may reasonably do so without jeopardizing or impairing any such Patents.  Each Party’s rights to Prosecute a Patent pursuant to this Section 9.3 will be subject to the applicable provisions of any agreements between the Party controlling such Patents and its licensor.  All information exchanged between the Parties under this Section 9.3 pertaining to any [***] will be deemed Confidential Information of Xencor, all information exchanged between the Parties under this Section 9.3 pertaining to any Janssen Patent will be deemed Confidential Information of Janssen, and all information exchanged between the Parties under this Section 9.3 pertaining to any Joint Patents will be deemed Confidential Information of both Parties.
9.4Patent Enforcement.  ​
9.4.1Notice. In the event that Xencor or Janssen becomes aware of any actual infringement or threat of infringement of any Xencor Patent, Xencor Research Patent, Janssen Patent or Joint Patent by means of the sale, including the manufacture for sale, by a Third Party of a Third Party Competitive Product or a biosimilar product with respect to any Licensed Antibody or any Licensed Product, or if any Xencor Patent, Xencor Research Patent, Janssen Patent or Joint Patent is challenged in any action or proceeding (other than any oppositions, cancellations, interferences, reissue proceedings or reexaminations, which are addressed above) as invalid or unenforceable (such infringements and challenges collectively, “Product Infringement” with respect to such Licensed Antibody or Licensed Product), such Party will notify the other Party promptly, and following such notification, the Parties will confer.  As used in this Section, a “Third Party Competitive Product” means any Antibody containing a CD28 Binding Domain and a Target Prostate Antigen Binding Domain.
9.4.2Enforcement of [***].​
9.4.2.1After earliest Candidate Selection, Janssen will have the first right to institute infringement suits or take other action under the [***], in each case to the extent the same is directed to a Product Infringement, including defense of a declaratory judgment action with respect to a potential Product Infringement (whether prior to or after the First Commercial Sale of such Licensed Product) (each, an “Infringement Action”).  Janssen will have the right to institute such suit or other appropriate action in the name of Xencor or of Janssen, or in the 

58
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

names of both of them.  For clarity, Janssen will have the right to institute infringement suits or take other action under Patents owned or controlled by Janssen (not Joint Patents), provided that Janssen will keep Xencor reasonably updated on the progress of any such suits or actions.
9.4.2.2If Janssen institutes or undertakes an Infringement Action in accordance with Section 9.4.2.1, Xencor will cooperate fully with Janssen in its efforts to protect such Patents and will agree to be a party in any suit, if required, in each case with respect to such Infringement Action, in each case at Janssen’s sole expense.  Xencor will have the right, in Xencor’s sole discretion and at Xencor’s expense, to join or otherwise participate in such Infringement Action with legal counsel selected by Xencor.  Janssen will notify and keep Xencor apprised in writing of such Infringement Action and will consider and take into account Xencor’s reasonable interests and requests regarding such Infringement Action.
9.4.2.3If Janssen does not institute or undertake an Infringement Action in accordance with Section 9.4.2.1 for a period [***] after being requested by Xencor to do so, or (if sooner) at least [***] prior to the last date such Infringement Action may be brought, Xencor may institute or undertake and thereafter control such Infringement Action.  In such event, Xencor will have the right, but not the obligation, to institute or undertake such suit or other appropriate Infringement Action in the name of Xencor or of Janssen or in the names of both of them.  Janssen will cooperate fully with Xencor in its efforts to protect such Patents and will agree to be a party in any suit, if required, in each case with respect to such Infringement Action, in each case at Xencor’s sole expense.  Janssen will have the right, in Janssen’s sole discretion and at Janssen’s expense, to join or otherwise participate in such Infringement Action with legal counsel selected by Janssen.  Xencor will notify and keep Janssen apprised in writing of such Infringement Action and will consider and take into account Janssen’s reasonable interests and requests regarding such Infringement Action.
9.4.3Enforcement of Joint Patents other than [***].
9.4.3.1Xencor will have the first right to institute infringement suits or take other actions directed to a Product Infringement of [***], including defense of a declaratory judgment action with respect to a potential Product Infringement.  Xencor will have the right to institute such suit or other appropriate action in the name of Xencor or of Janssen, or in the names of both of them.  Janssen will cooperate fully with Xencor in its efforts to protect such Patents and will agree to be a party in any suit, if required, at Xencor’s sole expense.  Xencor will notify and keep Janssen apprised in writing of such action and will consider and take into account Janssen’s reasonable interests and requests regarding such action.  
9.4.3.2If Xencor does not institute or undertake an action in accordance with Section 9.4.3.1 for a period of [***] after being requested by Janssen to do so, or (if sooner) at least [***] prior to the last date such action may be brought, then Janssen may institute or undertake and thereafter control such action, in the name of Xencor or of Janssen or in the names of both of them.  Janssen will cooperate fully with Xencor in its efforts to protect such Patents and will agree to be a party in any suit, if required, at Janssen’s sole expense.

59
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

9.4.4Conduct of Patent Litigation under the Biologics Price Competition and Innovation Act.  If either Party receives a copy of an application submitted to the FDA under subsection (k) of Section 351 of the PHSA or equivalent in any other jurisdiction pertaining to and naming a Licensed Product as a reference product (a “Biosimilar Application”) or otherwise becomes aware that such a Biosimilar Application has been filed (such as in an instance described in Section 351(l)(9)(C) of the PHSA), such Party will, within [***] Business Days, notify the other Party so that the other Party may seek permission to view the application and related confidential information from the filer of the Biosimilar Application under Section 351(l)(1)(B)(iii) of the PHSA or equivalent in any other jurisdiction.  If either Party receives any equivalent or similar certification or notice in any other jurisdiction, such Party will, within [***], notify and provide the other Party with copies of such communication.  Regardless of the Party that is the “reference product sponsor” for purposes of such Biosimilar Application, Janssen will have the sole right, but not the obligation, to initiate an Infringement Action against the filer of the Biosimilar Application to enforce any [***], including whether or not to utilize, in whole or in part, the procedures provided in Section 351 of the PHSA or equivalent in any other jurisdiction.  If Janssen institutes any such Infringement Action, then Xencor will join as a party to such claim, suit or proceeding requiring it as a party at Xencor’s sole cost and expense.  With respect to a [***] and to the extent the action is under this Section, Xencor will determine whether any infringement suit or other action will be initiated, and if so, which Party will have the right to initiate and undertake such action and other matters pertaining to such action.
9.4.5Cooperation. In any Infringement Action brought under this Section 9.4 in any jurisdiction, each Party will reasonably cooperate with each other, in good faith, relative to the other Party’s efforts to protect the applicable Patents and will agree to be a party to such Infringement Action, if necessary.  Notwithstanding anything to the contrary in this Section 9.4, neither Party will settle or compromise any related defense or infringement suit brought under the [***] pursuant to this Section 9.4 without the prior written consent of the other Party, which consent will not be unreasonably withheld.  Furthermore, each Party will provide the other Party with reasonable prior notice and opportunity to review and comment, and will consider in good faith all reasonable comments from the other Party on, any proposed arguments asserted or to be asserted in any enforcement action under this Section 9.4.
9.4.6Recoveries. With respect to any Infringement Action or other action against a Product Infringement initiated pursuant to this Section 9.4, any recovery obtained as a result of any such proceeding, by settlement or otherwise, will be applied in the following order of priority:
(a)first, the Parties will be reimbursed for all out-of-pocket expenses incurred by the Parties in connection with such Infringement Action or other action and not otherwise recovered (which reimbursement will be made proportionally if such recovery is less than the total of such out-of-pocket expenses); and
(b)any remainder will be (i) [***] if recovered by Janssen and (ii) if recovered by Xencor, allocated [***].

60
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

9.4.7Upstream Limitations.  Each Party’s rights to enforce or defend a Xencor Patent, Xencor Research Patent, or Joint Patent against a Product Infringement pursuant to this Section 9.4 will be subject to the applicable provisions of any agreements between the Party controlling such Patents and its licensor.
9.4.8Other Enforcement of Xencor Patents, Janssen Patents and Joint Patents. As between the Parties, Xencor will have the sole right, in its sole discretion, to enforce any [***] against any infringement that is not a Product Infringement and to retain all related recoveries, and Janssen will have the sole right, in its sole discretion, to enforce any Janssen Patent against any infringement that is not a Product Infringement and to retain all related recoveries.  If there is any infringement of any Joint Patent that is not a [***], then each Party will have the right to enforce such Joint Patent at its sole expense.
9.5Patent Term Extensions.  Janssen will have the sole discretion, after consultation with Xencor, to determine which [***], if any, are extended with respect to any Licensed Product pursuant to the U.S. Drug Price Competition and Patent Term Restoration Act of 1984, the Supplementary Certificate of Protection of Member States of the EU and other similar measures in other jurisdictions worldwide.  Upon Janssen’s request, the Parties will discuss whether any [***] will be extended with respect to any Licensed Product, which extension may be made only with Xencor’s written consent.  Xencor and Janssen will each cooperate and use reasonable efforts to gain any such patent term extension permitted under this Section 9.5.  All filings for such extensions will be made by the Party responsible for the Prosecution of such Patents.  
9.6Regulatory Data Protection.  To the extent required by or permitted by Law, Xencor and Janssen will each cooperate with one another and will use Diligent Efforts to promptly, accurately and completely list, with the applicable Regulatory Authorities during the Term, all applicable Licensed Products that Janssen intends to, or has begun to, Commercialize and that, in case of the United States, have become the subject of an application for a Marketing Approval submitted to FDA, such listings to include all so called “Purple Book” listings of biologic products by both the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) required under section 351(a) of the PHSA and any foreign equivalent, and will cooperate and use Diligent Efforts to secure all applicable exclusivity protection available as a Biologic Reference Product under the Purple Book.
9.7Patent Invalidity Claims.  ​
9.7.1Right to Respond. If during the Term a Third Party initiates a patent opposition, reexamination, or other proceeding in the US Patent Office, European Patent Office or foreign equivalent, asserting that [***] are invalid or otherwise unenforceable (an “Invalidity Claim”), the Parties will treat this as a Prosecution in accordance with Section 9.3.1 or Section 9.3.3.  For the avoidance of doubt, any response to a Third Party declaratory judgment action with respect to [***] claims or a counterclaim of invalidity or unenforceability of such claims made in the context of an Infringement Action, to the extent the same pertains to a potential Product Infringement, will be deemed an Infringement Action and will be governed by Section 9.4.

61
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

9.7.2Invalidity Claims. The non-controlling Party will cooperate with the controlling Party in the preparation and formulation of a response to an Invalidity Claim, and in taking other steps reasonably necessary to respond, to such Invalidity Claim.  The controlling Party will have the sole and exclusive right to select counsel for the response to such Invalidity Claim.  The non-controlling Party will also have the right to participate and be represented relative to such proceeding by its own counsel at its own expense.  The controlling Party will not settle or compromise any Invalidity Claim in a manner that admits the invalidity or unenforceability of any [***], or that requires a payment to the Third Party in respect of such Invalidity Claim, without the consent of the other Party, which consent will not be unreasonably withheld.  For clarity, “control” under this Section will mean final decision-making authority regarding Prosecution.  
9.8Claimed Infringement.  Each of the Parties will promptly notify the other in the event that any Third Party files any suit or brings any other action alleging patent infringement by Janssen or Xencor with respect to the Exploitation of any Licensed Antibody or a Licensed Product (any such suit or other action referred to herein as an “Infringement Claim”).  In the event of any Infringement Claim, the Parties will promptly, and within [***] of written notice from either Party to the other thereof, discuss which Party will control the response to such Infringement Claim, and if the Parties do not mutually agree upon which Party will control, then Janssen will have the right to control the defense of such Infringement Claim.  Upon the request of the Party controlling the response to the Infringement Claim, the other Party will reasonably cooperate with the controlling Party at the controlling Party’s expense in the reasonable defense of such Infringement Claim.  The other Party will have the right to consult with the controlling Party concerning any Infringement Claim and to participate in and be represented by independent counsel in any associated litigation at its own expense.  The damages or recovery obtained by the Third Party asserting such Infringement Claim will be paid by Janssen.  Notwithstanding the foregoing, (i) no settlement will be entered into, or accepted, without the prior written consent of the other Party if such settlement would materially adversely affect the rights and benefits of, or impose or adversely affect any obligations on, such other Party, which consent will not unreasonably be withheld, delayed or conditioned, and (ii) the Parties’ rights and obligations under this Section 9.8 will be subject to ARTICLE 12, if applicable.
9.9Acquirer Intellectual Property.  ​
9.9.1If Xencor undergoes a Change of Control, all Xencor Research Intellectual Property and Xencor Intellectual Property Controlled by Xencor immediately before the consummation of the Change of Control shall continue to be Xencor Research Intellectual Property or Xencor Intellectual Property, as applicable, for purposes of this Agreement.  “Acquirer Intellectual Property” means any Patents or Know-How Controlled by the Acquirer (or any other Affiliate of Xencor that becomes an Affiliate through any Change of Control of Xencor) that were Controlled by the Acquirer or such other Affiliate (and not Xencor) immediately prior to such Change of Control (other than as a result of a license or other grant of rights, covenant or assignment by Xencor or its other Affiliates to, or for the benefit of, the Acquirer or such Affiliate).  For purposes of this Section 9.9.1, references in the definition of “Control” to “a Party” will be deemed to include the Acquirer and its Affiliates.

62
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

9.9.2Notwithstanding anything to the contrary in this Agreement, Xencor Research Intellectual Property and Xencor Intellectual Property shall not be deemed to include (and Xencor and its Affiliates shall not be deemed to Control) any Acquirer Intellectual Property unless and solely to the extent such Acquirer Intellectual Property is used by Xencor or the Acquirer, or any of their respective Affiliates, to Research any Primary Antibody.  Xencor will notify Janssen in advance before using any Acquirer Intellectual Property to Exploit any Licensed Antibody or Licensed Product under this Agreement.
9.10Trademarks.  Janssen shall have the sole and exclusive right to, in its sole discretion, develop and select (and conduct clearance searches for) the trademark(s) used to brand the Licensed Products in the Territory, which may vary by country or within a country (the “Product Marks”).  For clarity, Product Marks do not include any corporate names and logos of Janssen.  As between the Parties, Janssen shall own all rights in the Product Marks and shall register and maintain, in its sole discretion and at its own cost and expense, the Product Marks in the countries and regions in the Territory that it determines to be appropriate.  Janssen shall have the sole right, in its discretion and at its expense, to defend and enforce the Product Marks.
ARTICLE 10​
CONFIDENTIALITY AND PUBLICITY
10.1Non-Disclosure and Non-Use.​
10.1.1During the Term and [***], the Party (the “Receiving Party”) receiving or otherwise in possession of Confidential Information of the other Party (the “Disclosing Party”) will: (a) maintain in confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain in confidence its own confidential or proprietary information of similar kind and value (but no less than reasonable efforts); (b) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted in Sections 10.3 and 10.4; and (c) not use such Confidential Information for any purpose except those permitted by this Agreement or internal management and operations directly related to this Agreement (it being understood that this ARTICLE 10 does not create or imply any rights or licenses not expressly granted under this Agreement).  
10.1.2“Confidential Information” means all non-public or proprietary information (a) disclosed orally, visually, in writing or other form by or on behalf of a Party (or an Affiliate or representative of such Party) to the other Party (or to an Affiliate or representative of such Party) pursuant to or in connection with this Agreement, whether prior to, on or after the Execution Date or (b) expressly designated as Confidential Information of a Party under another provision of this Agreement.   
10.1.3Any Know-How that is a Janssen Assigned Invention will be deemed the Confidential Information of Xencor only.  
10.1.4Any data or non-public information relating to the Licensed Antibodies generated by either Party in the performance of the Research Program activities under this Agreement 

63
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

(“Research Program Results”) is deemed to be the Confidential Information of both Parties during the Term.  After the Term, (a) all Research Program Results generated by Xencor shall be deemed the Confidential Information of Xencor (and not Janssen), and (b) all Research Program Results generated by Janssen shall be deemed the Confidential Information of Janssen (and not Xencor), subject to the license granted to Xencor by Janssen under Section 13.6.2.2. 
10.2Exceptions.  The obligations in Section 10.1 will not apply to the extent of any portion of the Confidential Information that the Receiving Party can show by competent written evidence:
(a)is publicly disclosed by the Disclosing Party, either before or after it is disclosed to the Receiving Party under this Agreement;
(b)was known to the Receiving Party or any of its Affiliates, without any obligation to the Disclosing Party to keep it confidential or any restriction on its use, before disclosure to the Receiving Party or any of its Affiliates by the Disclosing Party;
(c)is subsequently disclosed to the Receiving Party or any of its Affiliates on a non-confidential basis by a Third Party that, to the Receiving Party’s knowledge after due inquiry, is not bound by a duty of confidentiality to the Disclosing Party or restriction on its use;
(d)is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party or any of its Affiliates in violation of this Agreement, generally known or available, either before or after it is disclosed to the Receiving Party by the Disclosing Party; or
(e)is independently discovered or created by or on behalf of the Receiving Party or any of its Affiliates without the use of or reference to the Confidential Information of the Disclosing Party.
10.3Authorized Disclosure.  The Receiving Party may disclose Confidential Information of the Disclosing Party only to the extent such disclosure is reasonably necessary in the following instances: 
(a)filing, prosecuting, maintaining, enforcing or defending Patents as permitted by this Agreement; 
(b)as reasonably required in generating regulatory documentation (including INDs/CTAs and Drug Approval Applications) and filing for and obtaining regulatory licenses as permitted by this Agreement;
(c) prosecuting or defending litigation, including responding to a subpoena in a Third Party litigation; 

64
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

(d)subject to Section 10.4, complying with applicable Law (including regulations promulgated by securities exchanges) or court or administrative orders, including as a result of any actions taken by a Party not in violation of this Agreement; 
(e)complying with any obligation under this Agreement, or as otherwise expressly permitted under Section 5.2.4.1 or Section 7.6.2.2; or
(f)to its Affiliates and existing or prospective (sub)licensees, subcontractors, consultants, agents and advisors to the extent reasonably necessary for the Receiving Party to exercise its rights or fulfill its obligations under this Agreement or to a prospective Acquirer or sub(licensee) in connection with bona fide due diligence, each of whom before disclosure must be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are no less restrictive than the obligations in this ARTICLE 10, provided that the Receiving Party will remain responsible for any violation of such confidentiality provisions by any Person who receives Confidential Information pursuant to this Section 10.3(f) and provided further that Xencor may not disclose any Confidential Information of Janssen to a prospective Acquirer unless and until such Third Party has provided Xencor with a written proposal for a Change of Control transaction (including financial compensation) and Xencor’s board of directors has determined (or is considering whether) to pursue negotiations with such prospective Acquirer with respect to such proposal.
If and whenever any Confidential Information is disclosed in accordance with this Section 10.3, such disclosure will not cause such information to cease to be Confidential Information for purposes of this Agreement, except to the extent that such disclosure results in a public disclosure of such information (other than by breach of this Agreement).  Notwithstanding the foregoing, if a Party intends to make a disclosure of the other Party’s Confidential Information pursuant to Section 10.3(c) or Section 10.3(d), it will, except where impracticable or not legally permitted, give [***] advance notice (or, if [***] notice is not possible under the circumstances, reasonable advance notice) to the other Party of such disclosure and use not less than the same efforts to secure confidential treatment of such information as it would to protect its own confidential information from disclosure (but no less than reasonable efforts). 
10.4Terms of Agreement.  This Agreement and all of the terms of this Agreement will be treated as Confidential Information of each Party.  In addition to the disclosures permitted under Section 10.3, either Party may disclose the terms of this Agreement and other information relating to this Agreement or the transactions contemplated by this Agreement to the extent required, in the reasonable opinion of such Party’s counsel, to comply with the rules and regulations promulgated by the United States Securities and Exchange Commission or the Nasdaq Stock Market or similar security regulatory authorities or stock market in other countries, including as a result of any actions taken by a Party not in violation of this Agreement.  If a Party intends to disclose this Agreement or any of its terms or other such information in accordance with this Section 10.4, such Party will, except where impracticable or not legally permitted, give reasonable advance notice to the other Party of such disclosure and seek confidential treatment of portions of this Agreement or such terms or information, as may be reasonably requested by the other Party in a timely manner.

65
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

10.5Publicity.  ​
10.5.1Initial Press Release.  Each Party may, but is not obligated to, make a public announcement of the execution of this Agreement in the form attached as Exhibit 10.5.1 to this Agreement, which will be issued at a time to be mutually agreed by the Parties no later than one Business Day after the Execution Date.   
10.5.2Further Publicity.  Except as required to comply with applicable Law or as permitted by Section 10.3, 10.4 or 10.5.1, if either Party intends to issue any press release or make other public statement disclosing any information relating to this Agreement, it will give the other Party a reasonable opportunity to review and comment and will consider any such comments in good faith.  In addition, such Party will not issue such press release or public statement without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed.  If a Party intends to issue such a press release or other public statement as required to comply with applicable Law, such Party will, except where impracticable or not legally permitted, give reasonable advance notice to the other Party of such disclosure.  Notwithstanding the foregoing, once information relating this Agreement has been publicly disclosed as permitted under this Agreement, neither Party is required to obtain the other Party’s consent or provide notice of its further public disclosure, provided that such information remains accurate and not misleading in all material respects at the time of such further public disclosure.
10.6Prior Non-Disclosure Agreement.  As of the Execution Date, the terms of this ARTICLE 10 supersede the Mutual Confidentiality Disclosure Agreement by and between Janssen Research & Development, LLC (“JRD”) and Xencor, [***].  Any information disclosed pursuant to such agreement that was deemed “Confidential Information” under such agreement is deemed to be Confidential Information under this Agreement.
10.7Equitable Relief.  Given the nature of the Confidential Information and the competitive damage that may result to a Party upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy for any breach of this ARTICLE 10.  In addition to all other remedies, a Party is entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this.
10.8Publications.  ​
10.8.1Either Party may publish or present results of any Clinical Study conducted by such Party relating to a Licensed Product in journals or at conferences, subject to the prior review and comment by the other Party as set forth in Section 10.8.2.  The Party who conducted a Clinical Study is responsible for registering such Clinical Study in the appropriate clinical study registry and reporting Clinical Study results as may be required under applicable Law.
10.8.2The publishing Party will provide the non-publishing Party with the opportunity to review any such proposed abstract, manuscript or presentation by delivering a copy of it to the non-publishing Party no less than [***] before its intended submission for publication or presentation. The non-publishing Party will have [***] of its receipt of any such abstract, 

66
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

manuscript or presentation to comment, and the publishing Party will consider in good faith such non-publishing Party’s comments in such abstract, manuscript or presentation. If the non-publishing Party objects to the disclosure in writing within the applicable review period, the publishing Party must delete from the proposed disclosure any of the non-publishing Party’s Confidential Information upon the request of the non-publishing Party. In the event of concern over patent protection, the publishing Party may not submit such publication or make such presentation containing such information until the non-publishing Party is given a reasonable period of time, and in no event less than [***] days, to seek patent protection for any material in such publication or presentation which it believes is patentable, unless the publishing Party reasonably determines that publication of such information is required by applicable Law.
ARTICLE 11​
REPRESENTATIONS AND WARRANTIES; CERTAIN COVENANTS
11.1Representations of Authority.  Xencor and Janssen each represents and warrants to the other Party that, as of the Execution Date, it has full corporate right, power and authority to enter into this Agreement and to perform its respective obligations under this Agreement and that it has the right to grant to the other the licenses and sublicenses granted pursuant to this Agreement. 
11.2Consents.  Xencor and Janssen each represents and warrants to the other Party that, except for any regulatory licenses, pricing or reimbursement approvals, manufacturing approvals or similar approvals necessary for the Exploitation of the Licensed Antibodies and Licensed Products, all necessary consents, approvals and authorizations of all government authorities and other persons required to be obtained by it as of the Execution Date in connection with the execution, delivery and performance of this Agreement (as contemplated as of the Execution Date) have been obtained by the Execution Date, except for those required under the HSR Act or that would not, individually or in the aggregate, be reasonably expected to have a material adverse effect on the Exploitation of the Licensed Antibodies and Licensed Products.
11.3No Conflict.  Xencor and Janssen each represents and warrants to the other Party that, notwithstanding anything to the contrary in this Agreement, the execution and delivery of this Agreement by such Party, the performance of such Party’s obligations under this Agreement (as contemplated as of the Execution Date) and the licenses and sublicenses to be granted by such Party pursuant to this Agreement (i) do not conflict with or violate with such Party’s organizational documents or any requirement of Laws existing as of the Execution Date and applicable to such Party and (ii) do not conflict with, violate, breach or constitute a default under any contractual obligations of such Party or any of its Affiliates existing as of the Execution Date, except, in each case, for those conflicts, violations, breaches or defaults that would not, individually or in the aggregate, be reasonably expected to have a material adverse effect on the Exploitation of the Licensed Antibodies and Licensed Products.
11.4Enforceability.  Xencor and Janssen each represents and warrants to the other Party that, as of the Execution Date, this Agreement is a legal and valid obligation binding upon it and is enforceable against it in accordance with its terms, except as such enforcement may be 

67
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

limited by bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other Laws affecting the rights of creditors generally and general equitable principles (whether considered in a proceeding in equity or at law).
11.5Additional Representations and Warranties of Xencor.  Xencor represents and warrants to Janssen that, as of the Execution Date:  
11.5.1Except for [***], neither Xencor nor any of its Affiliates is party to any license agreement with a Third Party in effect on the Execution Date pursuant to which Xencor (or their respective Affiliates) is obligated to pay any amount to such Third Party to practice the Xencor Research Patents or Xencor Patents that Cover Specified Xencor Know-How, or any Specified Xencor Know-How that relates to the Xencor Binding Domains, with respect to Xencor’s (or their respective Affiliates’) Exploitation of Licensed Antibodies and Licensed Products pursuant to this Agreement.  
11.5.2Except for [***],  to the knowledge of Xencor, Xencor exclusively owns all Xencor Research Patents and Xencor Patents that Cover Specified Xencor Know-How, licensed to Janssen hereunder that exists on the Execution Date (the “Existing Xencor Intellectual Property”).  Except for [***], no Xencor Research Patents or Xencor Patents that relate to the Xencor Binding Domains licensed to Janssen hereunder are licensed to Xencor by a Third Party.  Except for [***], Xencor is the exclusive owner of all Patents set forth in Schedule 11.5.10.  There are no agreements with any Third Party pursuant to which Xencor has licensed to Third Parties rights with respect to the Licensed Antibodies or Licensed Products.  With respect to the inventions related to the CD28 Binding Domains set forth on Schedule 11.5.2 (the “Xencor CD28 Inventions”): (a) none of the Xencor CD28 Inventions are licensed to Xencor by a Third Party; (b) Xencor has not disclosed any sequence of any Xencor CD28 Invention to any Third Party; and (c) there are no agreements with any Third Party pursuant to which Xencor has licensed to such Third Party rights with respect to any of the Xencor CD28 Inventions. 
11.5.3Xencor has all rights necessary to grant the licenses under the Xencor Research Intellectual Property and Xencor Intellectual Property that it grants to Janssen in this Agreement.
11.5.4Xencor has not previously licensed, assigned, transferred, or otherwise conveyed to any Third Party any right, title or interest in, to or under the Existing Xencor Intellectual Property in any way that would legally conflict with the licenses and rights granted to Janssen under this Agreement.  Xencor has not previously otherwise granted any rights to any Third Party in any way that would legally conflict with the licenses and rights granted to Janssen under this Agreement.
11.5.5Xencor has not entered into any agreement that would create a lien, charge or encumbrance with respect to the Xencor Research Patents or Xencor Patents, and the Xencor Research Patents and Xencor Patents are free and clear of any liens, charges and encumbrances, in either case that would conflict with the license grants to Janssen under this Agreement.  For clarity, a license granted by Xencor to a Third Party does not constitute an “encumbrance” for purposes of this Section 11.5.5.

68
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

11.5.6To the knowledge of Xencor, neither Xencor nor any of its Affiliates or their respective current or former employees has misappropriated any of (i) the Know-How necessary or used by Xencor for the Exploitation of the Licensed Antibodies and Licensed Products by Xencor as of the Execution Date, or (ii) the Xencor Research Know-How, in each case from any Third Party, and Xencor is not aware of any claim by a Third Party that such misappropriation has occurred.
11.5.7Xencor has not received any written notice of any existing or threatened actions, suits or other proceedings pending against it with respect to the Xencor Research Intellectual Property or Xencor Intellectual Property (other than patent office actions or the actions of any Regulatory Authority) that have not already been disclosed to Janssen.
11.5.8Except as already disclosed, Xencor has not received written notice from a Third Party claiming that a patent owned by such Third Party would be infringed by the manufacture, use, sale, offer for sale or import of the Licensed Antibodies or Licensed Products in the Territory, and no Third Party has threatened in writing to make any such claim.
11.5.9 To the knowledge of Xencor, the use, practice or application by Xencor or Janssen (or their respective Affiliates or sublicensees) of any Specified Xencor Know-How that relates to the Xencor Binding Domains as contemplated under the Research Plan would not misappropriate the intellectual property of any Third Party.  To the knowledge of Xencor, the use, practice or application by Xencor or Janssen (or their respective Affiliates or sublicensees) of any Xencor CD28 Invention would not infringe any claim of an issued and unexpired patent of any Third Party.   
11.5.10 The Patents listed in Schedule 11.5.10 represent all Patents that are existing as of the Execution Date that Xencor or any of its Affiliates owns or Controls that Cover or first disclose in a Patent any invention Controlled by Xencor that Xencor reasonably believes may Cover a Primary Antibody.  Xencor: (i) is not aware of any claim made against it asserting the invalidity, misuse, unregisterability, unenforceability or non-infringement of any of such listed Patents other than patent office actions or the actions of any Regulatory Authority and; and (ii) is not aware of any claim made against it challenging Xencor’s Control of such listed Patents or making any adverse claim of ownership of the rights of Xencor to such listed Patents.
11.5.11  Xencor has not prepared, filed or obtained any INDs/CTAs, Drug Approval Applications or any other regulatory documentation or regulatory licenses for any Licensed Antibodies or Licensed Products in any jurisdiction.  
11.5.12  Xencor has conducted, and has used reasonable efforts to cause its contractors and consultants to conduct, the Research, Development and Manufacture of the Licensed Antibodies and Licensed Products in accordance in all material respects with applicable Law, including as applicable GCP and GLP.
11.5.13 Neither Xencor nor any of its Affiliates has conducted (or had a Third Party conduct on its behalf) before the Execution Date any Research, Development or Manufacture of any Antibody that comprises a Target Prostate Antigen Binding Domain and a 

69
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

CD28 Binding Domain or any product that contains such an Antibody, except to the extent that Xencor disclosed such Antibodies to Janssen before the Execution Date.  Xencor has made available to Janssen all material information in Xencor’s or its Affiliate’s Control relating to its activities concerning such Antibodies.
11.5.14 There is no claim, action, suit, arbitration, inquiry, audit or investigation by or before any Governmental Authority pending or, to the knowledge of Xencor, threatened against Xencor or involving any of the Licensed Antibodies or Licensed Products.  There is no award, stay, writ, judgement, injunction, decree or similar order of any Governmental Authority outstanding, or to Xencor’s knowledge pending, involving Xencor or any of the Licensed Antibodies or Licensed Products.  No clinical trial of any Licensed Product has been conducted by or on behalf of Xencor. 
11.5.15  Neither Xencor nor any of its Affiliates is or has been a party to any agreement with a Governmental Authority pursuant to which such Governmental Authority provided or may provide funding for the Development of any Licensed Antibody or Licensed Product.  None of the Xencor Research Patents, Xencor Patents or Xencor Research Know-How are or include any invention that was conceived or first actually reduced to practice in the performance of work under a funding agreement between Xencor and the U.S. government.
11.6No Warranties.  EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY, AND EACH PARTY HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT WITH RESPECT TO THE LICENSED ANTIBODIES AND LICENSED PRODUCTS.  EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE EXPLOITATION OF THE LICENSED ANTIBODIES AND LICENSED PRODUCTS PURSUANT TO THIS AGREEMENT WILL BE SUCCESSFUL OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO THE LICENSED PRODUCTS WILL BE ACHIEVED. 
11.7No Debarment or Exclusion.  Each Party represents and warrants that, as of the Execution Date, neither it nor any of its Affiliates, nor any of their officers, employees or agents has been debarred or is subject to debarment as authorized by Section 306 of the United States Federal Food, Drug, and Cosmetic Act or has been excluded or is subject to exclusion from participation in Government Health Care Programs under 42 U.S.C. § 1320a-7, and neither Party nor any of its Affiliates will use in any capacity, in connection with the Exploitation of the Licensed Antibodies or Licensed Products in the Field, any Person who has been debarred pursuant to Section 306 of the United States Federal Food, Drug, and Cosmetic Act, who is the subject of a conviction described in such section, who has been excluded from participation in Government Health Care Programs under 42 U.S.C. § 1320a-7 or who has been convicted of any crime or engaged in any conduct for which such Person could be excluded from participation in Government Health Care Programs under 42 U.S.C. § 1320a-7.  Each Party agrees to inform the other Party in writing immediately if it, any of its officers, employees or 

70
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

agents, or any Person who is performing services under this Agreement is debarred, is the subject of a conviction described in Section 306 of the United States Federal Food, Drug, and Cosmetic Act, is excluded from participation in Government Health Care Programs under 42 U.S.C. § 1320a-7 or is convicted of any crime for which such Person could be excluded from participation in Government Health Care Programs under 42 U.S.C. § 1320a-7, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to the best of such Party’s knowledge, is threatened, relating to the debarment, exclusion or conviction of such Party or any Person used in any capacity by such Party or any of its Affiliates in connection with the Exploitation of the Licensed Antibodies or Licensed Products.
11.8Compliance with Anti-Corruption Laws.  ​
11.8.1Notwithstanding anything to the contrary in this Agreement, each Party hereby agrees that:
(a)it will not, in the performance of this Agreement, perform any actions that are prohibited by local and other anti-corruption laws (including the provisions of the U.S. Foreign Corrupt Practices Act, collectively “Anti-Corruption Laws”) that may be applicable to one or both Parties to this Agreement;
(b)it will not, in the performance of this Agreement, directly or indirectly, make any payment, or offer or transfer anything of value, or agree or promise to make any payment or offer or transfer anything of value, to a government official or government employee, to any political party or any candidate for political office or to any other Third Party related to the transaction with the purpose of influencing decisions related to either Party and/or its business in a manner that would violate Anti-Corruption Laws;
(c)if Xencor exercises the Co-Funding Option, Xencor will designate an individual within its organization to receive training from Janssen on Anti-Corruption Laws as well as applicable rules on interactions with health care professionals, as mutually agreed to by the Parties.  Such designated individual will then provide such training on Anti-Corruption Laws, using applicable training materials to be provided by Janssen, on at least an annual basis to all persons employed by Xencor who perform any activities under this Agreement and interact with government officials or health care professionals in the normal course of their responsibilities.  Upon the Parties' mutual agreement, such training may also be provided directly by Janssen to such employees of Xencor.  If Xencor exercises the Co-Funding Option, Xencor and Janssen will each use reasonable efforts to provide such training or training materials to any contractors or subcontractors of such Party engaged to perform activities under this Agreement where such contracted or subcontracted activities include responsibility for, directly or indirectly, interacting with Public Officials.  Xencor may fulfill its obligation under the preceding sentence by requesting appropriate materials from Janssen and forwarding such materials, if any, received from Janssen to the applicable contractor or subcontractor.  If Xencor is not able to obtain a contractor or subcontractor’s agreement to receive such training or materials, Xencor will use reasonable efforts to facilitate an introduction of Janssen to such contractor or subcontractor and not object to reasonable efforts of Janssen to provide such training or materials to the applicable contractor or subcontractor.  Any training and materials provided by Janssen does not relieve 

71
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

Xencor of any obligations it has independent of this Agreement and Xencor will not rely on Janssen’s training and materials for any such obligations;
(d)if Xencor exercises the Co-Funding Option, it will, on an annual basis upon request by the other Party, verify in writing that to the best of such Party’s knowledge, there have been no violations of Anti-Corruption Laws by such Party or persons employed by or subcontractors used by such Party in the performance of this Agreement, or will provide details of any exception to the foregoing; and
(e)if Xencor exercises the Co-Funding Option, it will maintain records (financial and otherwise) and supporting documentation related to the subject matter of this Agreement in order to document or verify compliance with the provisions of this Section 11.8.1, and upon request of the other Party, up to once per year and upon reasonable advance notice, will provide a Third Party auditor mutually acceptable to the Parties with access to such records for purposes of verifying compliance with the provisions of this Section 11.8.1.  Acceptance of a proposed Third Party auditor may not be unreasonably withheld by either Party.  It is expressly agreed that the costs related to the Third Party auditor will be fully paid by the Party requesting the audit, and that any auditing activities may not unduly interfere with the normal business operations of Party subject to such auditing activities.  The audited Party may require the Third Party auditor to enter into a reasonable confidentiality agreement in connection with such an audit.
11.8.2Xencor hereby represents and warrants to Janssen that, to its knowledge as of the Execution Date, neither Xencor nor any of its subsidiaries nor any of their Affiliates, directors, officers, employees, distributors, agents, representatives, sales intermediaries or other Third Parties acting on behalf of Xencor or any of its subsidiaries or any of their Affiliates:
(a)has taken any action in violation of any applicable Anti-Corruption Law; or
(b)has corruptly, offered, paid, given, promised to pay or give, or authorized the payment or gift of anything of value, directly or indirectly, to any Public Official (as defined in Section 11.8.4 below), for the purposes of:
(i)influencing any act or decision of any Public Official in his official capacity; 
(ii)inducing such Public Official to do or omit to do any act in violation of his lawful duty;
(iii)securing any improper advantage; or 
(iv)inducing such Public Official to use his or her influence with a government, governmental entity, or commercial enterprise owned or controlled by any government (including state-owned or controlled veterinary or medical facilities) in obtaining or retaining any business whatsoever.

72
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

11.8.3Xencor hereby represents and warrants to Janssen that, as of the Execution Date, none of the officers, directors, employees of Xencor or of any of its subsidiaries acting on behalf of Xencor or any of its subsidiaries, in each case that are employed or reside outside the United States, are themselves Public Officials.
11.8.4For purposes of this Section 11.8, “Public Official” means:
(a)any officer, employee or representative of any regional, federal, state, provincial, county or municipal government or government department, agency or other division; 
(b)any officer, employee or representative of any commercial enterprise that is owned or controlled by a government, including any state-owned or controlled veterinary or medical facility;
(c)any officer, employee or representative of any public international organization, such as the African Union, the International Monetary Fund, the United Nations or the World Bank; and 
(d)any person acting in an official capacity for any government or government entity, enterprise or organization identified above. 
11.9Additional Third Party Technology.  Xencor shall obtain Janssen’s written consent prior to making, identifying, and characterizing any Primary Antibody that cannot be Exploited without Know-How Controlled by Xencor or its Affiliates (or Patents that Cover such Know-How) that is licensed to Xencor (other than pursuant to [***]).
11.10[***].  [***] are Controlled by Xencor as of the Execution Date.  Janssen acknowledges that Xencor’s license to [***] is non-exclusive.  Accordingly, notwithstanding anything to the contrary in this Agreement, all rights and licenses granted to Janssen under this Agreement with respect to the [***] are non-exclusive.  Any amounts due to [***] or any other Third Party under the [***] shall be the sole responsibility of Xencor.  With respect to the [***], Xencor will:  
(a)use Diligent Efforts to maintain in full force and effect such agreement (in accordance with its terms) and keep Janssen fully informed of any material development pertaining thereto for so long as the [***] are sublicensed to Janssen in accordance with Section 8.1;
(b)not take any action to terminate, modify, amend, waive any right, to the extent incompatible with the rights sublicensed to Janssen in accordance with Section 8.1;
(c)not fail to enforce any right, knowingly breach or otherwise take any other action with respect to the [***] that would reasonably be expected to materially impact the rights granted to Janssen under this Agreement, without the consent of Janssen;

73
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

(d)comply in all material respects with the terms of the [***];
(e)make all payments that become due under the [***] in accordance with the terms of the [***];
(f)if Xencor or any of its Affiliates receives written notice claiming that Xencor or any of its Affiliates has breached or defaulted under, or is in breach of or default under, its obligations under the [***], provide a copy thereof to Janssen promptly after receipt and, following consultation with Janssen, consider Janssen’s input in good faith and take such actions as may be reasonably necessary to cure any breach or default; and
(g)take all actions reasonably requested by Janssen to provide Janssen with the rights and/or benefits available to Xencor or Janssen as a sublicensee under the [***] with respect to the [***].
ARTICLE 12​
INDEMNIFICATION; INSURANCE
12.1Indemnification by Janssen.  Janssen will indemnify, defend and hold harmless Xencor and its Affiliates, and their respective officers, directors, employees, agents, sublicensees, and their respective successors, heirs and assigns and representatives (the “Xencor Indemnitees”), from and against any and all claims, threatened claims, damages, losses, suits, proceedings, liabilities, costs (including reasonable legal expenses, reasonable costs of litigation and reasonable attorney’s fees) or judgments, whether for money or equitable relief, of any kind brought by a Third Party or Governmental Authority (collectively, “Losses”), to the extent arising out of or relating to:
(a)the gross negligence, intentional misconduct of or violation of Law by Janssen, its Affiliates, or its sublicensees and its or their respective directors, officers, employees and agents;
(b)any breach of, or inaccuracy in, any representation or warranty made by Janssen in this Agreement, or any breach or violation of any covenant or agreement of Janssen in or pursuant to this Agreement; 
(c)the Exploitation of any Licensed Antibody or Licensed Product by or for Janssen or any of its Affiliates, sublicensees, agents and contractors; or 
(d)the conduct of any Independent Prostate Combination Regimen Study by or for Janssen or any of its Affiliates, agents and contractors;
except, in each case, to the extent such Losses arise out of or relate to the negligence of Xencor or any of the other Xencor Indemnitees or to the extent otherwise arising out of or relating to clause (a) or clause (b) of Section 12.2.  
12.2Indemnification by Xencor.  Xencor will indemnify, defend and hold harmless Janssen and its Affiliates, and their respective officers, directors, employees, agents, sublicensees, and 

74
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

their respective successors, heirs and assigns and representatives (the “Janssen Indemnitees”), from and against any and all Losses, to the extent arising out of or relating to:
(a)the gross negligence, intentional misconduct of or violation of Law by Xencor, its Affiliates, or its sublicensees and its or their respective directors, officers, employees and agents;
(b)any breach of, or inaccuracy in, any representation or warranty made by Xencor in this Agreement, or any breach or violation of any covenant or agreement of Xencor in or pursuant to this Agreement; 
(c)the Research of any Primary Antibody by or for Xencor or any of its Affiliates, sublicensees, agents and contractors (but not including Losses relating to intellectual property infringement or the subsequent Exploitation of any Licensed Antibody or Licensed Product arising out of or relating to such Research by or for Janssen or any of its Affiliates, sublicensees, agents and contractors); 
(d)the Detailing of any Licensed Product by or for Xencor or any of its Affiliates, sublicensees, agents and contractors; or
(e)the conduct of any Independent Prostate Combination Regimen Study by or for Xencor or any of its Affiliates, agents and contractors;
except, in each case, to the extent such Losses arise out of or relate to the negligence of Janssen or any of the other Janssen Indemnitees or to the extent otherwise arising out of or relating to clause (a) or clause (b) of Section 12.1.   
12.3Indemnification Procedures.  ​
12.3.1Indemnification Claims.  A claim to which indemnification applies under Section 12.1 or Section 12.2 will be referred to as an “Indemnification Claim”.
12.3.2Notice.  If any Person or Persons (collectively, the “Indemnitee”) intends to claim indemnification under this ARTICLE 12, the Indemnitee will notify the other Party (the “Indemnitor”) in writing promptly upon becoming aware of any claim that may be an Indemnification Claim; provided, however, that failure of the Indemnitee to give such notice will not relieve the Indemnitor of its indemnification obligation under this ARTICLE 12, except and only to the extent that the Indemnitor is actually prejudiced as a result of such failure to give notice.  Each claim notice will describe in reasonable detail the basis for such claim (the “Claim Basis”) and specify the amount or the estimated amount of Losses actually incurred or paid by the Indemnitee as a result of the Claim Basis, to the extent ascertainable.
12.3.3Defense of Indemnification Claims.  By delivering notice to the Indemnitee within [***] after delivery of notice described in Section 12.3.2, the Indemnitor may assume and control, with the sole power to direct, the defense of the Indemnification Claim at its own expense with counsel selected by the Indemnitor and reasonably acceptable to the Indemnitee.  If the Indemnitor does not assume control of the defense of the Indemnification Claim as described 

75
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

in this Section 12.3.3, the Indemnitee will control such defense at Indemnitor’s expense (subject to Sections 12.1 and 12.2).  The Party not controlling such defense may participate therein at its own expense.  The Party controlling the defense of an Indemnification Claim will keep the other Party advised of the status of such Indemnification Claim and the defense thereof and will reasonably consider recommendations made by the other Party with respect thereto.  The other Party will cooperate fully with the Party controlling such defense and will make available all pertinent information under its control, which information will be subject to ARTICLE 10, and cause its employees to be available in a deposition, hearing or trial.
12.3.4Resolution of Indemnification Claims.  Neither the Indemnitor nor the Indemnitee will admit fault on behalf of the other Party without the written consent of such other Party. The Indemnitee will not settle or compromise an Indemnification Claim without the prior written consent of the Indemnitor. The Indemnitor will not settle or compromise an Indemnification Claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the Indemnitee from all liability with respect thereto or that imposes any liability or obligation on the Indemnitee for which the Indemnitee is not indemnified under this Agreement, without the prior written consent of the Indemnitee.
12.4Insurance.  Each Party will acquire and maintain, at its own expense, insurance or self-insurance, as reasonably necessary to cover its own product liability and its obligations under this Agreement.  Within [***] days following written request from the other Party, each Party will furnish to such other Party a certificate of insurance evidencing such coverage.  
ARTICLE 13​
TERM AND TERMINATION
13.1Term.  Unless terminated earlier in accordance with this ARTICLE 13, this Agreement will remain in force for the period commencing on the Execution Date and ending, on a country-by-country basis and Licensed Product-by-Licensed Product basis, upon the expiration of the Royalty Term in such country for such Licensed Product (the “Term”).  The following provisions will become effective on the Execution Date: ARTICLE 1 (Definitions), ARTICLE 10 (Confidentiality and Publicity), ARTICLE 11 (Representations and Warranties; Certain Covenants), ARTICLE 14 (Efforts to Obtain Clearances), ARTICLE 15 (Dispute Resolution), ARTICLE 16 (Miscellaneous) and this Section 13.1 (Term), Section 13.2 (Termination for Material Breach), Section 13.5 (Provisions for Insolvency), Section 13.6.1.2, Section 13.6.4 (Non-Exclusive Remedy) and Section 13.6.5 (Survival) (with respect to any provisions that become effective on the Execution Date).  All other provisions of this Agreement will not become effective until the Effective Date.
13.2Termination for Material Breach.  ​
13.2.1Right to Terminate for Material Breach.  Either Party (the “Non-breaching Party”) may terminate this Agreement in its entirety in the event of a material breach of this Agreement by the other Party (the “Breaching Party”), by providing [***] prior written notice to the Breaching Party (the “Cure Period”).  Such notice will reasonably describe the alleged material breach in sufficient detail to put the Breaching Party on notice and clearly state the Non-breaching Party’s intent to terminate this Agreement if the alleged breach is not cured within the 

76
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

Cure Period.  Notwithstanding the foregoing: (a) the Cure Period in connection with a material breach of a payment obligation under ARTICLE 7 will be [***]; and (b) if the alleged material breach (other than a payment breach), by its nature, is curable, but is not reasonably curable within the Cure Period, then such Cure Period will be extended if the Breaching Party provides a written plan for curing such breach to the Non-breaching Party and uses Diligent Efforts to cure such breach in accordance with such written plan, provided that no such extension will exceed [***] without the consent of the Non-breaching Party.
13.2.2Disputes.  If the Breaching Party disputes in good faith the existence or materiality of a breach specified in a notice provided by the other Party in accordance with Section 13.2.1, and the Breaching Party provides the other Party notice of such dispute within the Cure Period, then the Non-breaching Party will not have the right to terminate this Agreement under Section 13.2.1 with respect to such alleged breach unless and until (a) the dispute resolution process in ARTICLE 15 has finally determined that the Breaching Party has materially breached this Agreement and (b) the Breaching Party fails to cure such material breach within [***] (or [***] in the case of the breach of a payment obligation) following such final determination.  It is understood and agreed that, during the pendency of such dispute, all of the terms and conditions of this Agreement will remain in effect and the Parties will continue to perform all of their respective obligations hereunder.
13.3Termination by Janssen Without Cause.  Janssen may, upon [***] prior written notice to Xencor, terminate this Agreement in its entirety without cause.
13.4Termination if No Candidate Selection.  Xencor may terminate this Agreement, upon [***] prior written notice to Janssen, if Janssen does not notify Xencor of its election to make Candidate Selection within the [***] period described in Section 3.7.2. 
13.5Provisions for Insolvency.  ​
13.5.1Right to Terminate for Insolvency.  Either Party may terminate this Agreement if, at any time, the other Party files in any court or agency pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of the Party or of substantially all of its assets, or if the other Party is served with an involuntary petition against it, filed in any insolvency proceeding, and such other Party consents to the involuntary bankruptcy or such petition is not dismissed within [***] after the filing thereof, or if the other Party will propose or be a party to any dissolution or liquidation, or if the other Party will make an assignment of substantially all of its assets for the benefit of creditors (each, an “Insolvency Event”).
13.5.2Section 365(n) of the Bankruptcy Code.  All rights and licenses now or hereafter granted by Xencor to Janssen under or pursuant to this Agreement, including, for the avoidance of doubt, the licenses granted to Janssen pursuant to Section 8.1, are, for all purposes of Section 365(n) of Title 11 of the United States Code, as amended (such Title 11, the “Bankruptcy Code”), licenses of rights to “intellectual property” as defined in the Bankruptcy Code.  Upon the occurrence of any Insolvency Event with respect to Xencor, Xencor agrees that Janssen, as licensee of such rights under this Agreement, will retain and may fully exercise all of 

77
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

its rights and elections under the Bankruptcy Code.  Without limiting the generality of the foregoing, Xencor and Janssen intend and agree that any sale of Xencor’s assets under Section 363 of the Bankruptcy Code will be subject to Janssen’s rights under Section 365(n), that Janssen cannot be compelled to accept a money satisfaction of its interests in the intellectual property licensed pursuant to this Agreement, and that any such sale therefore may not be made to a purchaser “free and clear” of Janssen’s rights under this Agreement and Section 365(n) without the express, contemporaneous consent of Janssen.  Further, each Party agrees and acknowledges that all payments by Janssen to Xencor hereunder, other than Sales Milestone Payments or Co-Funding Sales Milestone Payments, as applicable, under Section 7.3 and royalty payments under Section 7.4, do not constitute royalties within the meaning of Section 365(n) of the Bankruptcy Code or relate to licenses of intellectual property hereunder.  Xencor will, during the Term, create and maintain current copies or, if not amenable to copying, detailed descriptions or other appropriate embodiments, to the extent feasible, of all such intellectual property.  Xencor and Janssen acknowledge and agree that “embodiments” of intellectual property within the meaning of Section 365(n) include laboratory notebooks, cell lines, product samples and inventory, research studies and data, regulatory filings and marketing approvals.  If (i) a case under the Bankruptcy Code is commenced by or against Xencor, (ii) this Agreement is rejected as provided in the Bankruptcy Code, and (iii) Janssen elects to retain its rights hereunder as provided in Section 365(n) of the Bankruptcy Code, Xencor (in any capacity, including debtor-in-possession) and its successors and assigns (including a trustee) will:
13.5.2.1provide to Janssen all such intellectual property (including copies of embodiments of such intellectual property) held by Xencor and such successors and assigns, or otherwise available to them, immediately upon Janssen’s written request; and
13.5.2.2not interfere with Janssen’s rights under this Agreement, or any agreement supplemental hereto, to such intellectual property (including such embodiments), including any right to obtain such intellectual property (or such embodiments) from another entity, to the extent provided in Section 365(n) of the Bankruptcy Code.
If Xencor or any of its successors or assigns provides to Janssen any of the intellectual property licensed hereunder (or any embodiment thereof) under this Section 13.5.2, Janssen will have the right to perform Xencor’s obligations under ARTICLE 3 with respect to such intellectual property, but neither such provision nor such performance by Janssen will release Xencor from liability resulting from rejection of the license or failure to perform such obligations.
13.5.3Other Rights.  All rights, powers and remedies of Janssen provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including the Bankruptcy Code) in the event of the commencement of a case under the Bankruptcy Code with respect to Xencor.  The Parties agree that they intend the following rights to extend to the maximum extent permitted by law, and to be enforceable under Bankruptcy Code Section 365(n):
13.5.3.1the right of access to any intellectual property (including all embodiments thereof) of Xencor, or any Third Party with whom Xencor contracts to perform an obligation of Xencor under this Agreement, and, in the case of the Third Party, which is 

78
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

necessary for the manufacture, use, sale, import or export of Licensed Antibodies or Licensed Products; and
13.5.3.2the right to contract directly with any Third Party to complete the contracted work.
13.6Effects of Termination or Expiration.  ​
13.6.1Effects of Termination.  In the event of termination of this Agreement by either Party pursuant to Section 13.2, 13.3, 13.4 or 13.5, then the following provisions of this Section 13.6.1 will apply upon the effective date of such termination.
13.6.1.1All licenses and other rights granted to either Party pursuant to this Agreement will terminate, except those expressly stated to survive termination of this Agreement.  
13.6.1.2Each Party will use Diligent Efforts to return or destroy, at the Disclosing Party’s election, all Confidential Information of the other Party (provided, however, that the Receiving Party may keep one copy of such Confidential Information subject to an ongoing obligation of confidentiality for archival purposes only), except for any Confidential Information to which the Receiving Party has a continuing right of use.  This obligation to return or destroy Confidential Information does not extend to automatically generated computer back-up or archival copies generated in the ordinary course of information system’s procedures; provided, however, that except as expressly set out herein, the Receiving Party will not access nor make any use of such copies.
13.6.1.3Subject to Section 13.6.1, Janssen will wind down any Development, Manufacturing and Commercialization activities with respect to the Licensed Products, as quickly as reasonably practicable, subject to compliance with ethical and legal requirements.  Notwithstanding anything to the contrary, none of Janssen’s costs incurred in connection with winding down Development shall be considered Shared Development Costs (and Xencor shall have no obligation to be responsible for or share such costs) except: (a) with respect to Clinical Studies to the extent set forth in Section 13.6.2.8; or (b) to the extent Xencor directs Janssen to undertake such wind down activity.  Following the  date of notice of termination, Janssen will have no obligation to initiate any Clinical Study or to commence any other new Development activities for the Licensed Products.  
13.6.2Right of Reversion.  The following provisions of this Section 13.6.1 will apply upon the effective date of termination of this Agreement.
13.6.2.1​​
(a)“Applied Janssen Technology” means [***]. 
(b)“Research Clone Banking,” with respect to a Licensed Antibody, occurs when [***]. 

79
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

(c)“Reverted Antibody” means a Licensed Antibody contained in a Reverted Product. 
(d)“Reverted Derivative” for a Reverted Antibody, means [***].     
(e)“Reverted Variant” for a Reverted Antibody, means [***]. 
(f)“Reverted Product” means any Licensed Product containing (or that is) a Licensed Antibody for which: [***]. Notwithstanding the foregoing, if a Licensed Product described in the immediately preceding sentence is a Combination Product, a product containing only the Licensed Antibody within such Combination Product shall be deemed a Reverted Product, but the Combination Product shall not be deemed a Reverted Product.  
(g)“Reverted Product Derivative” means, with respect to a Reverted Product, any product that contains: [***]. 
13.6.2.2For each Reverted Product, Janssen hereby grants to Xencor, effective as of the effective date of termination, an exclusive (even as to Janssen), royalty-bearing, non-transferable, perpetual license, with a right to sublicense through multiple tiers, under the Applied Janssen Technology with respect to such Reverted Product, to Exploit such Reverted Product and/or any Reverted Product Derivatives of such Reverted Product in the Field in the Territory; provided, however, that if any Applied Janssen Technology was in-licensed or acquired from a Third Party and is subject to payment or other obligations to such Third Party, Janssen will promptly disclose such obligations to Xencor in writing and such Applied Janssen Technology will be subject to the license granted in this Section only to the extent Xencor agrees in writing to be bound by such obligations and reimburse all amounts owed to such Third Party as a result of Xencor’s exercise of such license with respect to such Applied Janssen Technology.  Notwithstanding the foregoing, the foregoing license does not include the grant of any rights to Exploit any active ingredient other than the Licensed Antibodies contained in a Reverted Product or Reverted Product Derivative.
13.6.2.3Xencor will pay to Janssen royalties on Net Sales of the applicable Reverted Product (or corresponding Reverted Product Derivative) at the Reversion Royalty Rate (where references to “Janssen” in the definition of Net Sales will be replaced with “Xencor”).  “Reversion Royalty Rate” means [***]. Such payments will be made in accordance with the terms set forth in Section 7.4, applied mutatis mutandis with respect to Net Sales of Licensed Products by Xencor, provided that the definition of Royalty Term in Section 7.4.2 will remain the same.
13.6.2.4Janssen will assign or otherwise transfer to Xencor all regulatory documentation and filings and regulatory approvals (including, without limitation, all INDs/CTAs and Drug Approval Applications and approvals thereof) for the Reverted Product (excluding any portion thereof pertaining to any product that is not the Reverted Product) (“Regulatory Documentation and Filings”) and copies of all clinical and nonclinical data relating to the Reverted Product Controlled by Janssen or any of its Affiliates or sublicensees.  Janssen will, and will procure that its Affiliates and sublicensees will, take such actions and 

80
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

execute such instruments, assignments and documents as may be reasonably requested by Xencor to effect the transfer of rights under such Regulatory Documentation and Filings to Xencor.  If applicable Law prevents or delays the transfer of ownership of any such Regulatory Documentation and Filings to Xencor, Janssen will grant to Xencor an exclusive and irrevocable right of access and reference to such Regulatory Documentation and Filings, and will cooperate with Xencor to make the benefits of such Regulatory Documentation and Filings available to Xencor or its designee(s).
13.6.2.5Upon request from Xencor, Janssen will deliver to Xencor all safety data contained in the global safety database for the Reverted Product and transfer control of and responsibility for maintaining the global safety database for the Reverted Product to Xencor.
13.6.2.6Janssen will, at Xencor’s request, use Diligent Efforts to facilitate an orderly and prompt transition of any Manufacturing of each Reverted Product that was clinically Developed by or for Janssen or its Affiliates (a “Clinical Reverted Product”) then being conducted by Janssen and any of its Affiliates or Third Party subcontractors to Xencor or its designee.  At Xencor’s request, Janssen will supply Xencor or its designee with such Clinical Reverted Product at a price equivalent to the Manufacturing Cost of Clinical Supply, provided that Janssen will not be obligated to continue to supply such Clinical Reverted Product for more than [***] following the effective date of termination.  Upon Xencor’s request, Janssen will promptly provide Xencor with Janssen’s inventory of Reverted Products and Licensed Antibodies with respect thereto at a price equal to [***].
13.6.2.7If the First Commercial Sale of the Reverted Product has occurred in a country before the effective date of termination of this Agreement, then, if requested by Xencor, Janssen shall continue to Commercialize the Reverted Product in such country in accordance with the terms and conditions of this Agreement, for a period requested by Xencor not to exceed [***] from the effective date of termination of this Agreement.  Janssen will be entitled to receive and retain all amounts invoiced on sales of Reverted Product during such period, subject to payment of royalties pursuant to Section 7.4.
13.6.2.8If, on the date of notice of termination, any Clinical Study of the Reverted Product is ongoing pursuant to the GDP (i.e., first patient has been dosed), then Xencor will notify Janssen in writing within [***] after the date of notice of termination whether Xencor elects to have Janssen either:
(a)wind down such Clinical Study as soon as practicable, subject to compliance with ethical and legal requirements; or
(b)transfer responsibility for and control of such Clinical Study to Xencor as soon as practicable.  Janssen will use Diligent Efforts to effect such transfer, and Xencor will use Diligent Efforts to assume responsibility for and control, of such Clinical Study as promptly as practicable after the effective date of termination and, in any event, within [***] following the effective date of termination.

81
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

Until the effective date of termination, the costs of such Clinical Study will be shared by the Parties as Shared Development Costs to the extent such costs are to be shared pursuant to Section 6.2.3.  After the effective date of termination: (x) costs incurred in the winding down of such Clinical Study in accordance with clause (a) above will be shared by the Parties as Shared Development Costs to the extent such costs are to be shared pursuant to Section 6.2.3; and (y) costs incurred to conduct any Clinical Study that Xencor elects to have transferred to Xencor in accordance with clause (b) above will be borne solely by Xencor.  If Xencor fails to notify Janssen which option ((a) or (b)) it chooses within the [***] time period, then Xencor will be deemed to have elected to have Janssen wind down the Clinical Study.
13.6.2.9The Parties will meet after the date of notice of termination to discuss a transition plan setting forth the steps and process for an efficient and orderly transition of Development, Manufacturing and Commercialization activities with respect to each Clinical Reverted Product, including the activities described in this Section 13.6.2.  Except as otherwise provided in this Section 13.6.2, each Party will bear its own costs of conducting transition activities.  
13.6.2.10Upon termination, at Xencor’s request, Janssen will assign to Xencor, all worldwide rights in and to any and all Product Marks used to Commercialize a Reverted Product in the Territory, including all trademark applications and registrations.  Xencor shall be solely responsible for all costs and expenses related to the assignments, including recordal of the same.  For a period of up to [***] after the termination date, at Xencor’s cost and expense, (a) Janssen shall provide to Xencor the necessary information to permit Xencor to effect and perfect the transfer of the applications and registrations of the Product Marks and (b) Janssen shall reasonably cooperate with Xencor in executing appropriate documents to effectuate the transfer or assignment for the Product Marks worldwide that are in the name of Janssen or any of its Affiliates.  After such period, Janssen shall have no further obligation with respect to the matters covered by this Section.
13.6.2.11For a period of [***] following the effective date of termination, Janssen will reasonably cooperate with Xencor to provide reasonable technical assistance, and to transfer to Xencor any Janssen Know-How licensed to Xencor under Section 13.6.2.2, as requested by Xencor.  Such cooperation will include providing Xencor with reasonable access by teleconference or in-person at Janssen’s facilities to any Janssen personnel involved in the performance of the Exploitation of Reverted Products or their underlying Licensed Antibodies.  
13.6.2.12At Xencor’s sole discretion and direction, Janssen shall reasonably cooperate with Xencor to provide to Xencor a copy of all promotional or marketing materials being used (or approved for use) by Janssen or its Affiliates prior to the effective date of termination in relation to Commercialization of the Reverted Products; provided that Janssen may redact the foregoing Commercialization documentation for any confidential or proprietary information of Janssen that is not related to the Commercialization of the Reverted Products.
13.6.2.13At Xencor’s sole discretion and direction, Janssen and its Affiliates shall assign all of Janssen’s right, title and interest in and to any agreements (or portions thereof) 

82
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

between Janssen and Third Parties entered into after the Effective Date that solely relate to the Development, Commercialization or Manufacture of the Clinical Reverted Products, where such assignment is permitted without charge to Janssen or its Affiliates and where Xencor shall assume all future payments due under any agreement assigned pursuant to this paragraph.
13.6.2.14Notwithstanding anything in ARTICLE 9, Xencor shall have with respect to a Reverted Product: (a) final decision-making authority over Prosecution of all [***]; (b) the sole right, but not the obligation, to initiate Infringement Actions with respect to [***]; (c) the sole discretion to determine which [***], if any, are extended with respect to any Reverted Product pursuant to the U.S. Drug Price Competition and Patent Term Restoration Act of 1984, the Supplementary Certificate of Protection of Member States of the EU and other similar measures in other jurisdictions worldwide; and (d) control over all Invalidity Claims for [***].  Additionally, the language in the first sentence of Section 9.6 above that reads “Janssen intends” shall be deemed to read “Xencor intends.”  
13.6.2.15Xencor will indemnify, defend and hold harmless the Janssen Indemnitees from and against any and all Losses to the extent arising out of or relating to the Exploitation of the Reverted Product by or for Xencor or any of its Affiliates, sublicensees, agents and contractors on or after the effective date of termination.  Any claim of indemnification by a Janssen Indemnitee under this Section will be subject to the procedures set forth in Section 12.3 of this Agreement.
13.6.3Effects of Expiration.  If this Agreement expires in accordance with Section 13.1, the licenses and other rights granted by one Party to the other Party with respect to the Licensed Products in the Field will survive on a fully-paid, royalty-free, non-exclusive, irrevocable and perpetual basis.
13.6.4Non-Exclusive Remedy.  Notwithstanding anything herein to the contrary, expiration or termination of this Agreement by a Party will be without prejudice to other remedies such Party may have at law or equity.
13.6.5Survival.  Unless otherwise expressly provided in this Agreement, in the event of any expiration or termination of this Agreement the Sections and Articles set forth below, as well as any other Sections, Articles or defined terms referred to in such Sections or Articles or necessary to give them effect, will survive: ARTICLE 5 (with respect to Permitted Prostate Combination Regimen Studies previously consented to by the non-proposing Party), ARTICLE 10, ARTICLE 15, ARTICLE 16, Sections 3.4.3, 7.6, 7.7 (with respect to amounts paid under the Agreement), 8.1.3, 8.1.4, 8.2 (with respect to the licenses granted under Sections 8.1.3 and 8.1.4), 9.2.3, 9.3.3, 9.3.4, 9.4.5, 9.6, 9.7, 11.6, 12.1, 12.2, 12.3, and 13.6.  Furthermore, any other provisions required to interpret such Parties’ surviving rights and obligations under this Agreement will survive to the extent required.  Termination or expiration of this Agreement does not affect any liabilities, including accrued payment obligations, that accrued prior to (and such liabilities will survive) termination or expiration of this Agreement.  Except as otherwise provided in this ARTICLE 13, all rights and obligations of the Parties under this Agreement, 

83
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

including any licenses and sublicenses granted under this Agreement, will terminate upon expiration or termination of this Agreement for any reason.
ARTICLE 14​
EFFORTS TO OBTAIN CLEARANCES
14.1Commercially Reasonable Efforts.  Subject to the terms and conditions of this Agreement, from the Execution Date to the Effective Date or the earlier termination of this Agreement pursuant to ARTICLE 13, each of the Parties will use its commercially reasonable efforts to take or cause to be taken all actions, to file or cause to be filed all documents, to give or cause to be given all notices to Governmental Authorities or other Persons, to obtain or cause to be obtained all authorizations, consents, waivers, approvals, permits or orders from Governmental Authorities or other Persons, and to do or cause to be done all other things necessary, proper or advisable, in order to cause the Effective Date to occur as soon as practicable following the Execution Date.  If the Effective Date has not occurred within [***] after the Execution Date, then either Party may terminate this Agreement upon notice, in which case, all provisions of this Agreement shall terminate and be of no force or effect whatsoever, except only that: (a) any liability of either Party for failing to comply with this Section 14.1 or ARTICLE 10 shall survive; and (b) ARTICLE 10 shall survive.
14.2Antitrust Filing.  ​
14.2.1In furtherance and not in limitation of the foregoing, each of the Parties will prepare and file, or cause to be prepared and filed, any required notification pursuant to the HSR Act that is required to be made by such Party or its ultimate parent with respect to the transactions contemplated by this Agreement (the “Contemplated Transactions”) as promptly as reasonably practicable after, and in no event more than [***] following the Execution Date.  The Parties will furnish each other with all necessary information and cooperate with each other in connection with the preparation of such filings, submissions and registrations and seek to secure the expiration or termination of all applicable waiting periods (or any extension thereof) under the HSR Act  and to obtain all such authorizations, consents, waivers, approvals, permits and orders as soon as practicable following the Execution Date.  Each Party will provide the other Party with a reasonable opportunity to review and comment on any filing, submission, registration or other written communication to be given to, and consult with each other in advance of any meeting or conference with, the FTC, the Antitrust Division of the DOJ or any other Governmental Authority in connection with the efforts taken pursuant to this Section or otherwise in connection with the Contemplated Transactions.  Janssen shall be responsible for any filing fees required under the HSR Act .  Notwithstanding anything in this Agreement to the contrary, Janssen shall, on behalf of the Parties, control and lead all communications and strategy for dealing with any Governmental Authority under the HSR Act.
14.2.2If any investigation, inquiry or other Action, whether initiated by a Governmental Authority or a private party, arising out of or relating to any such filing, submission or registration or otherwise relating to the Contemplated Transactions is initiated or threatened, each Party will keep the other Party reasonably informed of any material communications and developments in connection therewith.  Subject to applicable Laws relating to the exchange of 

84
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

information and appropriate confidentiality protections, Xencor and Janssen, or their counsel, to the extent practicable, shall have the right to participate in all substantive communications or meetings with any Governmental Authority in connection with review of the Contemplated Transactions under the HSR Act, to the extent permitted by such Governmental Authority.
14.2.3The Parties will use commercially reasonable efforts to promptly respond to all inquiries made by the FTC, DOJ and any other applicable Governmental Authorities in connection with such filings, submissions or registrations or otherwise in connection with the Contemplated Transactions and to promptly provide to such Governmental Authorities any additional information and documentary material requested under applicable Law.  If any objections are raised or asserted with respect to the Contemplated Transactions under applicable Law or if any Action is instituted (or threatened to be instituted) by the FTC, the DOJ or any other applicable Governmental Authority or any private party challenging any of the transactions contemplated under this Agreement as being in violation of any applicable Law or which would otherwise prevent, impede or delay the consummation of the Contemplated Transactions, the Parties will use their commercially reasonable efforts to resolve any such objections or Actions so as to permit consummation of the Contemplated Transactions as soon as reasonably practicable, provided that commercially reasonable efforts of Janssen will not require Janssen or any of its Affiliates to agree to any prohibition, limitation, divestiture or other requirement that would (a) limit or otherwise adversely affect the right of Janssen to Exploit the Licensed Antibodies and Licensed Products or (b) require or compel Xencor, Janssen or any Affiliate of Janssen to dispose of all or any portion of its properties or assets.
ARTICLE 15​
DISPUTE RESOLUTION
15.1Exclusive Dispute Resolution Mechanism.  The Parties recognize that a dispute may arise relating to this Agreement  (a “Dispute”).  The term “Dispute” excludes any Committee Matter, which will be subject to resolution under Section 2.5.  Any Dispute, including, to the extent related to this Agreement, disputes that may involve the parent company, subsidiaries, or Affiliates under common control of any Party, shall be resolved in accordance with this ARTICLE 15.
15.2Referral to Executive Officers.  Either Party may refer to the Executive Officers any Dispute.  The Executive Officers shall discuss any such matter referred to them in good faith and attempt to find a mutually satisfactory resolution to the issue.  If the Executive Officers do not reach consensus regarding, or do not resolve, such a matter within [***] after the date on which the matter is referred to the Executive Officers (unless a longer period is agreed to by the Parties), then the matter may be referred to mediation in accordance with Section 15.3 below.  
15.3Mediation.
15.3.1With respect to any Dispute that is not resolved by the Executive Officers under Section 15.2, the Parties shall first attempt in good faith to resolve such Dispute by confidential mediation in accordance with the then-current Mediation Procedure of the International Institute for Conflict Prevention and Resolution (“CPR Mediation Procedure”) (www.cpradr.org) 

85
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

before initiating arbitration.  The CPR Mediation Procedure shall control, except where it conflicts with these provisions, in which case these provisions control.  The mediator shall be chosen pursuant to CPR Mediation Procedure.  The mediation shall be held in New York, New York.
15.3.2Either Party may initiate mediation by written notice to the other Party for any Dispute that is not resolved by the Executive Officers under Section 15.2.  The Parties agree to select a mediator within [***] of the notice, and the mediation will begin promptly after the selection.  The mediation will continue until the mediator, or either Party, declares in writing, no sooner than after the conclusion of one full day of a substantive mediation conference attended on behalf of each Party by a senior business person with authority to resolve the Dispute, that the Dispute cannot be resolved by mediation.  In no event, however, shall mediation continue more than [***] days from the initial notice by a Party to initiate meditation unless the Parties agree in writing to extend that period.
15.3.3Any period of limitations that would otherwise expire between the initiation of mediation and its conclusion shall be extended until [***]after the conclusion of the mediation.
15.4Arbitration.  ​
15.4.1If the Parties fail to resolve the Dispute in mediation, and a Party desires to pursue resolution of the Dispute, the Dispute shall be submitted by either Party for resolution in arbitration pursuant to the then-current CPR Non-Administered Arbitration Rules (“CPR Rules”) (www.cpradr.org), except where they conflict with these provisions, in which case these provisions control.  The arbitration will be held in New York, New York.  All aspects of the arbitration shall be treated as confidential.
15.4.2The arbitrators will be chosen from the CPR Panel of Distinguished Neutrals, unless a candidate not on such panel is approved by both Parties.  Each arbitrator shall be a lawyer with at least 15 years’ experience with a law firm or corporate law department of over 25 lawyers or who was a judge of a court of general jurisdiction.  To the extent that the Dispute requires special expertise, the Parties will so inform CPR prior to the beginning of the selection process.
15.4.3The arbitration tribunal shall consist of three arbitrators, of whom each Party shall designate one.  If, however, the aggregate award sought by the Parties is less than [***] and equitable relief is not sought, a single arbitrator shall be chosen in accordance with the CPR Rules.  Candidates for the arbitrator position(s) may be interviewed by representatives of the Parties in advance of their selection, provided that all Parties are represented.
15.4.4The Parties agree to select the arbitrator(s) within [***] days of initiation of the arbitration.  The hearing will be concluded within [***] after selection of the arbitrator(s), and the award will be rendered within [***] of the conclusion of the hearing, or of any post hearing briefing, which briefing will be completed by both sides within [***] days after the conclusion of the hearing.  In the event the Parties cannot agree upon a schedule, then the arbitrator(s) shall set the schedule following the time limits set forth above as closely as practical.

86
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

15.4.5The hearing will be concluded in [***] hearing days or less.  Multiple hearing days will be scheduled consecutively to the greatest extent possible.  A transcript of the testimony adduced at the hearing shall be made and shall be made available to each Party.
15.4.6The arbitrator(s) shall be guided, but not bound, by the CPR Protocol on Disclosure of Documents and Presentation of Witnesses in Commercial Arbitration (www.cpradr.org) (“Protocol”).  The Parties will attempt to agree on modes of document disclosure, electronic discovery, witness presentation, etc. within the parameters of the Protocol.  If the Parties cannot agree on discovery and presentation issues, the arbitrator(s) shall decide on presentation modes and provide for discovery within the Protocol, understanding that the Parties contemplate reasonable discovery.
15.4.7The arbitrator(s) shall decide the merits of any Dispute in accordance with the law governing this Agreement, without application of any principle of conflict of laws that would result in reference to a different law.  The arbitrator(s) may not apply principles such as “amiable compositeur” or “natural justice and equity.”
15.4.8The arbitrator(s) are expressly empowered to decide dispositive motions in advance of any hearing and shall endeavor to decide such motions as would a United States District Court Judge sitting in the jurisdiction whose substantive law governs.
15.4.9The arbitrator(s) shall render a written opinion stating the reasons upon which the award is based.  The Parties consent to the jurisdiction of the United States District Court for the district in which the arbitration is held for the enforcement of these provisions and the entry of judgment on any award rendered hereunder.  Should such court for any reason lack jurisdiction, any court with jurisdiction may act in the same fashion.
15.4.10  Notwithstanding anything to the contrary in ARTICLE 15, each Party has the right to seek injunctive or equitable relief at any time from any court such as attachment, preliminary injunction, replevin, etc. to avoid irreparable harm, maintain the status quo, or preserve the subject matter of the Dispute.  Rule 14 of the CPR Rules does not apply to this Agreement.
15.5Waiver.   EACH PARTY HERETO WAIVES ITS RIGHT TO TRIAL OF ANY ISSUE BY JURY.
ARTICLE 16​
MISCELLANEOUS
16.1Assignment; Successors.  Neither Party may assign this Agreement or any of its rights or obligations under this Agreement without the written consent of the other Party; provided, however, that either Party may assign this Agreement in its entirety without such consent (but with notice to the other Party following such assignment), to: (a) an Affiliate, as long as the assignee remains an Affiliate of the assigning Party, provided that the assigning Party will remain responsible for the performance of, and primarily liable under, this Agreement notwithstanding such assignment; or (b) a Third Party that acquires all or substantially all of the 

87
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

business or consolidated assets of such Party (whether by merger, reorganization, acquisition, sale or otherwise).  No assignment of this Agreement will be valid and effective unless and until the assignee agrees in writing to be bound by the terms and conditions of this Agreement.  The terms and conditions of this Agreement will be binding on and inure to the benefit of the successors and permitted assigns of the Parties.  Any assignment of this Agreement not in accordance with this Section 16.1 will be null and void.
16.2Performance by Affiliates.  To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations.  Each Party may use one or more of its Affiliates to perform its obligations and duties under this Agreement, provided that such Party provides prompt written notice to the other Party.  Such Party will remain liable under this Agreement for the prompt payment and performance of all of its obligations under this Agreement.
16.3Subcontracting.  Each Party (or its Affiliate) may subcontract the performance of any Research Program activities with respect to the Licensed Products undertaken in accordance with this Agreement to one or more Third Parties (each such Third Party, a “Subcontractor”), provided that any such Third Party must satisfy any subcontractor criteria established by the JRC.  All subcontracted activities will be conducted pursuant to a written agreement between the subcontracting Party and the Subcontractor (a “Subcontract”), which will be consistent with the terms and conditions of this Agreement, will contain confidentiality provisions no less restrictive than those set forth in ARTICLE 10, and will contain a certification that such Third Party and its officers, employees and agents have not been debarred, and are not subject to debarment, pursuant to Section 306 of the United States Federal Food, Drug, and Cosmetic Act, and are not the subject of a conviction described in such section.  The subcontracting Party will oversee the performance of its Subcontractors, and each Party will have the right from time to time, but not more than once per Calendar Year, to audit the performance of the other Party’s Subcontractors.  Notwithstanding the foregoing, the subcontracting Party (or Party whose Affiliate enters into a Subcontract) will remain liable under this Agreement for the performance of all its obligations under this Agreement and will be responsible for and liable for compliance by its Subcontractors with the applicable provisions of this Agreement.
16.4No Consequential or Punitive Damages.  EXCEPT FOR A BREACH OF ARTICLE 10, NEITHER PARTY HERETO NOR ANY OF ITS AFFILIATES WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, PUNITIVE OR MULTIPLE DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS UNDER THIS AGREEMENT, OR FOR ANY LOSS OR INJURY TO A PARTY’S OR ITS AFFILIATES’ PROFITS, REVENUES, BUSINESS OR GOODWILL ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES.  NOTHING IN THIS SECTION 16.4 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY WITH RESPECT TO INDEMNIFICATION CLAIMS.  
16.5Choice of Law.  This Agreement will be governed by and interpreted under, and any court action in accordance with Section 16.6 will apply, the laws of the State of New York excluding:  (i) its conflicts of laws principles; (ii) the United Nations Conventions on Contracts 

88
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

for the International Sale of Goods; (iii) the 1974 Convention on the Limitation Period in the International Sale of Goods (the “1974 Convention”); and (iv) the Protocol amending the 1974 Convention, done at Vienna April 11, 1980.  Notwithstanding anything to the contrary herein, the interpretation and construction of any Patents will be governed in accordance with the laws of the jurisdiction in which such Patents were filed or granted, as the case may be.
16.6Submission to Jurisdiction.  Each Party (i) submits to the jurisdiction of the state and federal courts sitting in New York, New York, with respect to actions or proceedings arising out of or relating to this Agreement in which a Party brings an action in aid of arbitration, (ii) agrees that all claims in respect of such action or proceeding may be heard and determined in any such court and (iii) agrees not to bring any action or proceeding arising out of or relating to this Agreement in any other court, other than an action or proceeding seeking injunctive relief or brought to enforce an arbitration ruling issued pursuant to Section 15.4.  Each Party waives any defense of inconvenient forum to the maintenance of any action or proceeding so brought.  Each Party may make service on the other Party by sending or delivering a copy of the process to the Party to be served at the address and in the manner provided for the giving of notices in Section 16.7.  Nothing in this Section 16.6, however, will affect the right of any Party to serve legal process in any other manner permitted by Law.
16.7Notices.  All notices, requests, demands, waivers and other communications required or permitted to be given under this Agreement will be in writing and deemed given if delivered personally or sent by overnight courier to the receiving Party, in each case with a copy sent via electronic mail (if an electronic mail address of the party to whom the relevant communication is being made has been designated pursuant hereto and remains a working electronic mail address), at the following addresses (or at such other addresses as will be specified by like notice):
​
If to Xencor:
​
[***]
​
If to Janssen:  
[***]
​
​
All such notices, requests, demands, waivers and other communications will be deemed to have been received, if by personal delivery or overnight courier, on the day delivered or, if by facsimile, on the next Business Day following the day on which such facsimile was sent; provided, in each case that a copy is also sent by electronic mail in accordance with the first sentence of this Section 16.7.
16.8Severability.  The provisions of this Agreement will be deemed severable and the invalidity or unenforceability of any provision will not affect the validity or enforceability of the other provisions hereof.  If any provision of this Agreement, or the application of such provision to any Person or any circumstance, is invalid or unenforceable, (a) a suitable and equitable 

89
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

provision will be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the remainder of this Agreement and the application of such provision to other Persons or circumstances will not be affected by such invalidity or unenforceability, nor will such invalidity or unenforceability affect the validity or enforceability of such provision, or the application of such provision, in any other jurisdiction.
16.9Captions.  All captions in this Agreement are for convenience only and will not be interpreted as having any substantive meaning.
16.10Further Actions.  Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be necessary or appropriate to carry out the purposes and intent of this Agreement.
16.11Amendment; No Waiver.  No waiver, modification or amendment of any provision of this Agreement will be valid or effective unless made in writing and signed by a duly authorized officer of each Party. The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition.
16.12Integration.  This Agreement constitutes the entire agreement between the Parties with respect to the subject matter of this Agreement and supersedes all previous agreements, whether written or oral.  Notwithstanding the authority granted to the Committees under this Agreement, this Agreement may be amended only in writing signed by properly authorized representatives of each of Xencor and Janssen.  In the event of a conflict between the GDP, on the one hand, and this Agreement, on the other hand, the terms of this Agreement will govern.
16.13Independent Contractors; No Agency.  Neither Party will have any responsibility for the hiring, firing or compensation of the other Party’s employees or for any employee benefits.  No employee or representative of a Party, including the Xencor sales representatives, will have any authority to bind or obligate the other Party to this Agreement for any sum or in any manner whatsoever, or to create or impose any contractual or other liability on the other Party without said Party’s written approval.  For all purposes, and notwithstanding any other provision of this Agreement to the contrary, Janssen’s legal relationship under this Agreement to Xencor, and Xencor’s legal relationship under this Agreement to Janssen, will be that of independent contractor and will not constitute a partnership, joint venture or agency.
16.14Force Majeure.  Neither Party will be liable for delay or failure in the performance of any of its obligations hereunder (other than the payment of money) if such delay or failure is due to causes beyond its reasonable control, including acts of God, fires, typhoon, floods, earthquakes, tsunami, pandemics, embargoes, acts of war (whether war be declared or not), terrorism, strikes, lockouts, pandemics or other civil unrest, or omissions or delays in acting by any governmental authority (“Force Majeure”); provided, however, that the affected Party promptly notifies the other Party and further provided that the affected Party will use its Diligent Efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence, and will continue performance with the commercially reasonable dispatch whenever such causes are removed. When such circumstances arise, the Parties will negotiate in 

90
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

good faith any modifications of the terms of this Agreement that may be necessary or appropriate in order to arrive at an equitable solution.
16.15Counterparts; Signatures.  This Agreement may be executed in counterparts, each of which counterparts, when so executed and delivered, will be deemed to be an original, and all of which counterparts, taken together, will constitute one and the same instrument even if both Parties have not executed the same counterpart.  Signatures provided by facsimile transmission or by email of a .pdf attachment will be deemed to be original signatures.
16.16Construction.  References to Sections include subsections, which are part of the related Section.  Except as otherwise explicitly specified to the contrary, (i) references to a Section, Article, Exhibit or Schedule means a Section or Article of, or a Schedule or Exhibit to, this Agreement and all subsections thereof, unless another agreement is specified; (ii) references to a particular statute or regulation include all rules and regulations thereunder and any successor statute, rules or regulations then in effect, in each case, including the then-current amendments thereto; (iii) words in the singular or plural form include the plural and singular form, respectively; (iv) unless the context requires a different interpretation, the word “or” has the inclusive meaning that is typically associated with the phrase “and/or”; (v) terms “including,” “include(s),” “such as,” and “for example” as used in this Agreement mean including the generality of any description preceding such term and will be deemed to be followed by “without limitation”; (vi) whenever this Agreement refers to a number of days, such number will refer to calendar days unless Business Days are specified; (vii) when a time period set forth in this Agreement ends on a day that is not a Business Day, the last day of such time period will be the next Business Day; (viii) references to a particular Person include such Person’s successors and assigns to the extent not prohibited by this Agreement; (ix) all words used in this Agreement will be construed to be of such gender or number as the circumstances require; (x) the words “hereof,” “herein,” “hereby” and derivative or similar words refer to this Agreement (including any Exhibits); (xi) neither Party or its Affiliates will be deemed to be acting “on behalf of” the other Party under this Agreement, except to the extent expressly otherwise provided; and (xii) references to sublicensees include direct and indirect sublicensees.
[Signature Page Follows]
​
​
​

91
[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

IN WITNESS WHEREOF, the Parties have caused this Collaboration and License Agreement to be executed by their respective duly authorized officers as of the Execution Date.
​
	​
​ ​                    ​
​ ​                    ​
­­­­­­­­­­­­­­­­­­­___________________
​

	​
​ ​                    ​
​ ​                    ​
­­­­­­­­­­­­­­­­­­­___________________
​

	Xencor, Inc.
​
By: /s/ Bassil Dahiyat​ ​      
Name: Bassil Dahiyat​ ​       
Title: ­­­­­­­­­­­­­­­­­­­ CEO                              ​ ​       
	Janssen Biotech, Inc.
​
By: /s/ Serge Messerlian​ ​           
Name: Serge Messerlian​ ​            ​ ​
Title: President                           ​ ​

	​
	​

​
​
​
​
​
​

[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

LIST OF EXHIBITS AND SCHEDULES
​
	Exhibit 1.8
	Johnson & Johnson Universal Calendar
​

	Exhibit 3.2
	Research Plan
​

	Schedule 5.1.1
	Janssen Eligible Prostate Products and Xencor Eligible Prostate Products
​

	Exhibit 10.5.1
	Initial Press Release
​

	Schedule 11.5.2
	CD28 Binding Domains

	​
	​

	Schedule 11.5.10
	Certain Patents of Xencor 

​
​
​
​
​
​

[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

 Exhibit 1.8
Johnson & Johnson Universal Calendar
​
​
​
See attached.

[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

Exhibit 3.2
Research Plan
​
​
See attached.

[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

Schedule 5.1.1
Janssen Eligible Prostate Products and Xencor Eligible Prostate Products
​
[***]
​
​

[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

Exhibit 10.5.1
Initial Press Release
​
​
See attached.
​
​
​
​

[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

Schedule 11.5.2
CD28 Binding Domains
​
[***]
​

[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.

​

Schedule 11.5.10
Certain Patents of Xencor 
​
See attached.

[***] = CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS  HAVE BEEN MADE.Exhibit 10.6
​

FIRST AMENDMENT TO INVESTMENT MANAGEMENT AGREEMENT
​
This First Amendment to Investment Management Agreement (“First Amendment”) is made effective as of the 23rd day of February 2021, by and between FAIRHOLME CAPITAL MANAGEMENT, L.L.C., a Delaware limited liability company (“Manager”) and THE ST. JOE COMPANY, a Florida corporation (“Client”).  
​
WHEREAS, the parties entered into that certain Investment Management Agreement dated August 23, 2019 (the “Agreement”); and now desire to make certain modifications to the terms of the Agreement.
​
NOW THEREFORE, in consideration of the mutual promises and covenants contained in this First Amendment and in the Agreement, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties agree as follows:  
​
1.Recitals.  The recitals set forth above are true and correct and are hereby incorporated herein as if again set forth in their entirety.
​
2.Schedule B to the Agreement. The parties agree that Schedule B to the Agreement shall, as of the date hereof, be deleted in its entirety and replaced by Schedule B attached to this First Amendment.
​
3.Entire Agreement and Conflicts.  Except as modified herein, there are no changes to the Agreement, and the Agreement as herein modified, remains in full force and effect.  In the event of a conflict between the Agreement and this First Amendment, the terms of this First Amendment shall control.
​
4.Counterparts.  This First Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Execution of this First Amendment by the parties hereto may be evidenced by the transmission of electronic (including pdf) copies.
​
IN WITNESS WHEREOF, the parties have executed this First Amendment as of the day and year first above written.
​
	​

	​

	​

	​

	​

	FAIRHOLME CAPITAL MANAGEMENT, L.L.C.
	​
	ST. JOE COMPANY

	​
	​
	​
	​
	​

	​
	​
	​
	​
	​

	​
	​
	​
	​
	​

	By:
	/s/ Wayne Kellner
	​
	By:
	/s/ Marek Bakun

	​

	​

	​

	​

	​

	Name:
	Wayne Kellner
	​
	Name:
	Marek Bakun

	​

	​

	​

	​

	​

	Title:
	Chief Financial Officer
	​
	Title:
	EVP and Chief Financial Officer

	​

	​

	​

	​

	​

	Date:
	February 23, 2021
	​
	Date:
	February 23, 2021

	​
	​
	​
	​
	​

​
​
​
​

​

​

Schedule B
​
INVESTMENT GUIDELINES AND RESTRICTIONS
​
(As of February 23, 2021)
​
​
General Guidelines
For the purposes of these Investment Guidelines and Restrictions, the “St. Joe Investment Portfolio” shall refer to St. Joe Company brokerage accounts managed by Fairholme Capital Management LLC (“Manager”).
​
Restrictions listed on this Schedule B dated February 23, 2021 compose all St. Joe Investment Portfolio restrictions for transactions by the Manager (“Specific Restrictions”).  Specific restrictions from previous Investment Guidelines and Restrictions are terminated. 
​
The Manager will review its compliance with Specific Restrictions before a securities transaction.
​
Specific Restrictions
Securities for purchase must be issues of the U.S. Treasury or U.S. Treasury Money Market Funds. 
​
Authorized Signatories
​
	​

	​

	​

	​

	​

	FAIRHOLME CAPITAL MANAGEMENT, L.L.C.
	​
	ST. JOE COMPANY

	​
	​
	​
	​
	​

	​
	​
	​
	​
	​

	​
	​
	​
	​
	​

	By:
	/s/ Wayne Kellner
	​
	By:
	/s/ Marek Bakun

	​

	​

	​

	​

	​

	Name:
	Wayne Kellner
	​
	Name:
	Marek Bakun

	​

	​

	​

	​

	​

	Title:
	Chief Financial Officer
	​
	Title:
	EVP and Chief Financial Officer

	​

	​

	​

	​

	​

	Date:
	February 23, 2021
	​
	Date:
	February 23, 2021

	​
	​
	​
	​
	​

​

​

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00321-of-00352.parquet"}]]